| Full Text |
FORM 2
The Patents Act, 1970
(39 of 1970)
&
The Patent Rules, 2003
COMPLETE SPECIFICATION
(See section 10 and rule 13)
PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL
PEPTIDASE-IV (DPP-IV)
Abbott Laboratories, a company incorporated in USA having its Registered Office at D-377 AP6A-U00 Abbott Park Road, Abbott Park, IL 60064, USA.
WO 2004/026822
PCTAJS2003/029018
diabetes.
Summary of the Invention
The present invention is directed to compounds of formula (I),
or pharmaceutically acceptable salts orprodrugs thereof wherein
X is a member selected from the group consisting of CKb, CHF and CF2;
R is a member selected from the group consisting of alkylcarbonyl, arylcarbonyl, cyano, heterocyclecarbonyl, R4R5NC(0>, B(OR6)2, (l,2,3)-dioxoborolane and 4,4,5,5-tetramethyl-(l,2,3)-dioxoborolane;
Ri is a member selected from the group-consisting of alkoxyalkyl, alkyl, alkylcarbonyl, alkenyl, alkynyl, allenyl, arylalkyl, cycloalkyl, cycloalkylalkyl, cyano, haloalkyl, haloalkenyl, heterocycleaikyL and hydroxyalkyl;
R2 and R3 are independently selectediromJhe-group consisting of hydrogen, alkoxyalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycle, heterocyclealkyl, and hydoxyalkyl; or R2 and R3 taken together with the atoms to which they are attached form a mono or bicyclic heterocycle selected from the group consisting of 2-indolinyl, 2-indblyl, 3-isoquinoline, 2-piperazine, 2-piperidine, 2-pyrrolidine, 2-pyrrole, 2-pyridine, 2-quinolinyl, 2-tetrahydroquinolinyl, and 3=tetrahydroisoquinolinyl, wherein said heterocycle may be substituted with 0, l,.2_or 3 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylsulfonyJ, alkylthio, alkynyl, aryl, arylalkoxy, arylalkyl, arylcarbonyl, aryloxy, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyL halogen, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, phenyl, RARBN-, RCRDNC(0)-, and RcRoNS(0)r;
R4, Rs and R^jire each in^ep^ndently^selected fromthe group consisting of hydrogen, alkyl, and arylalkyl;
RA and RB are each independently selected from the group consisting of alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl; or RA and RB taken together with the nitrogen to which they are attached form a ring selected from the group consisting of piperidine, piperazine and morpholine; and
Re and RD are each independently selected from the group consisting of hydrogen and
2
WO 2004/026822
PCTAJS2003/029018
alkyl.
According to an embodiment of the present invention, there is provided a method to improve glucose tolerance in type II diabetes comprising administering a therapeutically effective amount of a compound of formula (I). According to another embodiment of the present invention, there is provided a method for treating type 2 diabetes, insulin resistance, hyperinsulinemia, impaired glucose tolerance, obesity, hypercholesterolemia, and hypertriglyceridemia comprising administering a therapeutically effective amount of a compound of formula (I).
According to still another embodiment, the present invention is directed to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) in combination with apharmaceutically acceptable carrier.
Detailed Description of the Invention
Definitions
As used throughout this specification and the appended claims, the following terms - have the following meanings:
The term "alkenyl," as used herein, refers toa-Straight orbranched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyL, 2-propenyl, 2-methyl-2-propenyl, 3-buten.yl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl.
The term "alkoxy," as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
The term "alkoxyalkyl," as used_herein,-refers to-an-alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples olalkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl, and methoxymethyl.
The term "alkoxycarbonyl," as used herein, refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkoxycarbonyl include, butarenot limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
The term "alkyl," as used herein, refers to a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl,
3
WO 2004/026822
PCT/US2003/029018
n-heptyl, n-octyl, n-nonyl, and n-decyl. The alkyl groups of the present invention may be optionally substituted with 0,1 or 2 substituents that are members selected from the group consisting of alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, carboxy, carbojcyalkyl, cyano, cyanoalkyl, formyl, halogen, hydroxy, 5 alkoxycarbonylNRg, alkylNRg wherein Rg is a member selected from the group consisting of
hydrogen and alkyl.
The term "alkylcarbonyl," as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkylcarbonyl include, but are not limited to, acetyl, l-oxopropyl, 10 -dimerhyi-l-oxopropyi, \-cnsfoufyl, rai \-s*wperfty\.
The term "alkylsulfonyl," as used herein, refers to an alkyl group, as defined herein,
appended to the parent molecular moiety through a sulfonyl group, as defined herein-
Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl and
ethylsulfonyl.
15 The term "alkynyl," as used herein, refers to a straight or branched chain hydrocarbon
group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-fcutynyl, 2-pentynyl, and 1-butynyl.
The alkynyl groups of this invention can be substituted with 0,1,2, or 3 substituents 20 independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,
alkylcarbonyl, alkylcarbouylalkyl, heterocycle, heterocyclealkyl, hydroxy, and hydroxyalkyl.
The term "allenyl," as used herein, refers to a straight or branched-chain hydrocarbon
containing from 3 to 10 carbons and containing two double bonds between three contiguous
carbons formed by the removal of four hydrogens. Representative examples of alkenyl
25 include, but are not limited to, propa-1,2 dienyl, penta-1,2 dienyL penta-2,3 dienyl, hexa-1,2-
dienyl and the like.
The term "aryl," as used herein, refers to a monocyclic-ring system, or a bicyclic- or a tricyclic-fused ring system wherein one or more of the fused rings are aromatic. Representative examples of aryl include, but are not limited to, anthracenyl, azulenyl, 30 fluorenyl, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl.
The aryl groups of the present invention can be substituted with 0,1,2, or 3 substituents independently^selected from alkyl, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, aikoxycarbonylalkyT, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, halogen, haloalkyl, 35 heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, mercapto, nitro, phenyl, RERFN-,
RORHNC(O)-, and RGRHNS(0)2-wherein RE and Rf are each independently selected from the group consisting of alkyl, alkylcarbonyl alkoxycarbonyU alkylsulfonyl. and Rq. and R«. are each independently selected from the group consisting of hydrogen and alkyl.
4
WO 2004/026822
PCT/US2003/029018
The term "arylalkoxy," as used herein, refers to an aryl group, as defined herein,
appended to the parent molecular moiety through an aikoxy group, as defined herein.
Representative examples of arylalkoxy include, but are not limited to, 2-phenylethoxy, 3-
naphth-2-ylpropoxy, and 5-phenylpentyloxy.
5 The term "arylalkyl," as used herein, refers to an aryl group, as defined herein,
appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and 2-naphth-2-ylethyl.
The term "arylcarbonyl," as used herein, refers to an aryl group, as defined herein, 10 appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of aryfearbony/ include, but are not limited to, benzoyl and naphthoyl.
The term "carbonyl," as used herein, refers to a -C(0)- group.
The term "carboxy," as used herein, refers to a -CO2H group.
15 The term "cyano," as used herein, refers to a -CN group.
The term "cyanoalkyl," as used herein, refers to a cyano group, as-defined herein,
appended to the parent molecular moiety through an alkyl group, as defined herein.
Representative examples of cyanoalkyl include, but are not limited to, cyanomethyL 2-
cyanoethyl, and 3-cyanopropyl.
20 The term "cycloalkyi," as used herein, refers to a monocyclic, bicyclic, or tricyclic
ring system. Monocyclic ring systems are exemplified by a saturated cyclic hydrocarbon
group containing from 3 to 8 carbon atoms. Examples of monocyclic ring systems include
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyciooctyl. Bicyclic ring
systems are exemplified by a bridged monocyclic ring system in which two non-adjacent
25 carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and
three additional carbon atoms. Representative examples of bicyclic ring systems include, but are not limited to, bicyclo(3.1.1)heptane- bicyclo(2.2.1)heptane, bicyclo(2.2.2)octane, bicyclo(3.2.2)nonane, bicyclo(3.3.1)nonane, and bicyclo(4.2.1)nonane. Tricyclic ring-systems are exemplified by a bicyclic ring system in which two non-adjacent carbon atoms of 30 the bicyclic ring are linked by a bond or an alkylene.bridge of between one and three carbon • atoms. Representative examples of tricyclic-ring systems include, but are not limited to, tricyclo(3.3.1.03'7)nonane and tricyclo(3.3.1.13,7)decane (adamantane).
The cycloalkyl groups of this invention may be substituted with 0,1,2 or 3
substituents selected from alkyl, alkylcarbonyl, aikoxy, alkoxycarbonyl, alkenyL alkynyl,
35 aryl, cyano, halogen, hydroxy, hydroxyalkyl, nitro, RERFN-, RGRMNC(O)-, and RGRHNS(0)2-
t wherein RE and RF are each independently selected from the group consisting of alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, and RQ and RH are each independently selected from the group consisting of hydrogen and alkyl
5
WO 2004/026822
PCT/US2003/029018
Ths term "cycloalkylalkyl," as used herein, refers to a cycloalkyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of cycloalkylalkyl include, but are not limited to, cyclopropylmethyl, 2-cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl, and 4-cycloheptylbutyl.
The term "halo" or "halogen," as used herein, refers to -CI, -Br, -I or -F.
The term "haloalkyl," as used herein, refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein-Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyI.
The term "haloalkenyl," as used herein, refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkenyl group, as defined herein-Representative examples of haloalkenyl include, but are not limited to, chloroethylenyl, 2-fluoroethylene, trifluorobutenyl, and dichloropropenyl.
The term "heterocycle" or "heterocyclic," as used herein, refers to a monocyclic, bicyclic, or tricyclic ring system. Monocyclic ring systems are exemplified by any 3- or 4-membered ring containing a heteroatom independently selected from oxygen, nitrogen and sulfur, or a 5-, 6- or 7-membered ring containing one, two or three heteroatoms wherein the heteroatoms are independently selected from nitrogen, oxygen and sulfur. The 5-membered ring has from 0-2 double bonds and the 6- and 7-membered ring have from 0-3 double bonds. Representative examples of monocyclic ring systems include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepinyl, 1,3-dioxolanyl, dioxanyl, dithianyl, furyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isothiazolinyl, isothiazolidinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolyl, oxadiazolinyl, oxadiazolidinyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrazinyl, tetrazolyl, thiadiazolyl, thiadiazolinyl, thiadiazolidinyl, thiazolyl, thiazolinyl, thiazolidinyL thienyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, triazinyl, triazolyl, and trithianyl. Bicyclic ring systems are exemplified by any of the above monocyclic ring systems fused to an aryl group as defined herein, a cycloalkyl group as defined herein, or another monocyclic ring system. Representative examples of bicyclic ring systems include but are not limited to, for example, benzunidazolyl, benzodioxinyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, benzofuranyl, benzopyranyl, benzothiopyranyl, cinnolinyl, indazolyl, indolyl, 2,3-dihydroindolyl, indolizinyl, naphthyridinyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isbquinolinyl, phthalazinyl, AH-pyrido(l,2-a)pyrimidin-4-one, pyranopyridinyl, quinolinyl, quinolizinyl, quinoxalinyl, quinazolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, and thiopyranopyridinyl.
6
WO 200-1/026822
PCT/US2003/029018
Tricyclic rings systems are exemplified by any of the above bicycHc ring systems fused to an
aryi group as defined herein, a cycloalkyl group as defined herein, or a monocyclic ring
system. Representative examples of tricyclic ring systems include, but are not limited to,
acridinyl, carbazolyl, carbolinyl, dibenzo(b,d)furanyl, dibenzo(b,d)thienylJ naphtho(2,3-
5 b)furan, naphtho(2,3-b)thienyl, phenazinyl, phenothiazinyl, phenoxazinyl, thianthrenyl,
thioxanthenyl and xanthenyl.
According to the present invention, heterocycles can be substituted with 0,1,2 or 3 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy,
10 alkylsulfonyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkyl, arylcarbonyl, aryloxy, carboxy,
carboxyalkyl, cyano, cyanoalkyj, fanny], halogen, haloaJkyl, hydroxy, hydroxyalkyl, mercapto, nitro, phenyl, RERFK-, RGRHNC(0)-, and RGRHNSCO^-, wherein RE anARF are each independently selected from the group consisting of alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, and Ro and RH are each independently selected from the group
15 consisting of hydrogen and allcyl.
The term "heterocyclealkyl," as used herein, refers to a heterocycle, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of heterocyclealkyl include, but are not limited to, pyridin-3-ylmethyi and 2-pyrimidin-2-ylpropyl and the like.
20 The term "hydroxy," as used herein, refers to an -OH group.
The term "hydroxyalkyl," as used herein, refers to a hydroxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxybutyl and the like.
25 The term "heterocyclecarbonyl," as used herein, refers to a heterocycle, as defined
herein, appended to the parent molecular moiety through an carbonyl group, as defined herein. Representative examples of heterocyclecarbonyl include, but are not limited to, pyridin-3-ylcarbonyland-2-pyrimidin-2-ylcarbonyl and the like. The term "nitro," as used hereinrrefers to a -NO2 group.
30 The present invention is directed to compounds of formula (I), wherein R, Ri, R2, R3,
R4, R5, R$, R/v, RB, RC and RD are defined herein.
The present invention is also directed to a method of treating disorders mediated by DPP-IV through inhibition of enzymatic activity. Disorders known to be regulated through enzymatic activity are diabetes, especially type II diabetes, as well as hyperglycemia,
35 Syndrome X, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory
diseases. Therefore, according to an embodiment of the present invention there are provided compounds of formula (I), which are useful for the treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis,
7
WO 2004/026822
PCTAJS2003/029018
and various immunomodulatory diseases.
According to a further embodiment of the present invention there is provided a
compound of formula (I), wherein R is cyano and wherein X, Rt, R2 R3, R4, R$ and Re are as
defined in formula (I).
5 According to a further embodiment of the present invention there is provided a
compound of formula (I), wherein R is cyano; Ri is a member selected from the group consisting of alkyl, alkenyl, alkynyl, and cycloalkyl and wherein X, R2, and R3 are as defined in formula (I).
According to a further embodiment of the present invention there is provided a 10 compound of formula (I), wherein R is cyano; Rj is a member selected from the group
consisting of alkyl, alkenyl, and alkynyl; R2 is a member selected from the group consisting of alkoxyalkyl, alkyl, cycloalkyl, cycloalkylalkyl, arylalkyl, and heterocyclealkyl and wherein X, and R3 are as defined in formula (T).
According to a further embodiment of the present invention there is provided a 15 compound of formula (I)^wherein R is cyano; Ri is a member selected from the group
consisting of alkyl, alkenyl, and alkynyl; R2 is selected from the group consisting of alkyl, cycloalkyl, and heterocycle; R3 is hydrogen and wherein X is as defined in formula (T). According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is a member selected from the group 20 consisting of alkynyl, wherein alkynyl is ethynyland propynyl; R2 is a member selected from the group consisting of alkyl, cycloalkyl, and heterocycle; R3 is hydrogen and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is a member selected from the group 25 consisting of alkyl, alkenyl, and alkynyl; R2 is a member selected from the group consisting of alkyl, cycloalkyl, jmd heterocycle; R3 is cycloalkyl, wherein cycloalkyl is a member selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, and cyclooctyl^nd-whereinX is as defined In formula (I). ^
According to a further embodiment of the present invention there is provided a 30 compound of formula (I), wherein R is cyano; Ri is alkynyl, wherein alkynyl is ethynyl or
propynyl; Ri is hydrogen; R3 is cycloalkyl, wherein cycloalkyl is a member selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, and cyclooctyl and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a 35 compound of formula (I), wherein R is cyano; Ri is a member selected from the group consisiting of alkyl, alkenyl, and alkynyl; R2 is hydrogen; and R3 is cycloalkyl, wherein cycloalkyl is a member selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, and cyclooctyl and wherein X is as defined in formula (I).
8
WO 20U4/U2()8ii
PCT/US2003/029018
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Rj is a member selected from the group consisting of alkyl, alkenyl, and alkynyl; R2 is a member selected from the group consisting of alkyl, cycloalkyl, and heterocycle; and R3 is Rg-O-cyclohexyl; R9 is a member selected from the group consisting of hydrogen, aryl, and heterocycle and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is alkynyl, wherein alkynyl is ethynyl or propynyl; R2 is hydrogen; and Rj is
Rg is a member selected from the group consisting of hydrogen, aryl, and heterocycleand wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is a member selected fromJhe group consisting of alkyl, alkenyl, andalkynyl; R2 is hydrogen; R3 is
R.9 is a member selected from the group consisting of hydrogen, aryl, and heterocycle and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is a member selected from the group consisting of alkyl, alkenyl, and alkynyl; R> is a member selected from the group consisting of alkyl, cycloalkyl, and-heterocycle; R3 is^alkyl; whereurthe alkyl group of R3 is substituted with a member of the group consisting of alkoxy, alkoxycarbonyl, aUcoxycarbonylNH, alkylNH, carboxy, and hydroxy and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is alkynyl, wherein alkynyl is ethynyl or propynyl; R2 is hydrogen; R3 is alkyl; wherein the alkyl group of R3 is substituted with a member of the group consisting of alkoxy, alkoxycarbonyl, alkoxycarbonylNH, alkylNH, carboxy, and hydroxy; and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is a member selected from the group
WO 2004/026822
PCTAJS2003/029018
consisting of alkyl, alkenyl, and alkynyl; R2 is hydrogen; R3 is alkyl; wherein the alkyl group of R3 is substituted with a member of the group consisting of alkoxy, alkoxycarbonyl, alkoxycarbonylNH, alkylNH, carboxy, and hydroxy; and wherein X is as defined in formula
CD-
According to a further embodiment of the present invention there is provided a
compound of formula (I), wherein R is cyano; Ri is a member selected from the group consisting of alkyl, alkenyl, and alkynyl; R2 is selected from the group consisting of alkyl, cycloalkyl, and heterocycle; R3 is a member selected from the group consisting of aryl and heterocycle; wherein said heterocycle is a member selected from the group consisting of azetidinyl, azepany\, azhi&inyl, drazEpinyl, l,S-dk>xo\aE$\, tlioxaEyV, &l3naaiiy\,farfl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isothiazolinyl, iswthiazolidinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolyl, oxadiazolinyl, oxadiazolidinyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazuiyl, pyranylj-pyrazinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridinyl, pyrimidinyl, pyxidaziny^jjyrrolyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrazinyl, tetrazolyl, thiadiazolyl, thiadiazolinyl, thiadiazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl, thienyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, triazinyl; triazolyl, and trithianyl and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (T), wherein R is cyano; Ri is alkynyl, wherein alkynyl is ethynyl or propynyl, R2 is hydrogen; and R3 is a member selected fromihe group consisting of aryl and heterocycle; wherein said heterocycle is a member selected from the group consisting of azetidinyl, azepanyl, aziridinyl, diazepinyl, 1,3-dioxolanyl, dioxanyl, dithianyl, furyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isothiazolinyl, isothiazolidinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolyl, oxadiazolinyl, oxadiazolidinyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyl, pyranyl, pyrazinyl, pyrazolyl,pyrazolinyl, pyrazolidinyl, pyridinyl, pyrimidmyl,.pyrida2inyl,pyjrolyl,_pyrrolinyl, pyrrolidinyl,-tetrahydrofuranyl, tetrahydrothienyl, tetrazmyl, tetrazolyl, thiadiazolyl, thiadiazolinyl, thiadiazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl, thienyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, triazinyl, triazolyl, and trithianyl; and wherein X is as defined in formula (I).
^ Awning toji_fi^er cgjwdjment of the present invention there is provided a_
compound of formula (I), wherein R is cyano; Ri is a member selected from the group consisting of alkyl, alkenyl, and alkynyl; R2 is hydrogen; R3 is a member selected from the group consisting of aryl and heterocycle; wherein said heterocycle is a member selected from the group consisting of azetidinyl, azepanyl, aziridinyl, diazepinyl, 1,3-dioxolanyl, dioxanyl, dithianyl, furyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isothiazolinyl, isothiazolidinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolyl,
10
WO 2004/026822
PCT/US2003/029018
oxadiazolinyl, oxadiazolidinyi, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyi, pyranyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, p>Tidinyl, pyximidiiiyl, pyridazinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrazinyl, tetrazolyl, thiadiazolyl, thiadiazoliayl, thiadiazalidinyl, thiazolyl, thiazolinyl, thiazolidinyl, thienyl, thiomorphoiinyl, 1,1-dioxidothiomoipholinyi (thiomorphoiine sulfone), thiopyranyl, triazinyl, triazolyl, and trithianyl; and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Rj is a member selected from the group consisting of alkyl and alkynyl; R2 is hydrogen; R3 is heterocycle; wherein said heterocycle is piperidine, and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is alkyl, alkenyl, and alkynyl; R2 is a member selected fromihergroup consisting of alkyl, cycloalkyl, and heterocycle; R3 is a member selected from the group consisting of arylalkyl and heterocyclealkyl; and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is alkynyl, wherein alkynyl is ethynyl or propynyl; R2 is hydrogen; R3 is a member selected from the group consisting of arylalkyl and heterocyclealkyl; and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Rj is a member selected from the group consisting of alkyl and alkynyl; R2 is a member selected from the group consisting of alkyl, cycloalkyl, and heterocycle; R3 is
R7is-£Jttemb£rselecteAfromihe group consistingjof_hydrogen-and~alkyl; Rj is a member selected from the group consisting of hydrogen, alkylcarbonyl, aryl and heterocycle; and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano, Ri is alkynyl, wherein alkynyl is ethynyl or propynyl, R2 is hydrogen; R3 is
R7 is a member selected from the group consisting of hydrogen and alkyl; Rg is a member
11
WO 2004/026822
PCIYUS2003/029018
selected from the group consisting of hydrogen, alkylcarbonyl, aryl and heterocycle; and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a
compound of formula (I), wherein R is cyano, Ri is a member selected from the group
5 consisting of alkyl and alkynyl; R2 is hydrogen; R3 is
R7 is a member selected from the group consisting of hydrogen and alkyl; R$ is a member
selected from the group consisting of arylcarbonyl, and heterocyciecarbonyl-; and wherein X
is as defined in formula (I).
10 According to a further embodiment of the present invention there is provided a
compound of formula (T), wherein R is cyano; Ri is alkynyl, wherein alkynyl is ethynyl or propynyl; R2 is hydrogen; R3 is
R7 is a member selected from the group consisting of hydrogen and alkyl; Rg is a member • 15 selected from the group consisting of arylcarbonyl and heterocyciecarbonyl-; and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is a member selected from the group consisting of alkyl, alkenyl, and alkynyl; R2 is hydrogen; R3 is heterocycle, wherein said 20 heterocycle is
R7 is a member selected from the group consisting of hydrogen and alkyl; Rg is a member selected from the group consisting of aryl, heterocycle; and wherein X is as defined in formula (I). Aryl and heterocycles at the R* position may: beSubstituted with 0,1,2 or 3 25 substituents-independently selected from the group consisting of alkyl, alkoxy, alkoxyalkyl, alkoxyalkenyl, alkanoyl, alkanqyloxy, alkanoyloxyalkyl, alkanoyloxyalkenyl, alkoxycarbonyl,- alkoxycarbonylalkyl, alkoxycarbonylalkenyl, alkylsulfonyl, alkylsulfonylalkyl, alkylsulfonylalkenyl, amino, aminoalkyl, aminoalkenyl, aminosulfonyl, aminosulfonylalkyl, aminosulfonylalkenyl, carboxaldehyde, (carboxaldehyde)alkyl,
WO 2004/026822
PCT/US2003/029018
(carboxaldehyde)alkenyl, carboxamido, carboxamidoalkyl, carboxamidoalkenyl, carboxy, carboxyalkyl, carboxyalkenyl, cyano, cyanoalkyl, cyanoalkenyl, halo, haloalkyl, haloalkenyl, hydroxy, hydroxyalkyl, hydroxyalkenyl, nitro, perfluoroalkyl, perfluoroalkoxy, perfluoroalkoxyalkyl, perfluoroalkoxyalkenyl thioalkoxy, thioalkoxyalkyl, thioalkoxyalkenyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heterocycle.
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Rj is a member selected from the group consisting of alkyl and alkynyl; R2 is hydrogen; R3 is heterocycle, wherein said heterocycle is
R7 is a member selected from the group consisting of hydrogen and alkyl; Rg is a member selected from the group consisting of arylcarbonyl and heterocyclecarbonyl; and wherein X is as defined in formula (T). The aryl group of thearylcarbonyl group of Rg of the compounds of the present invention may optionally substituted with 0,1,2 or 3 substituents independently selected from alkyL-alkoxy, alkoxyalkyl, alkoxyalkenyl, alkanoyl, alkanoyloxy, alkanoyloxyalkyl, alkanoyloxyalkenyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkenyl, alkylsulfonyl, alkylsulfonylalkyl, alkylsulfonylalkenyl, amino, aminoalkyl, aminoalkenyl, aminosulfonyl, aminosulfonylalkyl, aminosulfonylalkenyl, carboxaldehyde, (carboxaldehyde)alkyl, (carboxaldehyde)alkenyl, carboxamido, carboxamidoalkyl, carboxamidoalkenyl, carboxy, carboxyalkyl, carboxyalkenyl, cyano, cyanoalkyl, cyanoalkenyl, halo, haloalkyl, haloalkenyl, hydroxy, hydroxyalkyl, hydroxyalkenyl, nitro, perfluoroalkyl, perfluoroalkoxy, perfluoroalkoxyalkyl, perfluoroalkoxyalkenyl thioalkoxy, thioalkoxyalkyl, thioalkoxyalkenyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heterocycle. The heteroay^le-graup-of-heterocyclecarbonyl may be optionally substituted as described above for the aryl group of thearylcarbonyl group.
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; R\ is a member selected from the group consisting of alkyl and alkynyl; R2 is a member selected from the group consisting of alkyl, cycloalkyl, and heterocycle; R3 is a member selected from the group consisting of aryl-O-alkyl, aryl-NH-alkyl, heterocycle-O-alkyl and heterocycle-NH-alkyl; and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano, Ri is alkynyl, wherein alkynyl is ethynyl or propynyl, R2 is hydrogen; R3 is a member selected from the group consisting of aryl-O-alkyl,
WO 2004/026822
PCTAJS2003/0290I8
aryl-NH-alkyl, heterocycle-O-alkyl and heterocycle-NH-alkyl; and wherein X is as defined in
formula (T).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is a member selected from the group consisting of alkyl and alkynyl; R2 and R3 taken together with the atoms they are attached form a mono or bicyclic heterocycle selected from the group consisting of 3-isoquinoline, 2-pyrrolidinyl, 2-quinolinyl, 2-tetrahydroquinolinyl, and 3-tetrahydroisoqiu^olinyl; and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is alkynyl, wherein alkynyl is ethynyl or propynyl; R2 and R3 taken together with the atoms they are attached form a mono or bicyclic heterocycle selected from the group consisting of 3-isoquinoline, 2-pyrrolidinyl, 2-quinolinyl, 2-tetrahydroquinolinyl, and 3-tetrahydroisoqimolinyl; and wherein X is as defined in formula
(D-
According to a further embodiment of the present invention there is provided a
compound of formula (I), wherein R is cyano; Ri is a member selected from the group
consisting of alkyl, alkenyl, alkynyl; R2 and R3 taken together with the atoms theyare
attached form 3-isoquinolinyl, and wherein X is as defined in formula (I).
According to a further embodiment of the present invention there is provided a
compound.of formula (I), wherein R is cyano; Ri is a member selected from the group
consisting of alkyl and alkynyl; R2 is hydrogen; R$ is Rp-O-cycloalkyl, wherein said R9-O-
cycloalkyl is
R7 is a member selected from the group consisting of hydrogen and alkyl; R9 is a member 25 selected from the group consisting of hydrogen, aryl, pyridine, and pyrimidine; and wherein X is as defined in formula (I). The aryl group or pyridyl group of R9 may be optionally substituted with 0,1,2 or 3 substituents independently selected from alkyl, alkoxy, alkoxyalkyl, alkoxyalkenyl, alkanoyl, alkanoyloxy, alkanoyloxyalkyl, alkanoyloxyalkenyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkenyl, alkylsulfonyl, 30 alkylsulfonylalkyl, alkylsulfonylalkenyl, amino, ammo^kyJ^minoalkenyl, arninosulfonyl, . aminosulfonylalkyl, aminosulfonylalkenyl, carboxaldehyde, (carboxaldehyde)alkyl, (carboxaldehyde)alkenyl, carboxamido, carboxamidoalkyl,-carboxamidoalkenyl, carboxy, carboxyalkyl, carboxyalkenyl, cyano, cyanoalkyl, cyanoalkenyl, halo, haloalkyl, haloalkenyl, hydroxy, hydroxyalkyl, hydroxyalkenyl, nitro, perfluoroalkyl, perfluoroalkoxy,
14
WO 2004/026822
PCT/US2003/02Q018
perfluoroaikoxyalkyl, perfluoroalkoxyalkenyl thioalkoxy, thioalkoxyalkyl, thioalkoxyalkenyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heterocycle.
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Rj is a member selected from the group consisting of alkyl, alkenyl, alkynyl; R2 is hydrogen; R3 is a member selected from the group consisting of arylalkyl and heterocyclealkyl; and wherein X is as defined in formula (J). The aryl group of arylalkyl of and the heterocycle of heterocyclealkyl of R3 is optionally substituted with 0,1,2or 3 substituents independently selected from alkyl, alkoxy, alkoxyalkyl, alkoxyalkenyl, alkanoyl, alkanoyloxy, alkanoyloxyalkyl, alkanoyloxyalkenyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkenyl, alkylsulfonyl, alkylsulfonylalkyl, alkylsulfonylalkenyl, amino, aminoalkyl, aminoalkenyl, arninosulfonyl, aminosulfonylalkyl, aminosulfonylalkenyl, carboxaldehyde, (carboxaldehyde)alkyl, (carboxaldehyde)alkenyl, carboxamido, carboxamidoalkyl, carboxamidoalkenyl, carboxy, carboxyalkyl, carboxyalkenyl, cyano, cyanoalkyl, cyanoalkenyl, halo, haloalkyl, haloalkenyl, hydroxy, hydroxyalkyl, hydroxyalkenyl, nitro, perfluoroalkyl, perfluoroalkoxy, perfluoroaikoxyalkyl, perfluoroalkoxyalkenyl thioalkoxy, thioalkoxyalkyl, thioalkoxyalkenyl, unsubstituted or "substituted aryl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heterocycle. In one particular embodiment of the present invention the heterocycle of heterocyclealkyl is pyridine.
According to a further embodiment of the present invention there is provided a compound of formula (f), wherein R is cyano; Rj is a member selected from the group consisting of alkyl and alkynyl; R2 ishydrogen; R3 is a member selected from the group consisting of arylNHalkyl-, aryl-O-alkyl-, heterocycleNHalkyl- and heterocycle-O-alkyl-; and wherein X is as defined in formula (I). The aryl group of arylNHalkyl- and aryl-O-alkyl-and the heterocycle of heterocycleNHalkyl- and heterocycle-O-alkyl- of R3 is optionally substituted with 0,1,2 or substituents independently selected from alkyl, alkoxy, alkoxyalkyl, alkoxyalkenyl, alkanoyl, alkanoyloxy, alkanoyloxyalkyl,^dkanoyloxyalkenyli alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkenyl," alkylsulfonyl, alkylsulfonylalkyl, alkylsulfonylalkenyl, amino, aminoalkyl, aminoalkenyl, arninosulfonyl, aminosulfonylalkyl, aminosulfonylalkenyl, carboxaldehyde, (carboxaldehyde)alkyl, (carboxaldehyde)alkenyl, carboxamido, carboxamidoalkyl, carboxamidoalkenyl, carboxy, carboxyalkyl, carboxyalkenyl, cyano, cyanoalkyl, cyanoalkenyl, halo, haloalkyl, haloalkenyl, hydroxyrhydroxyalkyl, hydroxyalkenyl, nitro, perfluoroalkyl, perfluoroalkoxy, perfluoroaikoxyalkyl, perfluoroalkoxyalkenyl thioalkoxy, thioalkoxyalkyl, thioalkoxyalkenyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heterocycle.
According to a further embodiment of the present invention there is provided a
WO 2004/026822
PCT7US2003/029018
compound of formula (I), wherein R is cyano; Rj is a member selected from the group consisting of alkyl and alkynyl; R2 is hydrogen; R3 is alkyl; and wherein X is as defined in formula (I). In one particular embodiment of the present invention, the alkyl group of R3 is substituted with 0,1,2or 3 substituents independently selected from alkoxy, alkoxyailkyl, alkoxyalkenyl, alkanoyl, alkanoyloxy, alkanoyloxyalkenyl, alkoxycarbonyl, alkoxycarbonylalkenyl, alkylsulfonyl, alkylsulfonylalkenyl, amino, aminoalkenyl, arriinosulfonyl, aminosulfonylalkenyl, carboxaldehyde, (carboxaldehyde)alkenyl, carboxamido, carboxamidoalkenyl, carboxy, carboxyalkenyl, cyano, cyanoalkenyl, halo, haloalkenyl, hydroxy, hydroxyalkenyl, nitro, perfluoroalkyl, perfluoroalkoxy, perfluoroalkoxyalkenyl thioalkoxy, thioalkoxyalkenyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heterocycle.
According to a further embodiment of the present invention there is provided a compound of formula (I), wherein R is cyano; Ri is a member selected from the group consisting of alkyl, alkenyl, and alkynyl; R2 is hydrogen; R3 is a member selected from the group consisting of bicycloalkyl, cycloalkyl, heterocycle and tricycloalkyl; and wherein X is as defined in formula (1). The bicycloalkyl, cycloalkyl, heterocycle or tricycloalkyl of Rj of the present invention may be optionally substituted with 0,1,2 or 3 substituents independently selected from alkoxy, alkoxyalkyl, alkoxyalkenyl, alkanoyl, alkanoyloxy, alkanoyloxyalkenyl, alkoxycarbonyl, alkoxycarbonylalkenyl, alkylsulfonyl, alkylsulfonylalkenyl, amino, aminoalkenyL aminosulfonyl, aminosulfonylalkenyl, carboxaldehyde, (carboxaldehyde)alkenyl, carboxamido, carboxamidoalkenyl, carboxy, carboxyalkenyl, cyano, cyanoalkenyl, halo, haloalkenyl, hydroxy, hydroxyalkenyl, nitro, perfluoroalkyl, perfluoroalkoxy, perfluoroalkoxyalkenyl thioalkoxy, thioalkoxyalkenyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heterocycle. Specific compounds of the present invention include, but are not limited to:
(2S,5R)-5^%nyl-l-L4eucylpyrrolidine-2-carbonitrile;
(2S,SR>5-ethynyl-H(3S)-l ,2,3,4-tetrahydroisoquinolin-3-ylcarbonyl)pyrrolidine-2-carbonitrile;
(2S,5RH^(2S)-2-animo-2^yclopentylethanoyl)-5^myny^ (2S,5R)-l^(2S)-2-amino-2K;yclopentylethanoyl)-5-vinylpyrrolidine-2-carbonitrile;
(2S,5RH-((2S)-2-ammo-2^yciohexyle&anoyI)-5^&ynyl^^ (2S3s>5^myi-i-L-leucylpyrroUdine-2-carbonitrite;
(2S,5S)-1 ^(2S)-2-amino~2^yclohexylemanoyl)-5^mylpyrroUdine-2-riitrile; (2S,5R>l-{N-((lR,2R,4S)-bicyclo(2^.1)hept-2-yI)glycyl}-5-ethynyIpyrrolidine-2-carbonitrile;
(2S,5S)-l-L-leucyl-5-methylpyrrolidine-2-carbonitrile; (2S,5R)-5-emynyI-l-(N-(4-memyl-l-pyridm-2-ylpiperidjn-4-yl)glycyl)pyrrolidine-2-
WO 2004/026822
PCT/US2003/029038
carbonitrile;
(25,5^)-5-ethynyl-1 -(//-(4-methy 1-1 -(3 -cyano-pyridin-2-yl)piperidin-4-yl)glycyl)pyrrolidine-2-carbonitrile;
(2S,5i?)-5-ethynyl-l-(A^-(l-(3^yano-pyridinO-yl)piperidin-4-yl)glycyl)pyrrol.idine-2-carbonitrile;
(2S',5if)-5-ethynyl-1 - {N-(4-methyl-1 -(4-methoxycarbonylbenzoyl)piperidin-4-yl)glycyl} pyrrolidine-2-carbonitrile;
(25,5i?)-5-ethynyl-l-{AT-(4-methyl-l-(4-carboxy-pyridin-2-yl)piperidin-4-yl)gIycyl}pyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l^-{4-me%14-(5-(trifluoromethyl)pyridiii-2-yl)piperidin-4-y 1} glycy l)pyrrolidine-2-caibonitrile;
(2S,5R)4-{N-(1^4-chlorobenzoyl)piperidin^yI)glycyl}-5^tliynylpyrrolidine-2-carbonitrile;
(2S,5R)-l-{N-(l-(5^Woropyridin-2-yl)^me%lpiperidin-4-yl)glycyl}-5-ethynylpyrrolidine-2-carbonitrile;
(2Ss5R)-5-ethynyl-l^-(l-pyridin-2-ylpiperidin-4-yl)glycyl)pynolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-1 -(N- {4-methyl-1 ^4-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl} glycyl)pynolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-1 -(N-( 1 -isonic»tinoyl^methylpiperidin-4-yl)glycyl)pyrrolidine-2-carbonitrile;
(25,5/?)-5-ethynyl-l-(A^(4-methyl-l-(5-carboxy-pyrid^n-2-yl)piperidin-4-yl)glycyl)pynolidine-2-carbonitrile;
(25,5i?)-5-ethynyl-l-(iV-(4-methyl-l-(5-cyano-pyridin-3-yI)piperidin-4-yl)gIycyl)pyrrolidine-2-carbonitriIe;
(2S,5R)-5-ethynyl-l-(N-trans(4-hydroxycyclohexyl)glycyl)pyirolidine-2-carbonitrile;
(2S,5R>5-ethynyl-l-(N-(4-trans{(4'-fluoro-5-{trifluoromethyI)-l,l,-biphenyl-2-yl)oxy } cyclohexyl)glycyl)pynX)Jidine-2=carbonitriIe;
(2S,5R)-5-ethynyI-l-(N-{4- trans (4-(trifluorometIioxy)phenoxy)cycIohexyl}glycyl)pyrroIidine-2-carbomtrilc;
(2S,5R)-5-ethynyl-l-(N-(4-hydroxy-l-methylcycIohexyl)glycyl)pyrrolidine-2-carbonitrile;
(2S,5R>5-ethynyl-l-{N-(l-methyl-4- trans (pyridin-3-yloxy)cyclohexyl)glycyl}pyrroIidine-2-carbonitriIe;
(2S,5R>l-(N-{4- trans ((5-chloropyridin-3-yl)oxy)cyclohexyl}glycyl)-5-ethynyIpyrrolidine-2-carbonitrile;
(2S,5R)-1 - {N-(4- trans (4-cyanophenoxy)cyclohexy l)glycyl} -5-ethynylpyrrolidine-2-carbonitrile;
WO 2004/026822
PCT7US2003/0290U
(2S,5R)-5-ethynyl-l-(N-(4- trans {(5-(trifluoromethyl)pyridin-2-yI)oxy}cyclohexyl)gIycyl)pyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l-(N-{4- trans (3-pyridin-4-yl-4-(trifluoromethyI)phenoxy)cyclohexyl}glycyl)pyiroIidine-2-(^boriitrile;
(2S,5R)-5-ethynyl-l - {N-(4- trans (pyridin-2-yloxy)cyclohexyl)glycyl}pyrrolidine-2-
carbonitrile;
(2S,5iJ)-5-ethynyl-l-{iV-(l-methyl-4- trans (5-cyano-pyridin-2-yloxy)cyclohexyl)glycyl}pyrroHdine-2-carbonitrile;
(2S,5R)-5-ethynyM-{N-(4- trans (pyrimidin-2-yloxy)cycIohexyl)glycyl}pyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l~{N-{4~ trans (5-cyano-pyridin-2-yloxy)cyclohexyl)glycyl}pyirolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l-(N-{4 trans -(4-(tiifluoromethyl)phenoxy)cyclohexyl}glycyl)pyiToUdine-2-
(2S,5R)-5-ethynyl-l-(N-{4-((5-fluoropyridin-3-yl)oxy)-l-methylcyclohexyL}glycyl)pyrroHdine-2-carbonitrile;
(2S,5R)-5-eth.ynyl~l-(N-(4- trans (4-carboxy-phenoxy)cyclohexyl)glycyl)pyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l-(N-{4-(2-(2-oxopynoUdin-l-ylH-trans (trifluoromethyl)phenoxy)cyclohexyl}glycyl)pyiroUdine-2-carbonitrile;
(2S,5R)4-{N-(4-{4-cyano-2-metlioxyphenoxy)cyclohexyl)glycyl}-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R>l-(N-{4- trans ((S-chloropyridm^-yl^xyXyclohexyllglycyl)^-ethynylpyrrolidine-2-carbonitrilc;
(2S,5R)-5-ethynyl-l-{N-(l-methyl-4- trans (pyridin-2-yloxy)cyclohexyl)glycyl}pyrrolidine-2-carbonitriIe;
(2S;5R>5-ethynyl-l-(N-{4- trans ((5-fluoropyridin-3-yl)oxy)cyclohexyl}glycyI)pyrrolidine-2-carbonitrile;
(2S,5R)-l-(N-{4- trans ((5-bromopyridin-2-yl)oxy)cyclohexyl}gIycyl)-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l-{N-(4- trans (pyridin-3-yloxy)cycIohexyI)glycyl}pyrroIidine-2-carbonitrile;
(2S,5R)-5^thynyI-lKN^lJ,33-tetomethylbutyI)gIycyI)pyrroUdine-2^^rx)daTle;
(25,5J?)-l-{Ar-(l,l^methyl-2-(5-cyano-pyridin-2-yloxy)ethyl)glycyl}-5-ethynylpyrrolidine-2-carbonitrile;
(2S.5R)- I -(N-(tert-butyl)glycyl)-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R>l-{N-(ljKlimethyl-2-(quinolin-4-ylamino)ethyl)glycyl}-5-ethynylpyrrolidine-2-carbonitrile;
WO 2004/026822
PCTAJS2003/029018
(2S,5R)-5-ethynyl-1 -(N-(2-(4-fluorophenyl)-1,1 -dimethylethyl)glycyl} pyrrolidine-2-carbonitrile;
(2S,5R)-l-(N-(l,l-dimethylpropyl)glycyl)-5-ethynylpyn:oUdine-2-carbonitriIe;
(2S,5R)-l-{N-(2-(lJ3-benzothlazoI-2-ylamino)-l)l-diinethylethyl)glycyl}-5-ethynylpyirolidhe-2-carbonitrile;
(2S,5R)-l-{N-((lR,4S)-bicyclo(2.2.1)hept-2-yl)glycyl}-5-ethynylpyirolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l-((3S)-l,2,3,4-tetrahydroisoquinolin-3-ylcarbonyl)pyrrolidine-2-carbonitrile;
(2S,5R)-l-(N-l-adamantylglycyl)-5^thynylpyrrolidine-2-carbonitrile;
(2S,5R)-l-(N-cyc\ohexylgtycyl)-5^&y^
(2SJ5R)-5^
(2S,5R)-5^thynyM^-tetrahydro-2H-pyran^ylgty^
(2S,5R)-5-ethynyl-l-{N-((2S>2-hydroxycyclopentyI)glycyl}pyrrolidine-2-carbonitrile;
(2S,5R)-1 ^-cyclopentylglycyl)-5^thynylpynx>Udine-2-carboiiitrile;
(2S,5R)-5^1hynyl-l-{N-(l^ydroxymethyI)cyclopentyl)glycyl}pynoIidine-2-carbonitrile;
(2S,5R)-5-etb.ynyl-l-L-leucylpyirolidine-2-carbonitrile;
(2S,5R)-l-((2S)-2-amino-2K^clopentylethanoyl)-5^thynylpyrroUdine-2-carbonitrile;
(2S,5R)-l-((2R)-2-amino-2K;yclohexylethanoyl)-5^thynylpyiroUdine-2-c^bonitrile;
(2S,5S)-l-((2S)-2-amincH2^yclopentylethanoyl)-5-methylpyrrolidme-2-cai^boratrile;
(2SJ5R)-l-((2S)-2-amino-2-cyclopentylethanoyl)-5-prop-l-ynylpyrrolidine-2-carbonitrile;
(2S,5R)-5-prop-l -ynyl-l-(N-{4-(4-(trifluoromethyljphenoxyjcyclohexyljglycyljpyrrolidine^-^carbonitrile;
(2S,5R)-l-{N^l^ydroxymethyl)cyclopentyl)gly_cyl}^^^ carbonitrile;
(2S,5R)-l-(N-cycIopentyIgIycyl)-5-prop-l-ynylpyrrblidine-2-carbonitriIe;
(2S,5S)-l-(N-cyclopenty!gIycyl)-5-raethylpyrroIidine-2
(2S,5S)-4,4-difluoro-5-methyl-l-L-valylpyrroIidine-2-carbonitrile;
(2S,5S)-l-{N-(I-(hydroxymethyI)cycIopentyl)glycyl}-5-methylpyiTolidine-2-carbonitrile;
(2S,5S)-4,4-difluoro-l'L-leucyl-5-methylpyrrolidine-2-carbonitrile;
(2S,5R)-H(2S)-2-amino-2-cyclohexylethanoyI)-5-vinylpyrrolidine-2-carbonitrile;
(2S,5R)-l-((2R)-2-amino-2-cyclopeatylethanoyl)-5-vinyIpyrrolidine-2-carbonitrile;
(2S,5S)-l-{N
19
WO 2004/026822
PCT/US2003/029018
methylpyrrolidine-2-carbonitrile;
(25J5i?)-5-e%nyl-l-(A'-(l-tert-butoxycarbonyl-piperidin-4-yl)glycyl)pyrrolidine-2-
carbonitriie;
(25',5i?)-5-ethynyl-l-(M
carbonitrile;
(2S,5R)-l-{N-(l-(4-chlorobenzoyl)-4-methylpiperidin-4-yl)glycyl}-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-l-{N-(l-(3-cyanophenyl)-4-inethylpiperidin-4-yl)glycyl}-5-ethynylpyrrolidine-2-carbonitrile;
(2S55R>l-{N-(l-(4-cyanoben2oyl)-4-methylpiperidiii-4-yl)glycyl}-5- ' ethynylpyirolidine-2-carbonitrile;
N-(l-(3^Uorophenyl)-lH-indol-5-yl)-5-methyl-3-phenyUsoxazoIe^-K;arboxamide;
(2S;5R)-l-{N-(l-(4-biomobenzoyl)-4-methylpiperidin-4-yl)glycyl}-5-ethynylpyirolidine-2-carbonitrile;
(2S,5R>5^tliynyl-l-(N-{4-me%l-l
(2S?5R)-l-{N-(4- trans (4-cyano-2-fluorophaioxy)cyclohe3£yl)glycyl}-5-
ethynylpyrrolidine-2-carbonitrile; . -
(2S,5R)-5-ethynyl-l-{N-(4- trans (3-fluorophenoxy)-l-methylcyclohexyl)glycyl}pyrrolidine--2-carbonitrile;
(2S,5R)-l-{N-(4- trans (3^yanopheno3^)cyclohexyl)glycyl}-5-e1iiynylpyrrolidine-2-carbonitrile;
(2S,5R)-5^thynyl-l^
(2S,5R)-l-(N-{4- trans ((5-chloropyridin-2-yl)oxy)cyclohexyl}glycyl)-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l-(N-(4- trans {(4'-fluoro-2-(trifluoromethyl)-l,l,-biphenyl-*-yl)oxy}cycIohexyl)glycyl)pyrrolidhie-2-carbonitrile;
(2S,5R)-5-ethynyI-l-(N-(4- trans {(^fluoro-^-Ctrifluorometiiyl^l.l'-biphenyl-S-yI)oxy}cycIohexyl)glycyl)pyrrolidine-2-carbonitrile;
(2S,5R)-I-(N-{4-(3-cyano-4- trans (trifluoromethy0phenoxy)cyclohexyl}glycyf>5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-l-{N-(4- trans (3-bromophenoxy)cyclohexyl)glycyl}-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-l-{N-(4- trans (4-cyano-3-fluorophenoxy)cyclohexyl)glycyl}-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-l-(N-{4-(2-cyano-4- trans (trifluoromethyl)phenoxy)cyclohexyl}glycyl)-5-ethynyIpyrroIidine-2-carbonitriIe;
WO 2004/026822
PCT/US2003/029018
(2S,5R)-1 -{N-(4- trans (3-cyanophenoxy)-1 -methylcyclohexyl)giycyl}-5-ethynylpyrrolidine-2-carbonitrile;
(2S55R)-l-{N-(4-trans (4-chlorophenoxy)cyclohexyl)gIycyl}-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l-(N-(4- trans {(6-methyl-4-(trifluoromethyl)pyridin-2-yl)oxy}cyclohexyl)glycyI)pyrrolidine-2-carbonitrile;
(2S,5R)-l-(N-{4- trans (2-cyano-3-(trifluoromethyl)phenoxy)cyclohexyl}glycyl)-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l-(N-{4- trans (4-pyridin-4-yl-3-(Mfluoromethyl)phenoxy)cyclohexyl}glycyl)pyrroUdine-2-carrx)Ditrile;
(2S,5R>l-(N-{4^3^yano-5-(trifluoromethyl)phenoxy)cyclohexyl}glycyl)-5-eihynylpyrroIidine-2-carbonitrile;
(2S,5R)-5-etbynyl-l-{N-(4-(4-fluorophenoxy)-l-methylcyclohexyl)glycyl}pyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l-{N-(4-(3-fluorophenoxy>l-metb.ylcyclohexyl)glycyl}pyrrolidine-2-carbonitrile;
(2S,5R)-5^thynyl-l^
(2S,5R)-5-ethynyl-l-(N-{4-trans (3-(trifluorome1iyl)phenoxy)cyclohexyl}glycyl)pyrroUdine-2Karbonitrile;
(2S,5R)-l-(N-{4- trans ((3-bromopyridin-2-yl)oxy)cyclohexyl}glycyl)-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l-(N-(4- trans {(4
(2S,5R)-l-(N-{4- trans ((5-chloropyridin-2-yl)oxy)-l-methylcyclohexyl}glycyl)-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-l-{N-(4- trans (3-cyanophenoxy)-l-methylcyclohexyl)glycyl}-5-ethynyIpyrrolidine-2-carbonitrile;
(25,5/?)-5-ethynyl-l -(//-{4-(2-carboxy^- trans (trifluoromethyl)phenoxy)cyclohexyl}glycyl)pyrrolidine-2-K^rbonitrile;,
(2S,5R)-l-{N-(4-trans (3-chlorophenoxy)cycIohexyl)glycyl}-5-ethynylpyn:ortdine-2-carbonitrile;
(2S,5R)-5-ethynyI-l-(N-(l-methyl-4- trans {(5-(trifluoromeuiyI)pyridin-2-yl)oxy}cyclohexyl)gIycyI)pyrrolidine-2-carbonitrile;
(2S,5R)-1 - {N-(4- trans (4-bromophenoxy)cyclohexyl)glycyl} -5-ethynylpyrrolidine-2-carbonitrile;
(25,5/?)-l-(AT-{lJ-dimethyl-2-((3-cyano-6-methylpyria^-2-yl)arnino)ethyl}glycyl^ ethynylpyrrolidine-2-carbonitrile;
WO 2004/026S22
PCT/TJS2003/029018
(2SJ5R)4-(NKlJl-dimethyl-2-{(5-(trifluorometliyl)pyridixi-2-yl)oxy}ethyl)glycyl)-5--ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-1 -(/V- {1,1 -dimethyl-2-((3-cyano-6-methylpyridin-2-yl)oxy)ethyl} glycyl)-5-ethynylpyrTolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l^-(tetrahydrofurai)-2-ylmethyl)glycyl)pyrrolidine-2-
carbonitrile;
(2S,5R)-5-ethynyl-l^^yridin-2-ylmethyl)glycyl)pyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l^-(2-pyridin^yletliyl)glycyl)pyrroUdine-2H;arbonitrile;
(2iS,5i?)-5-ethynyl-l-{Ar-((l-tert-butoxycaibonylpiperidin-4-yl)methyl)glycyl}pyrrolidine-2-carbonitrile;
(2SJ5R)-5^thynyl-l-{N-(3-(me^ylamino)propyl)glycyl}pyrrolidine-2-carbonitrile;
(2S,5i?)-l-(//-(4-te^butoxycarbony^^
(2S,5R)-5^thynyl-1^^3-hydroxy-2^-dimethylpropyl)glycyl)pyrrolidine-2-carborutrile;
(2S,5R)-l -{N-(l, 1 Kiimethyl-2
(2S,5R)-1-(N-(1 J-dimethyl-2-{(4^timuorDmethyl)pyrimidin-2-yl)amino}ethyl)glycyl)-5^thynylpyrrolidine-2-carboni1rile;
(2S,5£)4-{N-(l,l-dimethyl-2^5-metJioxy
(2S,5R)-l-{N-(2-(2-cyano-5-fluorophenoxy)-l,l-dimethylethyl)glycyl}-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-5^1hynyl-1^^4-iodobenzyl)glycyl)pyrrolidiiie-2-carbonitrile;
(25',5/?)-5-ethynyl-l-{7/-(3-(N-tert-butoxycarbonyl-N-methylamino)propyI)glycyl}pyrrolidine-2-carbonitrile;
(25,5J?)-5-ethynyl-l-(A^-(4-
(2S,5R)-l-{N-(2-{(3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino}ethyl)glycyl)-5-ethynylpyrrolidine-2-carbonitriie;
(2S,5R)-5^thynyl-1^^3-isopropoxypropyl)glycyl)pyrrolidine-2-carbonitrile;
(2S,5R)-\ -{N-(\, l-dimethyl-2-(5-cyano-pyridin-2-ylamino)ethyl)glycyl}-5-ethynylpyirolidine-2-carbonitrile;
(25,5/?)-1 -(N-(2-(4-carboxy-anilino)-1,1 -dimethylethyl)glycyI)-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-5^thynyl-l-{N-(l-{l-hydroxy-l-methylethyl)cyclopentyl)gIycyl}pyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-l-{N-((2R)5S)-hexahydro-2,5-methanopentalen-3a(lH)-yl)glycyl} pyirolidine-2-carbonitrile;
(25,5/f)-l-(iV-cycIopentylglycyl-(N- methyl l-aminocyclopentanecarboxy)-5-
WO 2004/026S7.2
PCT/US2003/029018
ylpyrrolidine-2-carbonitriIe;
(2S,5R)-l-(N-cyclopropylglycyl)-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-5-ethynyl-1 "(N-piperidin-4-ylglycyl)pyrroHdine-2-carbonitrUe;
(2S,5R)-5-ethynyl-l-{N-((5R,7S)-3-hydrox7-l-adamantyl)glycyl}pyrrolidine-2-nitrile;
(2S35R)-5-ethynyl-l-(N4etrahydrofuran-3-ylglycyl)pyrToUdine-2-carbonitrile;
(2SJ5R)-l-(N-cyclobeptylglycyl)-5-ethynylpyrrolidine-2-carbonitrile;
(2S,5R)-l-(N
(2S,5R)-5^thynyl-H3-methyl-L-valyl)pyrrolidijQe-2-caibonitrile;
(2S,5R)-5^1hynyi-H3-pyridin^-yl-L-alanyl)pyirolidine-2-carbonitrile;
(2S,5R)-l-Weucyl-5-ptop-l-ynylpyrroIidine-2-caiboiutrile;
(2S,5R)-l-(3-methyl-L-valyl)-5-prop-l-ynylpyirolidine-2-carbonitiile;
(2S,5R)4^^yclobutylglycyl)-5-prop-l-ynylpynxiUdine-2Kiart>onitrile;
(2S,5R)-1 -(N-(4- trans hydroxycyclohexyl)glycyl)-5-prop-1 -ynylpyrrolidine-2-initrile;
(2S35R)-l-{N-((2S)-2-hydroxycyclopentyl)glycyl}-5-prop-l-ynylpyrrolidiiie-2-•nitrile;
(2SJ5S)-5-me%14-{N-((lSJ2S,3SJ5R)-2,6J6-trimethylbicyclo(3.1.1)hept-3-('cyl}pyrrolidine-2-carbonitrile;
(2S,5S)-l- {N-((5R,7S)-3-hydroxy-1 -adamantyl)glycyl}-5-methylpyiTolidine-2->nitrile;
(2S,5S)-l-{N-(2-(3,4-dimethoxyphenyl)ethyI)glycyl}-5-methylpyirolidirie-2->nitrile;
(2S,5S)4,4Kiifluoro-5-methyl-l
(2S,5S)-1 -(N-isopropylglycyl)-5-methylpyrrolidine-2-carbonitrile;
(2S,5S)-l-L-isoleucyl-5-methylpyrrolidine-2-carbonitrile;
(2S',55)-5-raethyI-1 - { AK2^5^yancHpyridin-2-ylamino)ethyl)glycy 1} pyrrolidine-2-mitrile;
(2S ,5 S)-5-methyl-1 -((3S)-1,2,3 ^-tetrahydroisoquinolin-S-ylcarbonylJpyrrolidine^->nitrile;
(2S,5S)-1 -{3-cyclopropyl-L-alanyl)-5-methylpynoIidine-2-carbonitrile;
(2S,5S)-5-methyI-1 -D-proIyIpyrrolidine-2-carbonitrile;
(2S,5S)-l-(N-2,3^hydro-lH-inden-l-yIglycyl)-5-methylpyrroIidine-2-carbonitrile;
(2S,5S)-5-methyl-l-L-valylpyrrolidine-2-carbonitrile;
(2S,5S)-5-methyl-l-(4-methyl-L-leucyl)pyrTOlidine-2-carbonitrile;
(2S,5S)-l-(N-(4- trans hydroxycycIohexyI)glycyl)-5-methylpyiroIidine-2-carbonitrile;
(2S,5S)-l-(N-(tert-butyl)glycyI)-5-methylpyrrolidine-2-carbonitriIe;
(2S,5S)-5-methyl-H(5S)-5-methyl-L-prolyl)pytroUdine-2-K^xbQrutrUe;aad
WO 2004/026822
PCT/US7003/029018
(2S,5S)-1 -(3-cyclohexyl-L-alanyl)-5-methylpyrrolidine-2-carbonitrile.
The present compounds can exist as therapeutically acceptable salts. The term "therapeutically acceptable salt," refers to salts or zwitterions of the compounds which are water or oil-soluble or dispersible, suitable for treatment of disorders without undue toxicity, irritation, and allergic response, commensurate with a reasonable benefit/risk ratio, and effective for their intended use. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group of the compounds with a suitable acid. Representative salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, isethionate, fumarate, lactate, maleate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, oxalate, maleate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, glutamate, para-toluenesulfonate,_undecanoate, hydrochloric, hydrobromic, sulfuric, phosphoric, and the like. The amino groups of the compounds can also be quaternized with alkyl chlorides, bromides, and iodides such as methyl, ethyl, propyl, isopropyl, butyl, lauryl, myristyl, stearyL and the like. The present invention contemplates pharmaceutically acceptable salts formed at the nitrogen of formula (I) to which R3 is attached".
Basic addition salts can be prepared during the final isolation and purification of the present compounds by reaction of a carboxyl group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation such as lithium, sodium, potassium, calcium, magnesium, or aluminum, or anorganic primary, secondary, or tertiary amine. Quaternary amine salts derived from methylamine, dimethylamine, trimemylamine, triethylamine, diethylamine, ethylamine, tributlyamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N- . dibenzylphenethylamine, 1-ephenamine, and N.N'-dibenzylemylenediamine, ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine, and the like, are contemplated as being within the scope of the present invention.
The present compounds can also exist as therapeutically acceptable prodrugs. The term "therapeutically acceptable prodrug," refers to those prodrugs or zwitterions which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use. The term "prodrug," refers to compounds that are rapidly transformed in vivo to the parent compounds of formula (I) for_example, by hydrolysis in blood.
Asymmetric centers can exist in the present compounds. Individual stereoisomers of the compounds are prepared by synthesis from chiral starting materials or by preparation of racemic mixtures and separation by conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, or direct separation of the
WO 2004/026822
PCT/US2003/029018
enantiomers on chiral chromatographic columns. Starting materials of particular stereochemistry are either commercially available or are made by the methods described hereinbelow and resolved by techniques well-known in the art.
Geometric isomers can exist in the present compounds. The invention contemplates the various geometric isomers and mixtures thereof resulting from the disposal of substituents around a carbon-carbon double bond, a cycloalkyl group, or a heterocycloalkyl group. Substituents around a carbon-carbon double bond are designated as being of Z or E configuration and substituents around a cycloalkyl or heterocycloalkyl are designated as being of cis or trans configuration.
Therapeutic compositions of the present compounds comprise an effective amount of the same formulated with one or more therapeutically acceptable excipients. The term "therapeutically acceptable excipient," as used herein, represents a non-toxic, solid, semi¬solid or liquid filler, diluent, encapsulating material, or formulation auxiliary of any type. Examples of therapeutically acceptablenexcipients include sugars; cellulose and derivatives thereof; oils; glycols; solutions; buffering, coloring, releasing, coating,_sweetening, flavoring, and perfuming agents; and the like. These therapeutic compositions can be administered parenterally, intracistemally, orally, rectally, or intraperitoneally.
Liquid dosage forms for oral administration of the present compounds comprise formulations of the same as emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the compounds, the liquid dosage forms can contain diluents and/or solubilizing or emulsifying agents. Besides inert diluents, the oral compositions can include wetting, emulsifying, sweetening, flavoring, and perfuming agents. Injectable preparations of the present compounds comprise sterile, injectable, aqueous and oleaginous solutions, suspensions or emulsions, any of which can be optionally formulated with parenterally acceptable diluents, dispersing, wetting, or suspending agents. These injectable preparations can be sterilized by filtration through a bacterial-retaining filter or formulated with sterilizing agents that dissolyeor disperse in the injectable media.
Inhibition of DPP-IV by the compounds of the-present invention can be delayed-by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compounds depends upon their rate of dissolution which, in turn, depends on their crystallinity. Delayed absorption of a parenterally administered compound can be accomplished by dissolving or suspending the compound in oil. Injectable depot forms of the compounds can also be prepared by microencapsulating the same in biodegradable polymers. Depending upon the ratio of compound to polymer and the nature of the polymer employed, the rate of release can be controlled. Depot injectable formulations are also prepared by entrapping the compounds in liposomes or microemulsions that are compatible with body tissues.
Solid dosage forms for oral administration of the present compounds include capsules,
WO 2004/026822
PCT/US2003/029018
tablets, pills, powders, and granules. In such forms, the compound is mixed with at least one inert, therapeutically acceptable excipient such as a carrier, filler, extender, disintegrating agent, solution retarding agent, wetting agent, absorbent, or lubricant. With capsules, tablets, and pills, the excipient can also contain buffering agents. Suppositories for rectal administration can be prepared by mixing the compounds with a suitable non-irritating excipient which is solid at ordinary temperature but fluid in the rectum.
The present compounds can be micro-encapsulated with one or more of the excipients discussed previously. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric^nd release-controlling. In these forms, the compounds can be mixed with at least one inert diluent and can optionally comprise tableting lubricants and aids. Capsules can also optionally contain opacifying agents that delay release of the compounds in a desired part of the intestinal tract
Transdermal patches have the added advantage of providing controlled delivery of the present compounds to the body. Such dosage forms are prepared by dissolving or dispensing the compounds in the proper medium. Absorption enhancers can also be used to increase the flux of the compounds across the skin, and the rate of absorption can be controlled by providing a rate controlling membrane or by dispersing the compounds in a polymer matrix or gel.
Disorders that can be treated or prevented in a patient by administering to the patient, a therapeutically effective amount of compound of the present invention in such an amount and for such time as is necessary to achieve the desired result The term "therapeutically effective, amount," refers to a sufficient amount of a compound of formula Q) to effectively ameliorate disorders by inhibiting DPP-IV at a reasonable benefit/risk ratio applicable to any medical treatment The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the compound employed; the specific_composition-employed; the age, body weight, general health, sex, and diet of the patient; the time of adjnirustration, route of ad^ninistration, rate of excretion; the duration of the treatment; and drugsjised in combination or coincidental therapy.
The total daily dose of the compounds of the present invention necessary to inhibit the action of DPP-IV in single or divided doses can be in amounts, for example, from about 0.01 mg/kg/day to about 50 mg/kg/day body weight In a more preferred range, compounds, of the present invention inhibit the action of DPP-IV in a single or divided doses from about 0.1 mg/kg/day to about 25 mg/kg/day body weight Single dose compositions can contain such amounts or multiple doses thereof of the compounds of the present invention to make up the daily dose. In general, treatment regimens comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compounds per day in single or multiple doses.
WO 2004/026822
PCT/US2003/029018
Biological Data
Isolation of rat DPP-IV
DPP-IV was purified to homogeneity (electrophoretic) from rat kidney as described in Arch, Biochem. Biophy. 1995,323,148-154. Rat kidney (120 g) was homogenized in 4 volumes of water and the homogenate centrifuged for 15 minutes at lOOOg. The pH of the supernatant was adjusted to 3.9 with 1A/HC1 and the enzyme solubilized by autolysis for 18 hours at 37 °C. The pH of the supernatant collected after centrifugation was adjusted to 7.2 with LWTrizma base and the enzyme was precipitated with (NH^SC^ at 90% saturation (662 g solid ammonium sulfate per liter of solution). The solubilized precipitate was chromatographed on Sephadex G-200 (1 m x 5 cm) equilibrated with a 10 mM Tris-HCl buffer pH 7.5 containing NaCl at a final concentration of 0.1 .Wand developed from the bottom. Fractions containing enzymatic activity were pooled, chromatographed on DE-52 (16 x 2.5 cm) equilibrated with 10 mM Tris-HCl, pH 7.5, and eluted with a 250-mL linear 0-0.4 MNaCl gradient prepared in 10 mM Tris-HCl. DPP-IV was then resolved from other
brush border peptidases by chromatography on a phenyl Sepharose column (12x2 cm) equilibrated with 25% (NH«)2 S04 at saturation (144 g ammonium sulfate per liter of 0.05 M
Tris-HCl, pH 7.5). The enzyme was eluted in a homogeneous form with a 200-mL linear gradientof 25-0% (NH4)2S04, prepared in 0.05 M Tris HCI buffer.
Human DPP-IV
Caco-2 cells were obtained from American Type Culture Collection (P.O. Box 3605, Manassas, VA), cultured and maintained at 37 °C with 5% CO2 in low glucose DMEM media supplemented with 10% Fetal Bovine Serum and antibiotic/antimycotic. In preparation for making an extract, cells were seeded at a density to achieve confluence within 7 days. The cells were cultured for an additional 14 days to allow for maximal DPPIV expression. On the day of harvest, cells were washed once with Dulbecco's PBS and solubilized in a IOTOM NaCl containing 50 mM Tris HCI, 0.5% Nonidet P40 and 0.3 ug/ml aprotinin a pH 8.0. The extract was clarified by centrifugation at 35,000 g for 30 minutes at 4 °C. Inhibition constant determination for DPP-IV
DPP-IV activity was determined by measuring the rate of hydrolysis of a surrogate substrate Gly-Pro-7-amido-methylcournarin (Gly-Pro-AMC, Catalogue #G-2761, Sigma, St Louis, MO). The assay is carried out at room temperature in black 96 well polypropylene or polyethylene plates in a total volume of 100 uL per well. Appropriate dilutions of the compounds are made in DMSO and then diluted ten fold into water. 10 uL of 5 concentrations of the compound of formula (I) (inhibitor) or 10% DMSO in water are added to individual wells containing 80 uL of DPP-IV diluted in assay buffer containing 25 mM HEPES (pH 7.5), 150 mM NaCl and 0.12 mg/mL BSA. After 10 minutes at room
WO 2004/026S22
PCTAJS2003/029018
temperature, the reaction is initiated by adding 10 pL of either 280, 700,1750, or 3500 uM -^ Gly-Pro-AMC in water. The DPP-IV activity results in the formation of the fluorescent product amido-methylcoumarin (AMC) which is continuously monitored by excitation at 350 nm and measurement of fluorescent emission at 460 nm every 112 seconds for 37 minutes using an appropriate plate reader. The fluorescence at 460 nm is converted to nanomoles of AMC using a standard curve and the initial rate of AMC formation is calculated. For each concentration of compound of formula (I) (inhibitor) or DMSO control, the initial rates are used to fit the rectangular hyperbola of Michaelis-Menten by non-linear regression analysis (GraphPad Software Prism 3.0). The ratio of the apparent Km/Vmax vs. inhibitor concentration is plotted and the competitive Ki is calculated by linear regression to be the negative x-intercept The uncompetitve Ki is similarly calculated from the x-intercept of the plot of the reciprocal of the apparent Vmax versus the inhibitor concentration (Cornish-Bowden.,A. 1995. Eundamentalsof Enzyme Kinetics. Revised edition. Portland Press, Ltd., London, U.K.).
The compounds of the present invention were found to inhibit DPP-IV induced fluorescence with inhibitory constants in a range of about 0.014 uM to about 7 uM. In a preferred range, the compounds ofme.present invention inhibited DPP-IV induced fluorescence with inhibitory constants in a range of about of about 0.014 uM to about 1 uM; and in a more preferred range, the compounds of the present invention inhibited DPP-IV induced fluorescence with inhibitory constants in a range of about of about 0.014 uM to about 0.5 uM.
As inhibitors of DPP-IV action, the compounds of the present invention are useful in treating disorders that are mediated by DPP-IV. Disorders that are mediated by DPP-IV include diabetes, type II diabetes, hyperglycemia, Syndrome X, hyperinsulinemia and obesity. Therefore the compounds of the present invention are useful in treating the disorder of diabetes, type II diabetes, hyperglycemia, Syndrome X, hyperinsulinemia and obesity.
Dipeptidyl-peptidase IV (DPP-IV, EC 3.4.14.5; CD26) is a post-proline cleaving serine protease with significant homology to other alpha-beta hydroxylases (e.g. prolyl oligopeptidase). DPP-IV is found throughout the body, both circulating in plasma and as a type II membrane protein produced by a variety of tissues, including kidney, liver and intestine. DPP-IV plays a role in the cleavage of specific substrates with accessible amino-terminal Xaa-Pro- or Xaa-Ala- dipeptide-sequences, resulting jn their inactivation or alteration in their biological activities. ImportantTjPP-rV^ubstrates-include growth hormone releasing hormone, glucagon-like peptides or (GLP)-1 and 2, gastric inhibitory polypeptide (GIP) and certain chemokines likeRANTES.(regulatedonactivation, normal Tcell expressed and secreted), stromal cell-derived factor, eotaxin, and macrophage-derived chemokine (Mentlein, R. Regulatory Peptides, 1999,85,9-24).
The DPP-IV substrate, glucagon-like peptide (GLP)-1, is released from L cells in the
WO 2004/026822
PCT/US2003/029018
distal small intestine and colon after oral ingestion of nutrients. The active GLP-1 (7-36) amide is an incretin that increases glucose stimulated insulin secretion (Drucker, D. J. Diabetes, 1998, 47, 159-169). Other activities attributed to GLP-1 (7-36) amide include stimulation of insulin gene expression, trophic effects on pancreatic beta cells, inhibition of glucagon secretion, promotion of satiety, inhibition of food intake, and slowing of gastric emptying (Drucker, D. J. Diabetes, 1998, 47,159-169). These effects of GLP-1 (7-36) amide contribute to glucose homeostasis and the normalization of blood glucose levels in conditions of impaired glucose tolerance. In this regard, GLP-1 (7-36) amide has been demonstrated to reduce postprandial and fasting glycemia in patients with insulin-dependent and non-insulin-dependent diabetes mellitus (Nauck, et al., Hormone Metab. Res. 2002,29, 411-416; Gutniak et al., J. Internal Medicine, 2001,250, 81-87; Rauchman, et al., Diabetologia. 1997, 40,205-11; Ahren, B. BioEssays 1998,20, 642-51). GLP-1 based therapy has therapeutic potential for the treatment of type 2 diabetes. However^ctive GLP-1 (7-36) amide is rapidly converted to GLP-1 (9-36) amide by DPP-IV cleavage of the ammo-terminal His-Ala- dipeptide of GLP-1 (7-36) amide (Mentlein, et al., Eur. J. Biochem. 1993,214, 829-835). The resulting GLP-1 (9-36) amide is inactive and is an antagonist of the GLP-1 receptor (Knudson, et al., Eur. J. Pharmacol. 1996,318,429-35). The short half-life of GLP-1 (7-36) amide in the circulation (1-1.5 minutes) makes it impractical as a therapeutic agent and has led to the development of alternative strategies to enhance the anti-diabetogenic activity of GLP-1. One strategy is to increase the circulating half-life of GLP-1, by inhibiting DPP-IV activity (Deacon, et al., Diabetes. 1995,44 1126-31). Inhibition of DPP-IV in vivo increases the level of circulating GLP-1 (7-36) amide with a concomitant increase in its insulinotropic effect (Deacon, et al., Diabetes. 1998,47,764-9). A DPP-IV inhibitor has been demonstrated to improve glucose tolerance in non-insulin-dependent diabetes mellitus (Ahren, B., et al., Diabetes Care 2002,25, 869-875). Therefore, the compounds of the present invention, including but not limited to those specified in the examples can be used in the treatment of conditions caused by or associated with impaired glucose tolerance including the prevention or treatment of diabetes, especially-non-insulin-dependent diabetes mellitus, hyperglycemia, hyperinsulinemia and metabolic syndrome (Johannsson, et al., J. Endocrinol. Invest. 1999,22(5 Suppl), 41-6).
Striking similarities exist between the metabolic syndrome (Syndrome X) and untreated growth hormone deficiency. Abdominal/visceral obesity and insulin resistance characterize both syndromes (Reaven, GM, Physiol. Rev. 1995, 75,473-86; Johansson, et al., Metabolism. 1995,44,1126-29). Growth hormone favorably effects some of the perturbations associated with abdominal/visceral obesity, including reduction in abdominal/visceral obesity, improved insulin sensitivity and lipoprotein metabolism and reduction in diastolic blood pressure (Barreto-Filho, et al., J. Clin. Endocrinol. Metab. 2002, 87(5), 2018-23; Colao et al., J. Clin. Endocrinol. Metab. 2002,87(3), 1088-93; Gotherstrom,
WO 2004/026822
PCT/US2003/029018
et al., J Clin Endocrinol Metab. 2001,86(10), 4657-65; Johannsson, et al., 1 Endocrinol. Invest. 1999,22(5 Suppl), 41-6; Johannsson, et al., /. Clin, Endocrinol. Metab. 1997, 52(3),
727-34).
For the treatment of diabetes or Syndrome X, compounds of the present invention may be used alone, or in combination with any existing anti-diabetic agent Agents which may be used in combination with the compounds of the present invention include, but are not limited to insulin, an insulin analog such as mecasermin and the like, an insulin secretagogue such as nateglinide and the like, a biguanide such as metformin and the like, a sulfonylurea such as chlorpropamide, glipizide, glyburide, and the like, an insulin sensitizing agent such as a PPARy agonist such as troglitazone, pioglitazone, rosiglitazone, and the like, an a-glucosidase inhibitor such as acarbose, voglibose, miglitol and the like, an aldose reductase inhibitor such as zopolrestat and the like, a metiglinide such as repaglinide and the like, a glycogen phosphorylase inhibitor, GLP-Loi^ajinmetic of GLP-1 such as exendin-4,or other such anti-diabetic agents that are known to one skilled in the art The ability of the compounds of the present invention to treat diabetes, alone or in combination with another agent, can be demonstrated according to the methods described by Zander, M; Mustafa, T.; Toft-Nielsen, M.-B.;Madsbad, S.;Hoist, J. J. mDiabetesCare 2001,24,720-725; or, according to the methods described herein.
DPP-IV-mediated proteolysis has been established as a major route of growth hormone releasing hormone (GHRH) degradation andinactivation (Kubiak, et al., Drug Metab. Dispos. 1989,17,393-7). GHRH-derivatives that are resistant to DPP-IV cleavage are more potent in increasing serum growth hormone levels when administered iv. due to longer stability in vivo. DPP-IV inhibition would be predicted to increase GHRH levels and thus serum growth hormone levels. Therefore, the compounds of the present invention, including but not limited to those specified in the examples can be used in the treatment of conditions associated with deficiency in growth hormone including metabolic disorders (central obesity, dyslipidemia), osteoporosis and frailty of aging.
Diabetic dyslipidemia is characterized by multiple lipoprotein defects including moderately high serum levels of cholesterol and triglycerides, small LDL particles and low levels of HDL cholesterol. The dyslipidemia associated with non-insulin-dependent diabetes mellitus is improved in conjunctton^with improved diabetic condition following treatment with GLP-1 (Junti-Berggren, et al., Diabetes Care. 1996,19,1200-6). DPP:rV inhibition is predicted to increase the level of circulating GLP-1 (7-36) amide_and-thereby would be effective in the treatment of.diabetic dyslipidemia and associated complications. Therefore, the compounds of the present invention, including but not limited to those specified in the examples can be used in the treatment hypercholesterolemia, hypertriglyceridemia and associated cardiovascular disease.
Parenteral injection of GLP-1 (7-36) amide in healthy men, obese men or patients
WO 2004/026822
PCT/US2003/029018
with non-insulin-dependent diabetes mellitus has been reported to promote satiety and to suppress food intake (Flint, et al., J. Clin. Invest. 1998,101, 515-520; Naslund, et aL,Am. J. Clin. Nutr. 1998, 68, 525-530; Gutzwiller, et al., Am. J. Physiol. 1999,276, R1541-R1544. DPP-IV inhibition is predicted to increase the level of circulating GLP-1 (7-36) amide and thereby increases satiety in obesity and non-insulin-dependent diabetes mellitus. Therefore, the compounds of the present invention, including but not limited to those specified in_the examples can be used in the treatment of obesity.
For the treatment of obesity, compounds of the present invention may be used alone, or in combination with any existing anti-obesity agent as described by Flint, A.; Raben, A.; Astrup, A.; Hoist, J. J. in J. Clin. Invest. 1998,101, 515-520 or by Toft-Nielsen, M.-B.; Madsbad, S.; Hoist, J. J. in Diabetes Care 1999,22,1137-1143. Agents which may be used in combination with the compounds of the present invention include, but are not limited to fatty-acidjuptake inhibitors such as orlistatand the like, monoamine reuptake inhibitors such as sibutramine and the like, anorectic agents such as dexfenfluramine, bromocryptine, and the like, sympathomimetics such as phentermine, phendimetrazine, mazindol, and the like, thyromimetic agents, or other such anti-obesity agents that are known to one skilled in the art.
DPP- IV is expressed on a fraction of resting T cells at low density but is strongly upregulated following T-cell activation. DPP-IV may have important functions on T cells and in the immune system. Synthetic inhibitors of the enzymatic activity of CD26 have been shown to suppress certain immune reactions in vitro and in vivo. In vitro recombinant soluble DPP-IV enhances proliferative responses of peripheral blood lymphocytes to stimulation with soluble tetanus toxoid antigen. In addition, the enhancing effect requires DPP-IV enzyme activity (Tanaka, et al., Proc. Natl. Acad Set USA, 1994, Pi,3082-86; Tanaka, et al., Proc. Natl. Acad. Sci. USA 1993,90,4583). Soluble DPP-IV up-regulates the expression of the costimulatory molecule CD86 on monocytes through its dipeptidyl peptidase IV activity suggesting that soluble DPP-IV enhances T cell immune response to recall antigen via its direct effect on antigen presenting cells (Ohnuma, et al., J. Immunol. 2001,767(12), 6745-55). Consequently, DPP-IV inhibition would bej)redicted to suppress certain immune responses and thus have therapeutic benefit in the treatment of immunomodulatory diseases. Therefore, the compounds of the present invention, including but not limited to those specified in the examples can be used in the treatment of rheumatoid arthritis, multiple sclerosis, scleroderma, chronic inflammatory bowel disease or syndrome and allograft rejection in transplantation.
Chemokine receptors, especially CCR5 and CXCR4, act as cofactors for HTV-1 entry. into CD4+ cells and their corresponding iigands can suppress HTV entry and thus replication. The CXC chemokine, stromal cell derived factor-1 (SDF-1) is a chemokine for resting T-lymphocytes and monocytes. SDF-1 exists as two splice variants, SDF-lalpha and SDF-lbeta that differ by four additional C-terminal residues in SDF-1 beta. Truncation of the N-
WO 2004/026822
PCT/US2003/029018
terminal Lys-Pro- residues from ix>th SDF-1 alpha and SDF-1 beta results in the loss of their-"
chemotactic and antiviral activities in vitro (Ohtsuki, et al, FEBSLett. 1998, 431,236-40;
Shioda, et al., Proc. Natl. Acad. Sci. USA 1998 95(11), 6331-6; Proost, et al., FEBSLett.
1998, 432,73-6). DPP-IV inactivates SDF-1 alpha as a ligand for CXCR4 that is a f cell
5 chemotactic receptor as well as the major co-receptor for T-tropic HTV-l strains. DPP-IV
inhibition would be predicted to increase full-length SDF-1 levels and thereby suppress HTV-1 entry into CXCR4+ cells. Therefore, the compounds of the present invention, including but not limited to those specified in the examples can be used in the treatment of HTV infection (AIDS).
10 Synthetic Methods
The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes which together illustrate the methods by which the compounds of the invention may be prepared. Starting materials can be obtained from commercial sources or prepared by well-established literature methods known to those 15 of ordinary skill in the art The synthesis of compounds of formula Q), wherein the groups R, Ri, R2 and R3 are as defined above unless otherwise noted below, are exemplified below.
As shown in Scheme 1, compounds of formula Y, which may either be purchased directly or modified from commercially available starting material through methods commonly known to those skilled in the art, may be reacted with compounds of formula 2 (wherein P is a nitrogen protecting group such as but not limited to tert- butyloxycarbonyl, benzyloxycarbonyl and acetyl) along with reagents such as but not limited to l-(3-. (dimemylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDCI) or 2-(l J/-benzotriazol-lyl)-l,l,3,3-tetramethyIuronium tetrafluoroborate (TBTU) and 4-dimemylaminopyridine (DMAP) in the presence of a base such as but not limited to N-methylmorpholine or diisopropylemylamine in solvents such as but not limited to dicrdoromethane to provide compounds of formula 3. Compounds of formula 3 may be reacted with reagents known to-deprotect the nitrogen protecting group as known to those skilled in the art or demonstrated in Greene, T.W. and Wuts, G.M. "Protective groups in Organic Synthesis", third ed. John Wiley & Sons, 1999, to provide compounds of formula 4, which are representative of compounds of formula (I).
WO 2004/026822
PCTAJS200J/029018
Alternatively, compounds of formula 4 which are representative of compounds of formula (I) can also be synthesized as described in Scheme 2. Compounds of formula X can be reacted with compounds of formula 5_ (where Y is either bromine or chlorine) in the presence of a base such as, but not limited to, triethylamine or diisopropylethylamine in solvents such as but not limited to THF to provide compounds of formula 6. Compounds of formula 6 can be reacted with amines of formula 7 in solvents such as, but not limited to, acetonitrile to provide compounds of formula 4.
As-shown-irLSchemeJ,-CQmpaunds-of formula 8 which are representative of compounds of formula (I) wherein R is alkoxycarbonyl can be modified through techniques known to those skilledin the art to pro vide compounds of formula 11 which are representative of compounds of formula (I) wherein R is cyano. Compounds of formula 8 may be reacted with reagents which will effect a hydrolysis of an alkoxycarbonyl group such as, but not limited to, lithium hydroxide or sodium hydroxide in aqueous alcoholic solvents such as but not limited to aqueous methanol or aqueous ethanol to provide of formula 9. Compounds of formula.9 can.be reacted witrLisobutyIchIorofonnate,-a-base-such as N-methylmorpholine in THF at-15 °C for 20 minutes followed by the addition of ammonia in dioxane to provide-compounds of formula K). Compounds of formula U) can then be reacted with phosphorous oxychloride, pyridine and imidazole at -35 °C or with trifluoracetic anhydride at 0 °C in a mixture of THF and DMF (1:1) to provide compounds of formula 11 A.
WO 2004/026822
PCTAJS2003/029018
The nitrogen protecting group of compounds of formula UA can be removed using conditions known to those skilled in the art to provide compounds of formula 11.
As shown in Scheme 4, compounds of formula 12 (wherein P is a nitrogen protecting group as previously described) can be reacted with organometallic reagents such as but not limited to 23 in solvents such as but not limited to THF at temperatures between -20 °C and -40 °C to providecompounds of formula 14. Compounds of formula'14 can be converted to
10 compounds of formula 15_ through the deprotection of the^amme protectmg group using methods known to those skilled in the art. Compounds of formula 15 can be reduced by hydrogenolysis using 50-60 psi of hydrogen gas and palladium on carbon in solvents such as but not limited to ethanol, methanol, or ethyl acetate or with a hydride source such as sodium borohydride to provide compounds of formula 16. Compounds of formula 16 can be reacted
15 according to the reaction conditions outlined in Scheme 1 or Scheme 2 to provide compounds of formula 8. Compounds of formula 8_ can be reactecLaccording to the reaction conditions outlined in Scheme 3 to provide compounds of formula _U whichareTTepresentative of compounds of formula (I).
WO 2004/026822
PCT/US2003/029018
As shown in Scheme 5, compounds of formula ]2 can be treated with reducing reagents such as lithium triethylborohydride in THF at -78 °C to selectively reduce the carbonyl functional group to the alcohol which can then be converted to the methyl ether upon treatment with para-toluensulfonic acid in methanol to provide compounds of formula Jj$. Compounds of formula 1JJ can be reacted with bis-trimethylsilylacetylene, tm(TV)chloride and AICI3, in solvents such as but not limited to dichloromethane to provide compounds of formula 19. Compounds of formula 19 can be converted to compounds of formula 20 using conditions known to those skilled in the art that will deprotect the amine protecting group as previously mentioned in Scheme 1. Compounds of formula 20 can be reacted according to the conditions outlined in Scheme 1 or Scheme 2 to provide compounds of formula 21^ which can be further reacted according to the conditions outlined in Scheme 3 to provide compounds of formula 22 which are representative of compounds of formula (I).
compounds under conditions described in Scheme 5 to provide compounds of formula 24 wherein R« is a member selected from the group consisting of alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyl, alkylcarbonylalkyl, heterocycle, and
WO 2004/026822
PCT/US2003/029018
heterocyclealkyl. Compounds of formula 24 can be treated under conditions known to
deprotecl nitrogen protecting groups as known to those skilled in the art or are described in Scheme 1 or Scheme 2 to provide compounds of formula 25. Compounds of formula 25 can be subjected to conditions outlined in Scheme 1 and 2 provide compounds of formula 26. Compounds of formula 26 can be subjected to conditions outlined in Scheme 3 to convert the ethyl ester to the corresponding nitrile providing compounds of formula 27 which are representative of compounds of formula (I).
As shown in Scheme 7, compounds of formula 28 may be converted to compounds of formula 29 which are representative of compounds of formula (J). The alcohol functionality of 28 can be reacted with diethyl azodicarboxylate and MphenylphosphineJnJTHF-followed by ormo-ru^benzenesulfonylhydrazme to provide compounds of formula 29. The protecting group of compound of formula 29 can be^emovedoinder conditions known to those skilled in the art.
As shown m Scheme 8, compounds of formula 22 can be converted to compounds of formula 30 which are representative of compounds of formula (I) under an atmosphere of hydrogen in the presence of a catalyst such as but not limited to palladium on barium sulfate poisoned with quinoline in a solvent such as but not limited to methanol or ethyl acetate.
WO 2004/026822
PCT/US2003/029018
As shown in Scheme 9, compounds of formula 30 can be converted to compounds of formula 31 which are representative of compounds of formula (I) under an atmosphere of oxygen in the presence of a catalyst of palladium chloride in solvents such as but not limited to THF or dioxane.
Compounds of the present invention may contain an R3 group that consists of an arnino-piperidine ring as described by formula 34 which are within the scope of compounds of formula 7. Such rings can be treated with compounds of general formula 6 according to conditions described in Scheme 2 to provide compounds of general formula 4 wherein R3 consists of a piperidine ring. Scheme 10 describes the synthesis of compounds of formula 34 (or 7) wherein R3 consists of a substituted piperidine ring. Amino-piperidine rings of formula 32, wherein P is an amino protecting group such as but not limited to tert-butyloxycarbonyl, can be treated with a halogen-substituted heterocycle or an aryl halide of formula Rs-Y, wherein R$ consists of a heterocycle or aryl moiety and Y consists of a halogen in the presence of a base such as diisopropyledrylamine in a solvent such as dioxane with heating between 50 °C and 200 °C from either a convention heat source or from a microwave source under microwave conditions to provide compounds of formula 33. Examples of Rg-Y include but are not limited to a 2-chloropyridine, 2-chloropyrimidine and chlorobenzene. Alternatively, compounds of formula 32 and halogen-substituted heterocycle or aryl halides of formula Rs-"Y, may be coup\ed using a paUadram catalyst such as Pd20ft>a)3 >wth an appropriate ligand such as XANTHPOS in the presence of a base such as cesium carbonate in a solvent such as dioxane with heating to approximately 100 °C. The protecting group can then be removed using conditions known to those skilled in the art to provide a compound of formula 7 which can be treated widi compounds of formula 6 as described in Scheme 2 to provide compound of formula 4 wherein Rj is a piperidine ring
Alternatively, compound of formula 32 may be reacted with an acid chloride of
WO 2004/026822
PCT/US2003/029018
formula RjC(0)Cl, wherein Rg is defined above, in the presence of a base such as triethylamine in a solvent such as dichloromethane or tetrahydrofuran to supply a compound of formula 33_ wherein RjC(0)- is an acyl group appended to the piperidine nitrogen. Alternatively, an acid of formula RgC(0)OH, may be coupled to the piperidine using a coupling reagent such as but not limited to a carbodiimide or uronium salt with additives such as HOBT or DMAP. The protecting group may be removed to furnish piperidines of formula 34 which can be treated with compounds of formula 6 as described in Scheme 2 to provide compounds of formula 4 wherein R3 is a piperidine.
Compounds of the^present invention may also contain an R3 group that consists of a cyclohexyl ring that is substituted with an ether group (R9O-) as described by formula 36. Cyclohexyl ethers of formula 36 are synthesized from compounds offormula 35 by treatment with aryl halides or halogen-substituted aromatic heterocycles such as chloropyridmes or cMoropyrirnidines. The appropriate 4-aminocyclohexanol offormula 35 is treated with a base such as sodium hydride in a solvent such as dimemylformamide at approximately 0 °C, followed by the addition of an aryl halide or halogen-substituted aromatic heterocycle. The reaction mixture may be heated to approximately 60 °C until complete. Further derivitization of functional groups on either the heterocycle or aryl ring may be accomplished by one skilledin^e-artrtOTJiowdexompoun^
appropriate protection and deprotection of the amine moiety. Compounds offormula 36 can then be treated with compounds of formula 6 as described in Scheme 2 to provide compounds of formula 4 where R3 is a substituted cyclohexyl ring.
Scheme~12~
Compounds of the present inventioamay contain mono or difluoro pyrrolidines as represented by compound of formula 43 in Scheme 12 are also within the scope of the compounds of formula j[ shown in Scheme 1. An amino acid of formula 37 wherein P is a 5 nitrogen protecting group and R12 is an alkyl group, may be treated with a fumarate of
formula 38 in the presence of a base such as sodium hydride in solvents such as toluene at room temperature to provide a pyrrolidine of formula 39. Compounds of formula 39 can be subjected to conditions known to cleave ester groups to provide the beta-keto dicarboxylic acid which can be subjected to conditions known to decarboxylate beta-keto carboxylic acids
10 to form a monocarboxylic acid as described by compounds of formula 40. Esterificationof the carboxylic acid in compounds of formula 40 using conditions known to those skilled in the art will provide compounds of formula 4L Treatment of compounds of formula 4J[jwith //,A/-diethylarmnosulfur trifluoride (DAST) in dichloromethane at—78 °C produces the fluorinated pyrrohdines of compounds of formula 42. Removal of the protecting group yields
15 the pyrrolidines described by the compounds of formula 43. Compounds of formula 43 which are within the scope of compounds of formula j_ can be treated according to the conditions described in Scheme I or 2 to provide compounds of formula 4 which contain a diflouropyrrolidine.
The compounds and processes of the present invention will be better understood by
20 reference to the following examples, which are intended as an illustration of and not a
limitation upon the scope of the invention. Further, all citations herein are incorporated by reference.
WO 2004/026822
PCT7US2003/029018
Compounds of the invention were named by ACD/ChemSketch version 5.01 (developed by Advanced Chemistry Development, Inc., Toronto, ON, Canada) or were given names consistent with ACD nomenclature.
Experimentals
Example 1 (2S,5R)-5-ethynyl-1 -L-leucylpyrrolidine-2-carbonitrile
Example 1A dimethyl (2S)-5-oxopyrrolidiiiB-l^-dicarboxylate To a cold (-78 °C) solution of methyl (S)-(+)-2-pyrrolidone-5-carboxylate (4.80 grams, 33.5 mmol) in tetrahydrofuran (90 mL) was addedjLSolutiort.o£Uthium bis(trimethylsilyl) amide (1 M solution in hexanes, 40.0 mL, 40.0 mmol) dropwise via syringe over 15 minutes; then methyl chloroformate.(2.90 mL, 36.9 mmol) was added dropwise via syringe over 5 minutes.. The resulting slurry was stirred at -78 °C for 1 hour after which the reaction was quenched with 1MHC1 (50 mL). The mixture was allowed to come to room temperature, concentrated under reduced pressure and the residue partitioned between ethyl acetate (200 mL) and 1 M HCl (200 mL). The aqueous layer was extracted with ethyl acetate (2 X 200 mL) and the combined organic layers were dried (sodium sulfate), filtered, and concentrated to provide the titled compound. MS (DCI/NH3) m/e 202 (M+H)+; 'H NMR (300 MHz, CDCI3): 5 ppm 4.70 (dd, 1H), 3.88 (s, 3H), 3.80 (s, 3H), 2.74-2.30 (m, 3H), 2.15-2.05 (m, 1H).
ExampleTB dimethyl (2S)-5-methoxypyrrolidine-1,2-dicarboxylate To a cold solution (-78 °C) of dimethyl (2S>5-oxopyrrolidine-l ,2-dicarboxylate (5.80 g, 28.8 mmol) in tetrahydrofuran (100 mL) was added a solution of lithium triethylborohydride (1 Min THF, 35 mL, 35 mmol) dropwise via syringe over 10 minutes. The resulting; solutiori'"was stirred at-78°C for 30 minutes, quenched bythecareful addition of saturated sodium bicarbonate solution (50 mL), allowed to warm to 0 °C and 30% hydrogen peroxide (6 mL) was carefully added dropwise. The mixture-was stirred for 30 minutes at room temperature, reduced in volume under reduced pressure, and diluted with ethyl acetate (300 mL) and brine (200 mL). The milky aqueous layer was separated and further extracted with ethyl acetate (2 X 300 mL). The combined organic layers were dried
WO 2004/026822
PCT/US2003/029018
(sodium sulfate), filtered, and concentrated to a light yellow oil. The yellow oil was taken up in methanol (50 rnL) containing panz-toluenesulfonic acid hydrate (487 mg, 2.6 mmol) and stirred at room temperature for 16 hours. The reaction was diluted with aqueous sodium bicarbonate solution (40 mL), the volatile solvents were removed under reduced pressure and the residue partitioned between ethyl acetate (200 mL) and brine (200 mL). The aqueous layer was further extracted with ethyl acetate (200 mL), the combined organic layers were dried (sodium sulfate), filtered, and concentrated to an oil which was chromatographed on a Biotage 40M with 60% hexane/40% ethyl acetate to provide the titled compound as a mixture ofdiastereomers. (mixture of amide bond rotomers) 'H NMR (300 MHz, CDCI3): 8ppm 5.37 (d, 1H), 5.33 (dd, 1H), 5.24 (d, 1H), 5.18 (dd, 1H), 4.44-4.31 (m, 2H), 3.76 (s, 3H), 3.73 (s, 3H), 3.72 (s, 3H), 3.42 (s, 3H), 3.34 (s, 3H).
Example IC and ID dimethyl (2S,5R)-5^(t]memylsavI)emynyl)pyrrolidme-l,2Kh'carboxylate and dimethyl (2S,5S)-5-((truitemylsUynemynyl)pviToUoUne-l^-dicarboxylate To a cold -45 °C solution of dimethyl (2S)-5-raethoxypyrrolidine-l}2-dicarboxylate (3.30 g, 15.20 mmol) and bistrimethylsilylacetylene (5.20 g, 30.4 mmol, 2.0 equiv) in methylene chloride (45 mL) was added a solution of tin (TV) chloride (1M in methylene chloride, 20.0 mL, 20.0 mmol, 1.3 equiv) dropwise via syringe over 15 minutes. To the dark yellow solution was added solid aluminum chloride (2.77 g, 20.8 mmol, 1.4 equiv) in one portion. The resulting mixture was allowed to warm to room temperature and stirred at room temperature for 48 hours. The reaction mixture was carefully poured into aqueous sodium bicarbonate solution (100 mL) with ice cooling. A white precipitate forms and 1 MUCl (ca. 50 mL) was added until the solids dissolved. This mixture was extracted with ethyl acetate (2 X 200 mL). The combined organic layers were filtered, dried (sodium sulfate), filtered, and concentrated. "The 'residue was chromatographed on agiotage flash 40 M eluting with 70% hexane/30% ethyl acetate to afford (2S^S)-5-((trimethylsilyl)ethynyI)pyrrolidine-l,2-dicarboxylate (trans compound Rf of 0.3 in 70% hexane/30% ethyl acetate) and dimethyl (2S,5R)-5-((trimethyIsilyl)ethynyl)pyrrciidine-l,2Hlicarboxylate-(cis compound Rf of 0.2 in 70% hexane/30% ethyl acetate). Data for example ID: MS (DCI/NH3) m/e 284 (M+H)+; The compound exists as a mixture of rotomers. !H NMR (300 MHz, CDCI3): 8 ppm 4.60 (d, 1H), 4.51 (d, 1H), 4.30 (d, 1H), 4.24 (d, 1H), 3.62 (s, 3H), 3.59 (s, 3H), 3.57 (s, 3H), 3.54 (s, 3H), 2.40-2.28 (m, 2H), 2.11-2.04 (m, 2H), 1.90-1.81 (m, 4H), 0.0 (s, 18H). Data for example IC: MS (DCI/NH3) m/e 284 (M+H)+; *H NMR (300 MHz, CDCI3): 8 ppm 4.55-4.40 (m, 1H), 4.20-4.15 (m, 1H), 3.59 (s, 6H), 2.15-1.89 (m, 4H), 0.00 (s, 9H).
WO 2004/026822
PCTAJS2003/029018
Example IE methyl (5R)-5-((trimethvlsilvl)etfaynylVL-prolinate A solution of dimethyl (2S,5R)-5-((trimethylsilyi)ethynyl)pyiroIidine-l,2-dicarboxylate (5.43 g, 19.16 mmol) and iodotrimethylsilane (3 mL, 28.74 mmol) in chloroform (100 mL) was heated to 65 °C for 3 hours, was cooled to room temperature, concentrated under reduced pressure and flash chromatographed with 35% ethyl acetate/ 65% hexane to provide the titled compound. MS (DCI/NH3) m/e 226 (M+H)+.
Example IF mefoyl/^fert-butoxycarbonylVL4euc^^
To a solution of methyl (5R)-5^(trimemykilyl)emynyl)-L-prolinate (1.6 grams, 7.48 mmol), dimemylaminopyridine (913 mg, 7i48 mmol)rN-methylmorpholine (1.23 mL, 11.22 mmol), and N-(tert-butoxycabonyl)-L-leucine monohydrate (2:24 g, 8.98 mmol) in dichloromethane (30 mL) at room temperature was added 1^3-dimethylaminopropyl)-3-emyl
Example 1G ^rerNbutoxvcarbonvl)-L-leucyl-(5R)-5-ethynvl-L-proline To a solution of methyl i^-(rcr/-butoxycarbonyl)-L-leucyl-(5R)-5-((trimethylsilyI)ethynyl)-L-prolinate (124 g, 2.83 mmol) in dioxane (12 mL) at room temperature was added a solution of 2 ^lithium hydroxide (3 mL, 6.0 mmol). The resulting mixture was stirred at room temperature for 6 hours. The reaction was diluted with 1 MHC1 solution (50 mL), and the aqueous mixture was extracted with ethyl acetate (3 X 50 mL). The combined organic layers were dried (sodium sulfate), filtered, and concentrated to provide the titled compound.
WO 2004/026822
PCTAUS2003/0290J8
Example 1H ^-(rerf-butoxycarbonvD-L-leucvl-fSRVS-eth^vl-L-proliriamide
To a cold (0 °C) solution of//-(rer/-butoxycarbonyl)-L-leucyl-(5R)-5-ethynyl-L-proline (2.83 mmol) andN-methyl moipholine (0.39 mL, 3.50 mmol) in THF (15 mL) was added isobutyl chlorofonnate (0.42 mL, 3.25 mmol). The resulting cloudy white mixture was stirred at 0 °C for 30 minutes followed by the addition of a solution of ammonia (0.5 M in dioxane, 10.0 mL, 5.0 mmol). The solution was allowed to warm to room temperature and stirred for 16 hours. The reaction mixture was diluted by the addition of 1 MKCl (100 mL), and extracted with ethyl acetate (3 X 100 mL). The combined organic layers were dried (sodium sulfate), filtered, and concentrated to provide the titled compound.
Example II
A^fe^butoxycarbonyl)-L-leucyl-(5R)-5-e^
To a cold solution (-40 °C) of iV-(ter/-butoxycarbonyl)-L-leucyl-(5/?>-5-ethynyl-L-prolinamide (1.07 g, 3.05 mmol) and imidazole (208 mg, 3.05 mmol) in pyridine (15.mL) wasadded POCI3 (0.57 mL, 6.10 mmol) via syringe. The resulting mixture was stirred, mamtainingthe^emperature below -20 °C, for 1 hour followed by the addition of1 Jl^ELCl (100 mL). The aqueous mixture was extracted with ethyl acetate (3 X100 mL), and the combined organic layers were dried (sodium sulfate), filtered, concentrated-and chromatographed with 30% ethyl acetate/hexane to provide the titled compound. MS (DCI/NH3) m/e 334 (M+H)+; *H NMR (300 MHz, CDCI3): 5 ppm 5.15 (t, 1H), 4.95 (d, 1H), 4.71 (t, 1H), 4.53 (ddd, 1H), 2.50 (d, 1H), 2.50-2.28 (m, 4H), 1.75-1.57 (m, 3H).
Example 1 (2S,5R)-5-ethynyl-l -L-leucylpyrrolidine-2-carbonitrile hydrochloride
To a solution of Ar-(/er/-butoxycarbonyI)-L-leucyl-(5R)-5-ethynyl-L-pyrrolidine-2-carbonitrile (250 mg) in ether (1 mL) was added 4 MHCl in dioxane (2 mL). The resulting mixture was stirred at roomlemperarureJbrJJionrs-andAe^olvjentsjxmovedjmder reduced . pressure. The white solid was triturated with ether to provide the titled compound. MS (DCI/NH3) m/e 234 (M+H)+; 'H NMR (300 MHz, MtOK-dj): 5 ppm 5.11 (d, 1H), 4.82 (m, 1H), 4.42 (dd, 1H), 3.19 (d, 1H), 2.58-2.56 (m, 1H), 2.49-2.24 (m, 3H), 2.05-1.95 (m, 1H), 1.87-1.81 (m, 2H), 1.08 (d, 3H), 1.04 (d, 3H).
Example 2 (2S,5R)-5-emvnYl-l-((3SVL2,3,4-tetrahydroisoquinolin-3-ylcarbonyOpyrrolidine-2-
carbonitrile hydrochloride
WO 2004/026822
PCI7US2003/029018
Example 2 was prepared using the same procedures as described for Example 1 substituting (3S)-2-^butoxycaibonyl)-l)2J3,44etTahydroisoquinolkie-3-carboxylic acid for N-(f-butoxycarbonyi)-L-leucine monohydratc in the step described in example IF. MS (DCI/NH3) m/e 280 (M+H)+; !H NMR (300 MHz, MeOH-dj): 5 ppm 7.33-7.26 (m, 4H), 5.18 (m, 1H), 4.80 (dd, 1H), 4.49 (m, 2H), 3.75 (m, 1H), 3.30-3.19 (m, 2H), 2.57-2.23 (m, 4H).
Example 3 (2S,5R)-1 -((2S)-2-ammo-2-cvclopentylethaaovl)-5-emvnYlpYrroUdine-2-carbomMle
Example 3A memvU5RVl-ff2SV2^(te/^butoxvcarbonyDammoV2^yclopenMethanoYl>-5-
((tiMethylsilynemYnYlVL-prolinate To a stirred solution of methyl (5R>5-((ume1hylsflyl)e1hynyl)-I^pn)linate (12 g, 5.32 mmol) in dichloromethane ( 30 mL ) at ambient temperatureimdernftrogen-was added 4-dimemylamino pyridine (0.65 g,-5.32 mmol), 4-methylmorpholine (0.9 mL, 7.98 mmol), 1-(3-(dimethylamino)propyl)-3-ethyl carbcKiiirnide hydrochloride (1.22 g, 6.39 mmol), and (2S)-((fe^butoxycarrK)nyl)amino)(cyclopentyl)acetic acid dicyclohexylamine salt (1.55 g, 6.39 mmol). The reaction mixture was stirred at room temperature for 16 hours, diluted with ethyl acetate and washed with 1MHC1. The aqueous layer was further extracted with ethyl acetate (2X) and the combined ethyl acetate layers were dried (Na2SC>4) and evaporated. The residue was purified by flash chromatography 30% ethyl acetate/hexane to provide the titled compound. MS (CI) m/e 451 (M+H)+.
Example 3B (5Ryi-U2Sy2^(terNbutoxycaibonvl)ammoV2-c^^
To a stirred solution of methyl (5R)-l-{(2S>2-((te^butoxyc^bonyl)amino)-2-cyclopentylethanoyl}-5-((trimethylsilyI)ethynyl)-L-prolinate (1.65 g, 3.66 mmol) in MeOH (10 mL) and H20 (10 mL) at room temperature was added LiOH«H20 (0.23 g, 5.49 mmol). The reaction rruxture was stirred at room temperature for 16 hours and concentrated under reduced pressure. The residue was taken up in water and extracted with diethyl ether (2X). The aqueous layer was acidified to pH ~ 4 by adding 4% KHSO4 dropwise. The clear solution was extracted with ethyl acetate ( 3X) and the combined ethyl acetate layers were washed with brine, dried (Na^SC^), filtered and concentrated under reduced pressure to provide the titled compound. MS (CI) m/e 365 (M+H)+.
WO 2004/026822
PCT/US2003/029018
Example 3C (SR)-l-((2S)-2-((/g/-/-butoxYcarbonyl)amino)-2-cvclopentvlethanovl>-5-ethYny^L-
prolinamide To a stirred solution of (5R)-l-{(2S)-2-((/err-butoxycarbonyl)araino)-2-cyclopentylemanoyl}-5-emynyl-L-proline (1.28 g, 3.38 mmol) inTHF (25 mL) at -15 °C under nitrogen, was added 4-methyImorpholine (0.44 mL, 4.05 mmol), and isobutylchloroformate (0.5 mL, 3.72 mmol) over 2 minutes. The reaction mixture was stirred at -15 °C under nitrogen for 30 minutes, and a solution of 0.5 JW"NH3 in dioxane (34 mL, 16.90 mmol) was added. The reaction mixture diluted with water, the pH adjusted to 4 by the addition of 4% KHSO4 and extracted with ethyl acetate (3X). The combined extracts were washed with brine, dried (Na2S04), filtered and evaporated. The residue was purified by flash column chromatography (5% MeOH/CH2Cl2) to provide the titled compound. MS (CI)m/e364(M+H)+.
Example 3D (5R)-l-((2S)-2^(rer^butoxycm^bonyl)animoV2^yclopenryIethanoyl}-5-ethvnyl-L-
pyrrolidine-2-carboriitrile Trifluoroacetic anhydride (0.086 mL, 0.605 mmol), was added dropwise to a stirred ice-cooled solution of (5R)-1 - {(2S)-2-((fer^butoxycarbonyl)amino)-2-cyclopentylethanoyl} -5-ethynyl-L-prolmamide (200 mg, 0.55 mmol) in anhydrous dioxane (7 mL) and anhydrous pyridine (0.089 mL, 1.1 mmol) at such a rate that the temperature was kept below 5 °C. The reaction mixture was allowed to warm to room temperature and stirred for 16 hours. Ice was added to the residue, the solid product was collected by filtration and washed with water. Purification by flash chromatography (30% ethyl acetate/hexane) provided the titled compound. MS (CI) m/e 346 (M+H)+.
Example 3E (2S,5RVl-((2SV2-ammo-2-cyclopentylethanoyl)-5-ethvnvlpyrrolidine-2-carbonitrile
hydrochloride (5R>l-{(2S)-2-((/e^butoxycarbonyl)amino)-2-cyclopentylethanoyl}-5-ethynyl-L-pyrrolidine-2-carbonitriIe (0.03 mg, 0.087 mmol), and 4 MHO in dioxane (0.15 mL, 0.6 mmol) were stirred at room temperature for 2 hours and evaporated under reduced pressure. Diethyl ether was added to the residue, and the formed precipitate filtered. The solid was
WO 2004/026822
PCT/US2003/029018
washed with diethyl ether (3x15 mL). The precipitate was dried in vacuo to provide the title4^ compound. MS (CI) m/z 246 (M+H)+; 'HNMR (300 MHz, MeOH-
Example 4 (2S3R)-H(2S)-2-ammo-2-cyclopentvlemanovl)-5-vmylpyirolidme-2-carbomtrile
hydrochloride
Example 4A fert-butyl (1 S)-2-((2S,5R)-2-cvano-5-vinylpym>lidin-l-yl')-l-cyclopentvl-2-
oxoethylcarbamate (5R)-1 - {(2S)-2-((re^butoxycarbonyl)amino)-2-cycIopeiitylethanoyl} -5-ethynyl-L-pvrrolidine-2-carbonitrile (60 mg) was stirred under hydrogen (60 psi) at room-temperature for 7 minutes in a mixture of quinoline (66 uL) and ethyl acetate (6 mL) using 5% Pd/BaSC*4 (24 mg). The mixture was filtered and the filtrate concentrated under reduced pressure. Purification by flash column chromatography with 20% ethyl acetate / hexane to provide the titled compound. MS (CI) m/e 348 (M+H)+.
Example 4 (2S,5R)-l-((2S)-2-amino-2K;yclopentylethanoylV5-vinylpyrrolidine-2-carbonitrile
hydrochloride Example 4 was prepared according to the procedure for Example 3E substituting Jer/-butyKlS^^S.SR^-cyano-S-vinylpyrrolidin-l-yO-l-cyclopentyl^-oxoethylcarbamate for(5R)-l-{(2S)-2-((/er/-butoxy
Example 5 (2S3R)-l-((2SV2-aminc>-2-cyclohexylethanoyl)-5-ethynylpyrrolidine-2-carbonitrile
hydrochloride Example 5 was prepared according to the procedures for Example 1F-J substituting N-(/-butoxy
WO 2004/026822
PCT/US2003/029018
monohydrate in the step described in Example IF. MS (CI) m/e 260 (M+H)+; *H NMR (300 MHz, MeOH-
Example 6 f2S,5S)-5-ethYl-l-L-leucylpyrrolidine-2-carbomtrile
Example 6 A emyl(2S)-2-((fe^butoxycarbonyl)aminoV5-oxoheptanoate Ethyl N-Boc (S)-pyroglutamate (2.33 g, 9.06 mmol, prepared as described in: (a) St-Denis, Y., Augelli-Szafran, C. E.; Bacband, B.; Berryman, K. A.; DiMaio, J.; Doherty, A. M.; Edmunds, J. J.; Leblond, L.; Levesque, S.; Narasirnhan, L. S.; Penvose-Yi, J. R.; Rubin, J. R,; Tarazi, M.; Winocour, P. D.; Siddiqui, M. A. Biorg. Med. Chern. Lett. 1998,8,3193-3198. (b) Jain, R. Org. Prep. Procd Intl. 2001,33,405-409.) was dissolved in THF (6 mL) and the mixture was cooled to -40 °C. Ethyl magnesiumbromide solution (1.0 M in THF, 10.84 mL, 10.84 mmol) was added slowly via syringe, and the mixture was stirred cold for 2 hours. Then the reaction flask was placed in a freezer (approx-20 °C) for 16 hours, the reaction was allowed to warm to room temperature and aqueous NH4CI and 1 NB.CI were added. The mixture was extracted with ethyl acetate (3X). The combined organic extracts were dried (Na2SC>4), filtered, concentrated and purified by flash chromatography (30% ethyl acetate /hexane) to provide the titled compound. MS (ESI) m/z 288 (M+H)+, 310 (M+Na)+.
Example 6B
ethyl (2S)-5-ethyl-3,4-dihydro-2//-pyiTole-2-carboxvlate
Ethyl (2S)-2-((ter/-butoxycarbonyl)arnino)-5-oxoheptanoate and trifluoroacetic acid
(3 mL) werestirred-in dichloromethane-(3 mL)^U:oom temperature-for 3 hours. The mixture
was concentrated under reduced pressure to provide the titled compound. MS (ESI) m/z 170
(M+H)+.
Example 6C ethyl (5S)-5-ethvl-L-prolinate Ethyl (2S)-5-ethyl-3,4-dihyoro-2if-pyrrole-2-carboxylate dissolved in ethanol (32 mL) was stirred with 0.30 g of 10% Pd/C and under hydrogen (60 psi) for 16hours. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure to provide the titled compound. MS (CI) m/z 172 (M+H)+.
WO 2004/026822
PCT/US2003/029018
Example 6D ethyl A^-(fgrf-butoxycarbonyl)-L-leucvl-(5S)-5-ethvl-L-proliDate A solution of ethyl (5S)-5-ethyl-L-prolinate (2.5 mmol), 2-(lif-benzotriazol-lyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (1.00 g, 3.13 mmol) and N^tert-butoxycarbonyl)-L-leucine hydrate (0.779 g, 3.12 mmol) were mixed in 4 mL of dimethylfonnamide. Triethylamine (approx 1.1 mL) was added until the pH reached about 6 (wet pH paper). After stirring for 16 hours, the mixture was concentrated under reduced pressure and the residue partitioned between 1 iVHCl and ethyl acetate. The organic layer was washed with saturated NaHCC>3, dried (Na2S04), filtered, concentrated under reduced pressure and purified by flash chromatography (30% to 50% ethyl acetate /hexane) to provide the titled compound. MS (ESI) m/z 385 (M+H)+.
Example 6E J\^te/f-butoxycarbdnyl)-L-leucyK5S)-5-ethyl-L-proline Ethyl 7/'e^butoxycarbonyI)-L-Ieucyl-(5S)-5^%l-L-prolmate (0.965 %, 2.5 mmol) was dissolved in 3 mL of ethanol. The resultant solution was treated with 1.2 MLiOH solution (3.8 mL, 4.52 mmol) at room temperature. After 4 hours, the volatiles were removed under reduced pressure, and 1N HCl was added. The mixture was extracted with ethyl acetate (3X), and the combined organics were washed with brine, dried (Na2S04), filtered and concentrated under reduced pressure to provide the titled compound. MS (ESI) m/z 357 (M+H)+.
Example 6F ^(/erfrbutDxyc^onyiyi^Ieucv^ A/-(rert-butoxycarbonyl)-L-leucyl-{5S)-5-ethyl-L-proline was mixed with triethylamine (0.426 mL, 3.25 mmol) in THF (4 mL) and cooled to 0 °C followed by the addition of ethyl chloroformate (0.287 mL, 3.0 mmol). After 20 minutes, 0.5 M ammonia in dioxane (6 mL) was added. After 4 hours, the mixture was concentrated, and the residue was partitioned between IN HCl and ethyl acetate! The organic extracts were washed with saturated NaHC03, dried (NajSO^, filtered, concentrated under reduced pressure and purified by flash chromatography (80% to 100% ethyl acetate /hexane) to provide the titled compound. MS (ESI) m/z 356 (M+H)+.
WO 2004/026822
PCT/US2003/029018
Example 6G Ar-('fer/-butoxycarbonvl')-L-Ieucyl-(5S)-5-etfayI-L-pYrroIidiDc-2-carbonitiile
A^(^/^-butoxycarbonyl)-L-leucyl-(5S)-5-ethyl-L-prolinamide (0.392 g, 1.10 mmol) and imidazole (0.082 g, 1.21 mraol) were mixed in pyridine (4mL) and cooled to -35 °C followed by addition of POCl3 (0.206 mL, 2.20 mmol). After 1 hour, aqueous NH4CI solution was added, and the mixture was concentrated under reduced pressure. 1JVHC1 was added to the residue, and the mixture was extracted with ethyl acetate (3X). The combined organic extracts were washed with 1 WHC1 and brine, dried (Na2SC>4), and concentrated under reduced pressure to prbvide the titled compound. MS (ESI) m/z 338 (M+H) . NOE from ROESY spectrum confirmed the cis- relationship between 2-cyano and 5-ethyl groups.
Example 6 (2S,5S)-5-emyl-l-L4eucylpyrroUd^e-2M^rbonitriletrifluoroacetate ^terf-butoxycarbonyl)4,-leucyH5S)-5^ was mixed with 2 mL each of dichlormethane and trifluoroacetic acid at room temperature. After 3 hours, the volatiles were removed under reduced pressure to provide the titled compound as the trifluoroacetic acid salt "H NMR (400MHz, CDCI3) 5 4.76 (J, 1H, J = 8.0 Hz), 4.27 (d, 1H, J = 8.6 Hz), 4.04 (s, 1H), 2.26-2.38 (m, 2H), 1.87-2:05 (m, 4H), 1.66 (m, 3H), 1.31 (m, 1H), 0.96-1.02 (m, 9H); MS (ESI) m/z238 (M+H)*".
Example 7 (2S,SS)-l-((2S)-2-arm^o-2-cyclohexylemanoyl)-5-emyIpyn-olidme-2-carbonitrile
trifluoroacetate The titled compound was prepared according to procedure described in Example 6 by substituting A^terf-butoxycarbonyO-Z-leucine hydrate with N-Boc-L-cyclohexylglycine in step-60. !H NMR
Example 8
35 (2S.5RV1 ~{N-((\ R^R,4SVbicyclo(2.2.1 )hept-2-vl)glvcvn-5-ethynylpyrrolidine-2-
carbonitrile
WO 2004/026822
PCT7US2003/029018
Example 8A methyl (5R)-l-(chloroacetyl)-5-((triinethylsilyl)ethynYl)-L-prolinate To a stirred solution of methyl (5£)-5-((trimemylsilyl)emynyl)-L-prolraate (2.76 g, 12.2 mmol) and triethylamine (2.13 mL, 15.3 mmol) in dry tetrahydrofuran ( 50 mL ) at 0 °C was gradually added a solution of chloroacetyl chloride (0.97 mL, 12.2 mmol) in dry tetrahydrofuran (10 mL). After stirring at room temperature for 2 hours, the mixture was filtered. The solid cake was washed with THF, and the filtrate and washings were combined, dried over sodium sulfate and concentrated under reduced pressure. The residue taken up in toluene and concentrated to dryness under reduced pressure to provide the titled compound. MS (CI) m/z 302 (MH)+.
Example 8B (5R>-1 -(chloroacetyl)-5-ethYnyl-L-proline To a stirred solution of methyl (5R)4^chloroa
Example 8C
(5R)-Hchloroacetyl)-5-ethynyl-L-prolinamide
To a stirred solution of (5R>1 -(chloroacetyl)-5-ethynyI-L-proline (1.89 g, 8.76 mmol)
in THF (50 mL) at -15 °C under nitrogen was added 4-methylmorpholine (1.16 mL, 10.52
mmol), and then isobutylchloroformate (1.25 mL, 9.64 mmol) over 3 minutes. A white
precipitate formed. The reaction mixture was stirred at -15 °C under nitrogen for 30 minutes,
and a solution of NH3 in aiorane{0XA?~88ln^^ The reaction
mixture was stirred at -15 °C for 30 minutes, warmed to room temperature, and stirred at that temperature for 16 hours. The reaction mixture was diluted with 4% KHSO4 to ~ pH 4 and extracted with ethyl acetate (3X). The extracts were combined, washed with brine, dried (Na2S04), filtered and concentrated under reduced pressure. Purification by flash column chromatography (60-75% ethyl acetate /hexane) provided the titled compound. MS (CI) m/z
WO 2004/026822
J*C 'HVSlWMv^vio
215 (M+l)+.
Example 8D (2S,5R)-HchloroacetvI)-5-ethynvlpyrrolidine-2-carbonitrile To a stirred solution of (5R)-l-(chloroacetyl)-5-ediynyl-L-prolinamide (0.16 g, 0.745 mmol) and imidazole (0.05 g, 0.745 mmol) in dry pyridine (4 mL) at -35 °C under nitrogen was added POCI3 (0.15 mL, 1.49 mmol) dropwise. The reaction mixture was stirred between -35 °C to -15 °C for 1 hour and evaporated. The residue was diluted with dichloromethane and washed with H20 (2X), dried (Na2SC>4), filtered and concentrated under reduced pressure. Purification by flash chromatography (10% ethyl acetate /hexane) provided the titled compound. MS (CI) m/z 197 (M+l)+.
Example 8 qS,5RVl-(iV-((lR,2R,4SVbicvclo(22.nhept-2-ylMycyl^5^mvnylpyrrolidine-2-
carbonitrile To a stirred solution of (2S,5R)-HchloroacetyI)-5-emynylpyrroUd^e-2-carbonitrile (0.03 g, 0.152 mmol) in acetonitrile (1 mL) at room temperature was added exo-2-aminonorborane (0.036 mL, 0.305 mmol) and a catalytic amount of tetrabutylammonium iodide. The reaction mixture was s'tirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanol: dichloromethane to provide the titled compound, MS (CI) m/z 271 (M+l)+; *H NMR (300 MHz, MeOH-tf4): 8 ppm 4.7-4.8 (m, 2H), 3.61-3.8 (m, 2H), 3.2-3.3 (m, 1H), 3.02-3.11 (1H, s), 2.62-2.72 (m, 1H), 2.37-2.44 (m, 3H), 2.2-2.3 (br s, 2H), 1.0-1.7 (m, 8H).
Example 28 (2S,5S)~ 1 -L-leucyl-5-methy lpyrrolidine-2-carbonitrile The title compound was prepared in the manner described for example 6 except methyl magnesium bromide was substituted for ethyl magnesium bromide in the step corresponding to Example 6A. !H NMR (400MHz, MeOH-c/4) 8 4.79 (dd, 1H, J = 8.1 Hz), 4.40 (m, 1H), 4.30 (dd, 1H, J = 4.1,9.4 Hz), 2.37-2.50 (m, 2H), 2.08 (m, 1H), 1.75-1.92 (m, 3H), 1.66 (m, 1H), 1.36 (d, 3H, J = 6.5 Hz), 1.05 (d, 3H, J = 4.3 Hz), 1.04 (d, 3H, J = 4.3 Hz); l3C NMR (100MHz, MeOH-dA) 5 119.9 for CN group; MS (ESI) m/z 224 (M+H)+.
Example 29
WO 2004/026822
PCTAJS2003/029018
(2SJRV5-ethynYl-l-(N-(4-methyl-l-pYridin-2-vlpiperidin-4-vl)glycvl')Pvrrolidine-2- -
carbonitrile
Example 29A 4-Methvl-3,4.5,6-tetiahydro-2H^ia')bipyridmyl^ylamine
A stirred solution of (4-methyl-piperidin-4-yl)-carbamic acid benzyl ester (0.15 g, 0.61 mmol, Example 30B) and 2-fluoropyridine (0.3mL, 3.5mmol) was heated to 175 °C under microwave conditions for 1 hour. The reaction mixture was concentrated under reduced pressure and purified by chromatography (silica gel, eluting with 20% to 35% ethyl acetate in hexane) to provide (4-memyl-3,4,5,6-teti^ydrcH2H^l,2')bipyridinyl-4-yl)-carbamic acid benzyl ester. MS (CI) m/z 326(M+1)+; ]H NMR (300 MHz, CDC13) 8 ppm 8.06 (dd 1H), 7.52 (m, 1H), 7.37-7.26 (m, 5H), 6.80 (d, 1H), 6.62 (t, 1H), 5.04 (s, 2H), 4.84 (s, 1H), 3.78 (m, 2H), 3.25-3.16 (m, 2H), 2.08 (m, 2H), 1.64-1.55 (m, 2H), 1.35 (s, 3H).
To a stirred solution of (4-memyl-3,4,5,6-tetrahydro-2H-(l ^bipyridinyl^yl)-carbamic acid benzyl ester (0.06 g, 0-185 mmol) in isopropanol (1.8 mL) at room temperature was added ammonium formate (0.047 g, 0.75mmol) and 5 mg of 10% Pd/C under nitrogen. The reaction mixture was heated under microwave conditions at 150 °C for 30 minutes, cooled, filtered through Celite and concentrated under reduced pressure to provide the titled compound. MS (CI) m/z 192 (M+l).
Example 29B (2S,5R)-5-emynyl-l-(N-(4-memyl-l-pyridm-2-ylpiperidm-4-yl)glycyl)pyn^olidm
carbonitrile
To a stirred solution of (2S, 5R)-l-(cUoroa
(0.039 g, 0.2 mmol, Example 8D) in acetonitrile (3 mL) at room temperature was added 4-
methyl-S^^.e-tetrahydro^H^l^^bipyridinyl-^ylamine (0.076 g, 0.4 mmol). The reaction
mixture was-stirred at 66 °G for 48 hours, concentrated under reduced pressure and purified
by chromatography (silica gel, eluting with 2%-5% methanolrdichloromethane). The product
was mixed with 4M HCI in dioxane (2mL), and after 0.5 hours, the solvents were removed
under reduced pressure. The residue was solidified by trituration with diethyl ether to
provide the tided compound as the HCI salt MS (CI) m/z 352 (M+l)+; 'H NMR (300 MHz,
methanol-^) 6 ppm 8.10(mv lH)r8.01 (d, lH)r7^6 (d, 1H);7.07 (OH)74.93 (hi, 1H), 4.77
(m, 1H), 4.39-4.15 (m, 3H), 3.59-3.46 (m, 4H), 3.24 (m, 1H), 2.47-233 (m, 4H), 2.13-2.10
(m,4H), 1.61 (m,3H).
Example 30 (2^,5Jg)-5-emynyl-l-fA^(4-memyl-l-P-cyano-pyridm-2-yl)piperidm-4-yl)glycyl)pyrroIidine-
WO 2004/026822
PCTAJS2003/029018
10
15
2-carbonitrile
Example 30A 4-Benzvloxycarbonylamino-4-methvl-piperidine-l-carboxylic acid tert-butyl ester
To a solution of the 4-methyl-piperidine-l,4-dicarboxylic acid mono-tert-butyl ester (5 g, 20.6 mmol) in toluene (40 mL) at 23 °C was added triethylaraine (4.3 mL, 31 mmol) and diphenylphosphoryl azide (6.1 mL, 28.0 mmol). The resulting mixture was stirred at 23 °C for 45 minutes after which benzyl alcohol (11.1 mL, 103 mmol) was added. The reaction mixture was then heated to 80 °C for 16 hours. The reaction mixture was allowed to cool to room temperature and the excess solvents were removed under reduced pressure. The crude residue was purified by chromatography (silica gel, eluting with 10%ethyl acetate/90% hexane to 30% ethyl acetate/70% hexane) to provide the titled compound (5.6 grams). MS (CI) m/z 249 (M-99)+; !H NMR (300 MHz, CDC13) 6 ppm 7.38-7.31 (m, SH), 5.05 (s, 2H), 4.57 (s, 1H), 3.67-3.60 (m, 2H), 3.18 (m, 2H), 1.98-1.90 (m, 2H), 1.44 (s, 9H), 1.37 (s, 3H).
Example 30B (4-Memyl-pir>eridin-4-yl)-carbarnic acid benzyl ester A mixture of Example 30A (4.7 g, 13.4 mmol) in 4 M HC1 in dioxane (20 mL) was stirred at 23 °C for 12 hours. The dioxane was removed under reduced pressure and the crude solid was triturated several times with diethyl ether. The resulting white solid was dried in vacuum oven overnight to afford the HC1 salt of the titled compound (2.75 g). MS (CI) m/z 249 (M+l)+; 'H NMR (300 MHz, methanol-^) 8 ppm 7.37-7.29 (m, 5H), 5,05 (s, 2H), 3.19-3.07 (m, 4H), 1.76-1.70 (m, 4H), 1.37 (s, 3H).
Example 30C (5'-Cyano>4-methyl-3>4,5,6-tetrahydro-2H-(l,2')bipyridinyl-4-yl)-carbamic acid benzyl ester A solution of (4-methyl-piperidin-4-yl)-carbamic acid benzyl ester hydrochloride salt (198 mg, 0.697 mmol), 2-chIoro-5-cyanopyridine (90 mg, 0.65 mmol) and diisopropylethylamine (400 uL) in dioxane (2 mL) in a sealed tube was heated to 170 °C under microwave conditions for 20 minutes. The reaction mixture was cooled, concentrated and then purified by chromatography (silica gel, eluting with 10% hexane/ethyl acetate to 60% ethyl acetate/hexane) to provide the titled compound (167 mg) as a white foam. MS (CI) m/z 380 (M+l)+; 'H NMR (300 MHz, DMSO-ck) 6 ppm 8.45 (s, 1H), 7.80 (dd, 1H), 7.37 (m, 5H), 7.18 (s, 1H), 6.93 (d, 1H), 5.00 (s, 2H), 4.00-3.95 (m, 2H), 3.35-3.26 (m, 2H),
WO 2004/026822
PCT/US2003/029018
2.19-2.07 (m, 2H), 1.49-1.43 (m, 2H), 1.27 (s, 3H).
Example 30D 4-Amino^methyl-3,4,5,6-teti^vdro-2H-(l,20bipvridinyl-5'-carboDitrile A solution of (5,
Example 30 (25,5Jg)-5-emynyl-l-(7^-(4-memvl-H3-CYano^pyrid^~2-yl)piperidm-4-
2-carbonitrile A mixture of Example 30D (60mg, 0.31 mmol) and (2S,5R>l-(chloroacetyl)-5-emynylpyrroUdme-2-c^bonitrile (105 mg, 0.49 mmol, Example 8D) in acetonitrile (2mL) was stirred at 23 °C for 72 hours. The reaction mixture was concentrated under reduced pressure, and the crude residue was purified by chromatography (silica gel, eluting with 96% dichloromethane/4% methanol/0.1% ammonium hydroxide) to provide the titled compound as a white foam. MS (CI) m/z 377 (M+l)+; lE NMR (300 MHz, CDCI3) 8 ppm 8.38 (s, 1H), 7.58 (dd, 1H), 6.59 (d, 1H), 4.74 (t, 1H), 4.63-4.57 (m, 1H), 3.78-3.68 (m, 6H), 2.53 (s, 1H), 2.43-2.34 (m, 2H), 1.69-1.50 (m, 4H), 1.19 (s, 3H).
Example 31 (2^,5i?V5-emyDvl-HA^(l-(3-cyano-pyridin-3-yl)pir>eridm-4-yl)glYcyl)pym)hdme-2^
carbonitrile
Example 31 A* 4-AnTmo-3,4,5,6-tetrahvdro-2H-(130bipyridmyl-5,-K^rrK)nirrile Pd2(dba)3 (0.040 g, 0.044 mmol, XANTHPOS (0.070 g, 0.122 mmol), dioxane (5mL), and CS2CO3 (1.10g, 3.15 mmol) were added into a dry Schlenk flask which was purged with nitrogen several times at room temperature. Then piperidin^yl-carbamic acid tert-butyl ester (0.50g, 2.34 mmol) was added followed by 5-bromo-nicotbomtrile (0.52g, 0.285 mmol)
WO 2004/026822
PCT/US2003/029018
and purging again with nitrogen. The reaction mixture was heated at 100 °C for 48 hours. The reaction was then cooled to room temperature and taken up in ethyl acetate (20 mL), washed with brine (2x) and water (2x), dried over MgS04, and concentrated under reduced pressure to provide the crude product The residue was purified by flash chromatography on silica gel eluting with 5% to 35% ethylacetate in hexane. MS (CI) m/z 303(M+i)+; !H NMR (300 MHz, methanol-^) 5 ppm 8.47 (d, 1H), 8.19 (m, 1H), 7.65 (d, 1H), 4.84 (m, 1H), 3.83 (m, 2H), 3.60 (m, 1H), 3.01 (t, 2H), 1.98 (m, 2H), 1.65-1.51 (m, 2H), 1.44 (s, 9H).
To a stirred solution of (5'
Example 3 IB • (25',5ig)-5-emynyl-l-(AKl-(3-cyano"pyriddn-3-yl)piperidm-4-vl)gl^^
carbonitrile To a stirred solution of (2S, 5R)-l-(cUoroacetyI)-5-emynylpyiToHdme-2-c^bonitrile (0.050 g, 0.26 mmol, Example 8D) in acetonitrile (1.5 mL), dioxane (0.1.5 mL), dimethylformamide (0.5 mL),and water (0.5 mL) at room temperature was added 4-amino-3,4)5,6-tetrahydro-2H-(lJ30bipyridinyl-5,-carbonitrile hydrochloride salt (0.028 g, 0.125 mmol) and diisopropylethylamine (0.145mL, 0.41mmol). The reaction mixture was stirred at room temperature for 48 hours, concentrated under reduced pressure and purified by flash chromatography on silica eluting with 5% methanol in dichloromethane. The product was mixed with 4M HC1 in dioxane (4mL) and after 0.5 hour, the solvents were removed under reduced pressure, and4he residue^was^solidified-by trituration with diethyl ether to provide the titled compound as the HC1 salt MS (CI) m/z 363 (M+l)+; 'H NMR (300 MHz, methanol-*/,) 5 ppm 8.48(d, 1H), 8.19 (d, 1H), 7.66 (m, 1H), 4.81-4.72 (m, 1H), 3.88-3.86 (m, 2H), 3.80-3.60 (q, 2H), 3.09 (d, 1H), 2.97-2.88 (m, 2H), 2.80-2.71 (m, 2H), 2.46-2.26 (m, 5H), 2.04 (m, 2H),1.54-1.44 (m, 2H).
Example 32
(2S.5R )-5-ethynyl-1 - (#-(4-methyl-1 -(4-methoxycarbonylbenzoyl)piperidin-4-
yQglycyl) pyrrolidine-2-carbonitrile
WO 2004/026822
PCTAJS2003/029018
Example 32A 4^4-BeDZVloxvcarbonylamino-4-metiiyl-piperidine-l-carbonYl)benzx>ic acid methyl ester To a stirred solution of (4-methyl-piperidin-4-yl)-carbamic acid benzyl ester hydrochloride salt (0.15 g, 0.53 mmol, Example 30B) in dichloromethane (3 mL) at room temperature was added methyl 4-chlorocarbonylbenzoate (0.125 g, 0.62 mmol) and triethylamine (0.17 mL, 1.2 mmol). The reaction mixture was stirred at room temperature for 3 hours, aqueous ammonium chloride was added, and the mixture was extracted with dichloromethane (2x). The combined organic layers were washed with 10% KHSO4, sat. NaHCC>3, brine, dried (MgSCU), and concentrated under reduced pressure to provide the titled compound. MS (CI) m/z 411 (M+l)+; 'H NMR (300 MHz, CDC13) 8 ppm 8.07(d, 2H), 7.46 (d, 2H), 7.33 (m, 5H), 5.06 (s, 2H), 4.63 (m, 1H-NH), 4.18-4.13 (m, 2H), 3.95 (s, 3H), 3.36 (m, 2H), 2.09 (m, 2H), 1.78-1.42 (m, 2H), 1.41 (s, 3H).
Example 32B 4-(4-Airuno-4-memyl-T3iperidme-l-carbonyl)-benzoic acid methyl ester To a stirred solution of Example 32A ( 0.2g, 0.49 mmol) in acetonitrile (4.0 mL) at room temperature was added iodotrimethysilane (0.11 mL, 0.75 mmol). The reaction mixture was stirred at 50 °C for 30 minutes and then concentrated under reduced pressure. The solid residue was washed with acetone and ether and filtered to provide titled compound. MS (CI) m/z 277(M+1)+; *H NMR (300 MHz, X)MSO-d6) 5 ppm 8.04(d, 2H), 7.90 (bs, 2H NH2-DMSO solvent), 7.50(d, 2H), 3.88 (s, 3H), 3.35-3.20 (m, 4H), 1.79-1.58 (m, 4H), 1.35 (s, 3H).
Example 32
(2£5/Q-5-ethynyM - (,7V-(4-methyl-I -(4-methoxycarbonylbenzoyl)piperidin-4-yl)glycyl |pyrrolidine-2-carbomtrile
To a stirred solution of (2S, 5R)-l-(cUoroacetyI)-5-emynylpyrrolidine-2-carbonitrile (0.03 g, 0.152 mmol, Example 8D) in acetonitrile (3 mL) at room temperature was added Example 32B (0.125 g, 0.31 mmol) and diisopropylethylamine (0.06mL, 0.31 mmol). The reaction mixture was stirred at room temperature for 48 hours, concentrated under reduced pressure and purified by high pressure liquid chromatography with acetonitrile and water buffered with ammonium acetate to provide the titled compound. MS (CI) m/z 437 (M+l)+; !H NMR (300 MHz, CDCI3) 5 ppm 8.07(d, 2H), 7.45(
WO 2004/026822
PCT/US200J/029018
Example 33 x
(2&5iQ-5-ethynyl-1 - (//-(4-metfayl-1 -(4-carboxy-pyridm-2-v0piperidin-4-
yl)glycyl) pyrrolidine-2-carbonitrile
Example 33 was prepared in the same manner as Example 40 by substituting 2-
fluoroisonicotinic acid for 6-fluoronicotinic acid MS(CI) m/z 396 (M+l)+; lHNMR
(300MHz, methanol-*/,) 5 ppm 8.17(d, 1H), 7.67(s,lH), 7.31(d,d 1H), 4.84(m, 2H), 4.34-4.15
(m, 4H), 3.41-3.35 (m, 2H), 3.20 (m, 1H), 2.52-2.24 (m, 5H), 2.07-2.00 (m, 4H), 1.59 (s, 3H).
Example 34 (2S,5R)-5-e&>Tiyl-l-(N44-memyl-l-(5-(trffl^^
yl} glycyl)pyrrolidine-2-carbonitrile
Example 34A
4-Memyl-5'-trifluoromemyl-3A5,6-te1iah^
To a stirred solution of (4-metb.yl-piperidin-4-yl)-carbamic acid benzyl ester hydrochloride salt (0.15 g, 0.53 mmol, Example 30B) in dioxane (1.0 mL) at room temperature was added 2-cUoro-5-trifluoromethyl-pyridine (0.11 g, 0.6 mmol) and diisopropylethyl-amine(0.21 mL, 1.2 mmol). The reactioiunixtnre was stirred at 150 °C in a microwave for 180 minutes, concentrated under reduced pressure and purified by flash chromatography with 30% ethyl acetate in hexane to provide (4-memyl-5,-trifluoromethyl-S^^.e-tetrahydro^H^lj^bipyridinyM-yO-carbamic acid benzyl ester. MS (CI) m/z 394 (M+l)+; ]HNMR (300 MHz, CDC13) 5 ppm 8.38(d, 1H), 7.61(d,d 1H), 7.40-7.30 (m, 5H),
6.66 (d, 1H), 5.07 (s, 2H), 4.71-4.67 (m, 1H), 3.93 (m, 2H), 3.36 (m, 2H), 2.10 (m, 2H), 1.68
(m,2H),1.42(s,3H).
To a stirred solution of (4-methyl-5Ltrifluoromethyl-3,4,5,6-tetrahydro-2H-(l,20bipyridinyl-4-yl)-carbamicacid benzyl ester(0.37g,0.95 mmol) inacetonitrile(4.0 mL) at room temperature was added iodotrimethysilane (0.2 mL, 0.125 mmol). The reaction mixture was stirred at 50 °C for 30 minutes, concentrated under reduced pressure and purified by flash chromatography with 2% methanol in dichloromethane to provide the titled compound. MS (CI) m/z 260 (M+l)+; 'H NMR (300 MHz, methanol-**/) 5 ppm 8.31 (d, 1H),
7.67 (d,d 1H), 6.87 (d, 1H), 4.83 (m, 2H), 3.79 (m, 2H), 3.63 (m, 2H), 1.63-1.54 (m, 4H),
1.22 (s,3H).
Example 34 (2S,5R)-5-ethynyl-l-(N-(4-memyl-l-(5-(trifluoromethyl)pyridin-2-vl)piperidin-4-
WO 2004/026S22
PCTAJS2003/029018
yl}glycyl)pyrrolidine-2-c5rbonitrilg
To a stirred solution of (23,5R)-l-(chloroacetyl)-5-ethynylpyrrolidine-2-carbonitrile
(0.064 g, 0.325 mmol, Example 8D) in acetonitrile (3 mL) at room temperature was added 4-
memyl-5'-rrifluoromemyI-3,4,5,6-tetiahydro-2H-(l,2>^ (0.110 g, 0.31
mmol) and diisopropylethylamine (0.15mL, 0.86mmol). The reaction mixture was stirred at room temperature for 48 hours, concentrated under reduced pressure and purified by flash chromatography with 1.5% methanoirdichloromethane. The product was mixed with 4M HC1 in dioxane (2mL) and after 0.5 h, the solvent were removed under reduced pressure, and the residue was solidified by trituration with diethyl ether to provide the titled compound as the HC1 salt. MS (CI) m/z 420 (M+l)+; *H NMR (300 MHz, CDC13) 5 ppm 8.38(d, 1H), 7.60 (dd 1H), 6.63 (d, 1H), 4.74 (m, 1H), 4.61 (m, 1H), 3.74-3.61 (m, 5H), 3.45 (m, 1H), 2.51 (bs, 1H), 2.31-2.51 (m, 4H), 1.55-1.71 (m, 4H), 1.18 (m, 3H).
Example 35 (2S.5R)-l-fN-(H4^Morobenz»yl)pir)eri^
Example 35A (l-(4-CMoro-r^n2pyI)-piperid^-4-yl)-carbaimc acid tert-butyl ester To a stirred solution of piperidin-4-yl-carbamic acid fer/-butyl ester (1 g, 5 mmol) and triethylamine (1.05 ml, 7.5 mmol) in THF (30 mL) at 0 °C was slowly added 4-chloro-benzoyl chloride (0.77 ml, 6 mmol). The reaction mixture -was stirred from 0 °C to room temperature for 2 hours. The reaction mixture was diluted with CH2CI2 and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the titled compound. MS (DO) m/z 339 (M+H)Example 35B (4-Amino-piperidin-l-vlH4-chloro-phenyl)-methanone To a stirred solutionof (l-(4-chloro-benzoyl)-piperidin-4-yl)-carbamic acid ter/-butyl ester (46 g, 0.23 mmol) in CH2C12 (0.5 mL) was added trifluoroacetic acid (0.5 ml). The reaction mixture was stfrred at room temperature for 1/2 hour. The reaction rnixture was concentrated under reduced pressure to provide the titled compound. MS (DCI) m/z 239 (M+H)+.
WO 2004/026822
PCT/US200.V02V«ie
(2S.5R)-1 - {N-( 1 -^-chlorobenzoy^piperidin^-vOqlycyl) -5-ethynylpyn olidine-2-carbonitriIe To a stirred solution of (2S,5R)-l-(chloroacetyl)-5-propynylpyrrolidine-2'Carbonitrile (0.023 g, 0.118 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added (4-amino-piperidin-l-yl)-(4-chloro-phenyl)methanone (56 mg, 0.235 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanohdichloromethane to provide the titled compound. MS (ESI) m/z 399 (M+H)+.
Example 36
f2S,5RVl-m^H5^rJoropyridm-2~vl)^memylpiperidin-4-yDglycyl>-5-
ethynylpyrrolidine-2-carbonitrile
Example 36A 5'-Cmoro^memyl-3,4,5,6^teti^ydro-2H^lJ0bipyridmyl4-ylamine
To a stirred solution of (4-methyl-piperidin-4-yl)-carbamic acid benzyl ester (0.5 g, 2.02 mmol, Example 30B) in dioxane (5.0 mL) at room temperature was added 2,5-dichloro-pyridine (0.4 g, 2.79 mmol) and diisopropylethyl amine (0.2 mL, 1.1 mmol). The reaction rnixture was stirred at 80 °C for 48 hours, concentrated under reduced-pressure and purified by flash chromatography with 10% to 40% ethyl acetate in hexane to provide (5'-chloro-4-memyl-3,4,5,6-tetiahydro-2H-(l,20bipyridmyl^yl)-carbamic acid benzyl ester. MS (CI) m/z 360 (M+l)+; *HNMR (300 MHz, CDC13) 8 ppm 8.01(d, 1H), 7.49 (dd, 1H), 7.36-7.27 (m, 5H), 726 (m, 1H), 6.78 (d, 1H), 5.04 (s, 2H), 3.82 (m, 2H), 3.21 (m, 2H), 2.15 (m, 2H), 1.58 (m,2H), 1.35 (s,3H).
To a stirred solution of (5'-chloro-4-methyl-3,4,5,6-tetrahydro-2H-(l,2')bipyridinyl-4-yl)-carbamic acid benzylester (0.060 g, 0.17 mmol) in acetonitrile (1.0 mL) at room temperature was added iodotrimethysilane (0.04 mL, 0.25 mmol). The reaction mixture was stirred at 50 °C for 30 minutes, concentrated under reduced pressure, and purified by flash chromatography with 3% methanol in dichloromethane to provide titled compound. MS (CI) m/z226(M+l)+.
Example 36
(2S,5RVl-fN4U5^hloropyridin-2-vlV4-methylpipeTidin4-yl)glvcyU-5-
emynylpyrroIidine-2-carbonitrile
To a stirred solution of (2S, 5R)-l-(chloroacetyl)-5-ethynylpyiTolidine-2-carbonitrile
(0.013 g, 0.066 mmol, Example 8D) in acetonitrile (0.75 mL) and dioxane (0.75 mL) at room
temperature was added S'MjWoro^memyl-S^jSje^etrahydro^H^l^'Jbipyridmyl^ylamine
WO 200-1/026822
PCTAJS2003/029018
(0.028 g, 0.125 mmol). The reaction mixture was stirred at 70 °C for 48 hours, concentrated -^'f under reduced pressure and purified by high pressure liquid chromatography with acetonitrile and water containing 0.02% TFA. The residue was solidified by trituration with diethyl ether to provide the titled compound as the TFA salt. MS (CI) m/z 386 (M+l)+; 'H NMR (300 MHz, methanol-^) S ppm 8.10 (m, 1H), 7.56 (d,d, 1H), 6.87 (d, 1H), 4.93 (m, 1H), 4.81 (m, 2H), 4.34-4.12 (m, 4H), 3.35 (m, 1H), 3.23 (d, 1H), 3.15-3.06 (m, 2H), 2.46-2.31 (m, 4H), 1.88-1.99 (m,4H), 1.55 (m,3H).
Example 37 (2S.5RV5-emynyl-l-(N-(l-pyridm-2-ylpiperidm-4^^
Example 37A 3A5,6^TetrahYdVo-2H-(l,2Qbipyridmyl-4-ylamine
Pd2(dba)3 (0.040 g, 0.044 rnmol),JCANTHPOS (0.070 g, 0.122 mmol), dioxane (5mL), and CS2CO3 (1.10g, 3.15 mmol) were added into a dry Schlenk flask which was purged with nitrogen several times at room temperature. Then piperidin-4-yl-carbamic acid tert-butyl ester (0.50g, 2.34 mmol) was added followed by 2-bromopyridine (0.452g, 0.285 mmol) and additional nitrogen purges. The reaction mixture was heated at 100 °C for 48 hours. The reaction was then cooled to room temperature, taken up in ethyl acetate (20 mL), washed with brine (2x), water (2x), dried over MgSC«4, and concentrated under reduced pressure. The residue was purified by flash chromatography with 5% to 35% ethyl acetate in hexane. MS (CI) m/z 278 (M+l)+; !H NMR (300 MHz, methanol-^) 8 ppm 8.03 (d, 1H), 7.57 (t, 1H), 6.86 (d, 1H), 6.65 (t, 1H), 4.84 (m, 1H), 4.16 (m, 2H); 3.58 (m, 1H), 3.04-2.95 (m, 2H), 1.92 (m, 2H), 1.52-1.47 (m, 2H), 1.44 (s, 9H).
To a stirred solution of (3,4,5,6-tetrahydro-2H-(l,2')bipyridinyl-4-yI)-carbamic acid tert-butyl ester (0.45 g, 1.49 mmol) in dioxane (3.0 mL) at room temperature was added 4M HC1 in dioxane (8mL). JThereactionmixture was^tin^atTO
Example 37 (2S,5R)-5-ethynyl-1 -(N-( 1 -pyridin-2-ylptperidtn-4-yl)Rlycyl)pym)lidme-2-l-(chloroaceryl)-5-emynylpyn^oUdine-2-carbonitrile (0.027 g, 0.14 mmol. Example 8D) in acetonitrile (0.5 mL), dioxane(0.5 mL), and water (0.7 mL) at room temperature was added 3,4,5,6-tetrahydro-2H-(l,20bipyridmyl-4-ylarriine (0.028 g, 0.125 mmol) and diisopropylethylamine (0.072mL, 0.41mmol). The reaction mixture was stirred at room temperature for 48 hours, concentrated under reduced pressure and purified by
WO 2004/026822
PCT/US2003/0290I8
flash chromatography with 5% methanol in dichloromethane. The product was mixed with 4M HC1 in dioxane (2mL), and after 0.5 h, the volatiles were removed under reduced pressure, and the residue was solidified by trituration with diemyi ether to provide the titled compound as the HC1 salt MS (CI) m/z 338 (M+l)+; !H NMR (300 MHz, methanol-d4) 5 ppm 8.09(m, 1H), 7.99 (d, 1H), 7.47 (d, 1H), 7.05 (t, 1H), 4.88 (m, 1H), 4.45-4.19 (m, 5H), 3.61-3.35 (m, 2H), 3.21 (m, 1H), 2.47-2.33 (m, 6H), 1.86-1.82 (m, 2H), 1.37-1.15 (m, 2H).
Example 38 (2S,5R)-5-ethynyl-1 -QJ- (4-methyl-1 -(4-ftrifluoromemyDpyriirudin-2-vl')piperidin-4-
yl) glycvl)pyrrolidine-2-carbonitrile
Example 38A 4-Memyl-H4-trifluoromemyl-pyrinri
To a stirred solution of (4-methyl-piperidin-4-yl)-carbamic acid benzyl ester hydrochloride salt (0.15 g, 0.53 mmbi, Example 30B) in dioxane (1.0 mL) at room temperature was added 2-cM6ro-4^trifluoromethyl-pyrirnidine (0.1 g, 0.55 mmol) and diisopropylethyl amine (0.2 mL, 1.1 mmol). The reaction mixture was stirred at 150 °C in a microwave for 30 minutes, concentrated under reduced pressure and purified by flash chromatography with 30% ethyl acetate and hexane to provide (4-methyl-l-(4-trifluoromethyl-pyrirnid^-2-yl)-piperid^^yl)-carbarnic acid benzyl ester. MS (CI) m/z 395 (M+l)+; !H NMR (300 MHz, CDC13) 5 ppm 8.48(d, 1H), 7.37-7.32 (m, 5H), 6.72 (d, lH), 5.08 (s, 2H), 4.67 (bs, 1H), 4.22 (m, 2H), 3.49 (m, 2H), 2.08 (m, 2H), 1.68-1.60 (m, 2H), 1.35 (s,3H).
To a stirred solution of (4-memyl-l-(4-trifluoromethyl-pyrimidin-2-yl)-piperidin-4-yl)-carbamic acid benzyl ester (0.060 g, 0.17 mmol) in acetonitrile (1 .OmL) at room temperature was added iodotrimethysilane.(0.04 mL, 0.25 mmol). The reaction mixture was stirred at 50 °C for 30 minutes, concentrated under reduced pressure and purified by flash chromatography with 3% methanol in dichloromethane to provide the titled compound. MS (CO m/z261(M+l)+; 'HNMR(300 MHz, methanol-**,) 5ppm 8.61(d, 1H), 6.92 (d, 1H), 4.83 (m, 2H), 4.50 (m, 2H), 3.51 (m, 2H), 1.90-1.74 (m, 4H), 1.51 (s, 3H).
Example 38 (2S,5R)-5-emynyl-l
yl) Rlycyl)pyrrolidine-2-carponitrile To a stirred solution of (2S, 5R)-l-(chloroacetyl)-5-ethynylpyrrolidine-2-carbonitriIe (0.04 g, 0.205 mmol, Example 8D) in acetonitrile (3 mL) at room temperature was added
61
WO 2004/026822
PCT/US2003/029018
Example 38A (0.140 g, 0.54 nnnol) and diisopropylethylamine (O.lOmL, 0.58mmol). The reaction mixture was stirred at room temperature for 48 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanol:dichloromethane with 0.03% ammonia. The product was mixed with 4M HCI in dioxane (2mL), and after 0.5 h, the solvent were removed under reduced pressure and the residue was solidified by trituration with diethyl ether to provide the titled compound as the HCI salt MS (CI) m/z 421 (M+l)+; !H NMR (300 MHz, methanol-^) 6 ppm 8.61(d, 1H), 6.95 (d, 1H), 4.85 (m, 2H), 4.21 (q, 2H), 3.12-3.23 (m, 6H), 2.28-2.45 (m, 4H), 1.80-2.03 (m, 4H), 1.6 (m, 3H).
Example 39 (2S,5RV5-e&ynyl-l-(N-(l-isom(X)tmoyl^
carbonitrile
Example 39A . (4-Ammo-4-mefayl-piperidm-l^
To a stirred solution of (4-memyl-piperidin-4-yl)-carbarnic acid benzyl ester hydrochloride salt (0.15 g, 0.53 mmol, Example 30B) in dicnloromethane (3 mL) at room temperature was added isonicotinoyl chloride (0.4 g, 2.79-mmoI) and triemylamine (0.17 mL, 1.2 mmol). The reaction mixture was stirred at room temperature for 3 hours, aqueous ammonium chloride was added, and the mixture was extracted with dicnloromethane (2x). Combined organic layers were washed with 10% KHSO4, sat NaHC03, and brine before drying (MgSCv), and concentration under reduced pressure to provide (4-methyl-l-(pyridine-4-carbonyl)-piperidin-4-yl)-carbamic acid benzyl ester. MS (CI) m/z 354 (M+l)+; !H NMR (300 MHz, CDCb) 5 ppm 8.69 (d, 2H), 7.40-7.31(m, 7H), 5.06 (s,5H),_4.15 (m, 1H), 4.62 (m, 4H), 2.12 (m, 2H), 1.77-1.45 (m, 2H), 1.42 (s, 3H).
To a stirred solurion-(4^mefeyM~(pyridme^ benzyl ester ( 0.085& 0.24Tnmol) in acetonitrile (2.0 mL) at room temperature was added iodotrimethysilane (0.06 mL, 0.36Tnmol). The reaction mixture was stirred at 50 °C for 30 minutes and concentrated under reduced pressure. The solid residue was washed with acetone and filtered to provide titled compound. MS(CI)m/z220(M+l)+; !H NMR (300 MHz, DMSO-de) 5 ppm 8.89(di 2H), 7.74(d, 2H), 4.04 (m, 2H, NH2), 3.42-3.25 (m, 4H), 1.77-1.45 (m,4H), 1.42 (s,3H).
Example 39 (2S,5R)-5-ethynyl-l -(N-( 1 -isonicotmoyl-4-methylpiperidin-4-yl)glycyl)pyrrolidine-2-
carbonitrile
WO 2004/026822
PCTAJS2003/029018
To a stirred solution of (2S, 5R)-l-(chloroacetyl)-5-ethyuylpyrrolidine-2-carbonitrile (0.03 g, 0.152 ramol, Example 8D) in acetonitrile (3 mL) at room temperature was added (4-ammo-4-memyl-pir^ridm-l-yl)-pyridin-4-yl-methanone (0.110 g, 0.31 mmol) and dusopropylethylamine (0.06mL, 0.3 lmmol). The reaction mixture was stirred at room temperature for 48 hours, concentrated under reduced pressure and purified by high pressure liquid chromatography with acetonitrile and water buffered with ammonium acetate. The product was mixed with 4M HC1 in dioxane (2 mL) and after 0.5 hours, the solvent were removed under reduced pressure, and the residue was solidified by trituration with ether to provide the titled compound as the HC1 salt MS (CI) m/z 380 (M+l)+; 'H NMR (300 MHz, CDC13) 5 ppm 8.69(d, 2H), 7.27 (d, 2H), 4.78 (m, 1H), 4.59 (m, 1H), 4.01(m, 1H), 3.2-3.75 (m, 6H), 2.62 (bs, 1H), 2.31-2.58 (m, 4H), 1.41-1.78 (m,_4H), 1.17 (m, 3H).
Example 40 (2S,5jR)-5-emynyl-l-(#-(4-memyn
vl)^ycyl)pyrrolidine-2-carbonitrile
Example 40A 6-Fluoro-nicotinic acid tert-butyl ester To a stirred and refluxed solution of 6?fiuoro-nicotinic acid (0.092 g, 6.52 mmol) in benzene and 2-methyl-propan-2-ol (2:1,15:7 mL) was added dropwise N,N-dimethylformamide di-fer^butyl acetal (8.2 mL, 29.6 mmol). The reaction mixture was refluxed for 3 hours, cooled to room temperature and partitioned between aqueous NaHCC>3 and dichloromethane. The organic layer was washed with water and brine, dried (MgSC^), filtered, concentrated under reduced pressure and purified by flash chromatography with 15% to 30% ethyl acetate in hexane to provide the titled compound. MS (CI) m/z 197 (M+l)+; *H NMR (300 MHz, CDC13) 5 ppm 8.82(d, 1H), 8.38(m, 1H), 6.98(d, 1H), 1.64 (s, 9H).
Example 40B 4-Amino-4-methyI-3,4,5,6-tetrahydro-2H-(l,2')bipvridinyl-5'-carboxylic acid tert-butyl
ester To a stirred solution of (4-methyl=piperidin-4-yl)-carbamic acid benzyl ester (0.31 g, 1.28 mmol, Example 30B) in dioxane (5.0 mL) at room temperature was added 6-fluoro-nicotinic acid tert-butyl ester (0.21 g, 1.07 mmol). The reaction mixture was stirred at 80 °C for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 10% to 30% ethyl acetate in hexane to provide 4-benzyloxy(arbonylarjamo-4-methyl-3,4,5,6-
WO 2004/026822
PCT/US2003/029018
tetrahy&o-2H-(l,2>ipyrid^yl-5'-carboxyHc acid tert-butyl ester. MS (CI) m/z 426 (M+l)+; 'H NMR (300 MHz, CDC13) 8 ppm 8.74(d, 1H), 7.97 (dd, 1H), 7.35 (m, 5H), 7.26 (s, 1H), ' 5.07 (s, 2H), 4.68 (s, 1H), 3.97 (m, 2H), 3.37 (m, 2H), 2.08 (m, 2H), 1.66 (m, 2H), 1.56 (s, 9H),1.42(s,3H).
To a stirred solution of 4-benzyloxycarbonylamino-4-methyl-3,4,5)6-tetrahydro-2H--(l,2')bipyridinyl-5'~carboxylic acid tert-butyl ester (0.29 g, 0.68 mmol) in isopropanol, methanol and ethyl acetate (1:1:1,5.0 mL) at room temperature was added ammonium formate (0.25 g, 1.07 mmol) and 10% Pd/C (25 mg) under nitrogen. The reaction mixture was stirred at 80 °C for 30 minutes, cooled, filtered through Celite, and concentrated under reduced pressure to provide the titled compound. MS (CI) m/z 292 (M+l)+; *H NMR (300 MHz, methanol-^) 5 ppm 8.61(d, 1H), 7.95 (d,d IH), 6.79 (d, IH), 4,80 (s, 2H), 3.85-3.79 (m, 2H), 3.66-3.60 (m, 2H), 1.67-1.59 (m, 4H), 1.58 (s, 9H), 1.23 (s, 3H).
Example 40 (2S,5J0-5-emvnyl-l-(JV'-(4-memyl-l-(5-car^
yl)dycyl)pynt)u'dine-2-carbonitrile To a stirred solution of (2S, 5R)-l-(cUoroacetyl)-5-emynylpyrroUdme-2-carbonitrile (0.058 g, 0.30 mmol, Example 8D) in dioxane(3.0 mL) and water (l.OmL) at room temperature was added 4~anlmo-4-memyl-3,4,5,6-tetrahydro-2H-(l^^bipyridinyI-5,-carboxylic acid tert-butyl ester (0.170 g, 0.58 mmol). The reaction mixture was stirred at room temperature for 48 hours, concentrated under reduced pressure and purified by flash chromatography with 5% methanol in dichlorometnane. The product was mixed with TFA in dichloromethane(l :1,6mL), and after 2 h, the volatiles were removed under reduced pressure. The residue was solidified by trituration with diethyl ether to provide the titled compound as the TFA salt MS (CI) m/z 396 (M+l)+; 'H NMR (300 MHz, methanol-^) 6 ppm 8.68(d, 1H), 8.15 (d,d, 1H), 7.03 (d, 1H), 4.84 (m, 2H), 4.47 (d, 2H), 4.32-4.14 (q, 2H), 3.31-3.25 (m, 2H), 3.20 (d, 1H), 2.51-2.23 (m, 5H), 2.06-1.93 (m, 4H), 1.59 (m, 3H). .
Example 41 (2iS',5Jg)-5-emynyl-l-(^-(4-methyl-l-(5-cyano-pyridin-3-yl)piperidin-4-yl)glycvl)pyrrQlidine-
2-carbonitrile
Example 41A 4-AmmcM^-memyl-3,4,5,6-tetrahya>o-2H-(130bipyridinyl-5'-carbonitriIe Pd(AcO)2 (0.008 g, 0.036 mmol, BINAP (0.032 g, 0.052mmol) toluene (3mL), and CS2CO3 (0.280g, 0.85 mmol) were added into a dry Schlenk flask which was purged with
WO 2004/02(>822
PCTAJS20C3/029018
nitrogen several times at room temperature. Then (4-methyl-piperidin-4-yl)-carbamic acid benzyl ester (0.280g, 0.85 mmol. Example 30B) was added followed by 5-bromo-nicotinonitrile (0.280g, 0.85 mmol), and the reaction vessel wa purged with nitrogen again. The reaction mixture was heated at 100 °C for 72 hours. The reaction was then cooled to room temperature and taken up in ethyl acetate (20 mL), washed with brine (2x), water (2x), dried over MgSC>4, and concentrated under reduced pressure to give crude product The residue was purified by flash chromatography with 10% to 35% ethylacetate/hexane. MS (CI)m/z351(M+l)+.
To a stirred solution of (S'^yano^-memyl-S^^.e^etrahydro-IH-fl^ObipyridiiiyM-yl)-carbamic acid benzyl ester (0.051 g, 0.15 mmol) in isopropanol, (3.0 mL) at room temperature was added ammonium formate (0.050 g, 0.8 mmol) and 10% Pd/C (15 mg) under nitrogen. The reaction mixture was stirred at 90 °C for 18 hours, cooled, filtered through Celite and concentrated under reduced pressure to provide the titled compound. MS (CI) m/z292 (M+l)+; ^NMRpOO MHz, methanol-^) 8 ppm 8.48 (d, 1H), 8.18 (d, 1H), 7.65 (m, 1H), 3,49-3.36 (m, 2H), 3.32-3.36 (m, 2H), 1.73-1.61 (m, 4H), .L20 (s,JH).
Example 4 IB (2^,5Jg)-5-emynyl-H^-(4-memyl-l^(5-cyano^pyridm-3-yl)piperidm-4-yl)glycyl)pv^
2-carbonitrile
To a stirred solution of (2S, 5R)-l-(cWoroa(^tyl)-5-emynylpyrroU6^e-2-
(0.013 g, 0.066 mmol, Example 8D) in acetonitrile (0.8 mL) at room temperature was added
4-ammo-4-memyl-3,4,5,6-teti^ydro-2H^^ (0.028 g, 0.13
mmol). The reaction mixture was stirred at 70 °C for 48 hours, concentrated under reduced pressure and purified by flash chromatography with 2-4% methanohdichloromethane. The product was mixed with 4M HC1 in dioxane(2mL) and after 0.5 h, the volatiles were removed under reduced pressure, and the residue was solidified by trituration with diethyl ether to provide the titled compound as the_HCLsalt. MS (CI) m/z 377 (M+l)+; 'H NMR (300 MHz, methanol-*/,) 5 ppm 8.48(d, 1H), 8.18 (d, 1H), 7.66 (m, 1H), 5.01 (m, 1H), 4.77-5.0 (m, 2H), 3.78-3.45 (m, 4H), 3.34 (m, 1H), 3.08 (d,lH), 2.51 (bs, 1H), 2.05-2.41 (m, 4H), 1.70-1.77 (m, 4H), 1.19 (m, 3H).
Example 42 (2S,5R)-5-emynyl-l-(N-n'ans(4-hydroxvcvclohexyl)glycyl)pynDUdme-2-(arbonitrile To a stirred solution of (2S,5R)-l-(cbJoroacetyl)-5-emynylpyrToUdine-2-
WO 2004/026822
PCT/US2003/029018
chromatography with 3% methanolrdichloromethane to provide the titled compound. MS (ESI) m/z 276 (M+H)+; 'H NMR (CDC13) 6 4.73 (m, 1H), 4.60 (m, 1H), 3.62 (m, 2H), 3.60 (m, 1H), 2.52 (d, 1H), 2.48 (m, 1H), 2.38 (m, 2H), 1.98 (m, 4H), 1.25 (m, 4H).
5
Example 43
(2S,5R)-5^mvnyl-l-(N^4-trans((4'-fluoro-5-(tiifluorometbvlVl.l'-biphenvl-2-
yl)oxy)cyclohexyl)glycvl)pvrroHdine--2-carbonitiile
10
Example 43 A 4-faans(2-bromo^-trifluoromemyl-phenoxy)-cyclohexylamine To a stirred solution of trans^aminocyclohexanol (115 mg, 1 mmol) in DMF (3 mL) at 0 °C was added 60%-NaHinmineral oil (120 mg, 3 mmol). The reaction mixture was 15 stirred at 0 °C for V2 hour and then 3-bromo-4-fluoro-l-trifluoromethyl benzene (0.17 ml, 1.2 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the titled compound. MS (DCI) m/z 338 (M+H)+. 20
Example 43B (4-trans(2-bromo^trifluoromethyl-phenoxy)^yclohexylV
mmol) in CH2CI2 (1 mL) solution via syringe. The reaction mixture was stirred from 0 °C to room temperature for 2 hours. It was diluted with CH2CI2 and washed with water (2 times) and brine^The organic layer was dried (sodiunusulfete),-filtered,xoncentrated under reduced pressure and purified by flash chromatography with 30% ethyl-acetate/hexane to provide the 30 titled compound. MS(ESI)/»6438(M+H)+.
- - Example 43C
(4-trans(4'-fluoro-5-trifluorome&yl-biphenyl-2-yto
35 ' ester
To a cold solution of (4-(2-bromo-4-trifluoromethyI-phenoxy)-cyclohexyl)-carbamic acid ter/-butyl ester (219 mg, 0.5 mmol) in isopropanol (5 mL) was added 4-fluorophenylboronic acid (84 mg, 0.6 mmol), Pd(PPh3)2Cl2 (35 mg, 0.05 mmol), and K2CO3
WO 2004/026822
FCT/US2003/U29U1S
(207 mg, 1.5 mmoi). The reaction mixture was heated to 85 °C for 3 hours. It was diluted with ethyl acetate and washed with water (2 times) and brine. The organic layer was dried (sodium sulfate), filtered, concentrated under reduced pressure and purified by flash chromatography with 30% ethyl acetate/hexane to provide the titled compound. MS (ESI) m/z454(M+H)+.
Example 43D 4-trans(4,-fluoro-5-trifluoromemyl-biphenyl-2-yloxY)K;yclohexyIarrjine To a solution of (4^4'-fluoro-5-trifluoromethyl-biphenyI-2-yloxy)-cyclohexyl)-carbamic acid ferf-butyl ester (139 mg, 0.31 mmol) in CH2CI2 (1 mL) was added 4N HCl/dioxane (3 ml). The reaction mixture was stirred at room temperature for 3 hours and concentrated under reduced pressure to provide the titled compound. MS (ESI) m/z 354 (M+H)+.
Example 43
(2S,5RV5^mwl-W^1rarisf(4'^uorc^
yl)oxy}cyclohexyl)glycyl)pyrrolidme-2-carbonitrile
To a stirred solution of (2S,5R)-l^cUoroacetyI)-5-emynylpyrrohdme-2-carrK)rutrile (0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(4'-fluoro-5-trifluoromemyl-biphenyl-2-yloxy)^yclohexylamine (0.31 mmol) andNEt3 (0.063 ml, 0.45 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanohdichloromethane to provide the titled compound, MS (ESI) m/z 514 (M+H)+; *H NMR (DMSO) 5 7.58 (m, 3H), 7.43 (d, 1H), 7.25 (m, 2H), 7.15 (d, 1H), 4.98 (m, 1H), 4.85 (m, 1H), 4.35 (m, 2H),3.87 (m, 1H), 3.14 (m, 1H), 2.29-2.45 (m, 3H); 2.15 (m, 6H), 1.60 (m, 4H).
Example 44
(2S,5R)-5-ethynyl-l-(N>f4-trans(4-
(trifluoromemoxy)phenoxy')cyclohexyl|glycyl)pyrTolidine-2-carbonitrile
Example 44A 4-trans(trifluoromethoxy-phenoxy)-cyclohexylamine To a stirred solution of trans-4-aminocyclohexanol (230 mg, 2mmol) in DMF (10 mL) at 0 °C was added 60% NaH in mineral oil (240 mg, 6 mmol). The reaction mixture was
WO 2004/026822
PCT/US2003/029018
stirred at 0 °C for lA hour and then l-fluoro-4-(trifluoromethoxy)benzenc (432 mg, 2.4 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced 5 pressure to provide the titled compound. MS (DCI) trt/z 276 (M+H)+.
Example 44
(2S,SR)-5-ethynYl-l-(N-(4-trans(4-
10 (trlfluoromemoxy)phenoxy)cyclohexvUgW
To a stirred solution of (2S,5R)-l-(cUoroaceryl)-5-emynylpyn-olio!me-2-carbonitrile (0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(trifluoromemoxy-phenoxy)^yclohexylamine (84 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and 15" purified by flash chromatography with 3% methanolrdichlorornethane to provide the titled
compound. MS (ESI) m/z436 (M+H)+; *HNMR(GD3OD)5 7.19 (d, 2H), 6.99 (d, 2H), 4.32 (m, 2H), 4.18 (m, 1H), 3.21 (m, 1H), 2.44 (d, 3H), Z27 (m, 6H); 1.67 (m,3H); 1.55 (m, 2H), 1.37 (m,2H).
20
Example 45 (2S,5R)-5^&ynyl-1^^4-hydroxy-l-memyl(^clote
25 Example 45A
4-(tert-Butyl^unethyl-silanvloxvVcyclohexanecarboxylic acid ethyl ester To a solution of 4-hydroxy-cyclohexanecarboxy-lic-acid ethyl ester (10.32 g, 59.92 mmol) in dimethylformamide (50 mL) was added imidazole (8.16 g, 119.8 mmol), followed by tert-butyldimethylsilyl chloride (9.94 g, 65.9 mmol). The resulting mixture was stirred at
30 room temperature for 16 hours. Diethyl ether was added (150 mL), and the mixture was washed with 1M HC1 (150 mL). The aqueous layer was extracted with diethyl ether (150 mL). The combined organic layers were washed with 1M HC1 (100 mL) and saturated sodium chloride solution (100 mL), dried over-magnesium sulfate, filtered and concentrated to afford a clear oil. MS (CI) m/z 287 (M+l)+
35 .
Example 45B 4^tert-Butyl^imethyl-silanvloxy)-cyclohexanecarboxylie acid To a solution of Example 45 A (6.6 g, 23.0 mmol) in tetrahydrofuran (31 mL) and
68
WO 200-1/026822
PCTYUS2003/029018
methanol (20 mL) was added lithium hydroxide monohydrate (1.93 g, 46.1 mmol). The resulting mixture was heated at 60 °C for 2 hours. The heat was removed and the reaction mixture was stirred at room temperature overnight. The solvents were removed in vacuo and the solution was neutralized with 1M HCl. Ethyl acetate (200 mL) was added and the layers were separated. The aqueous layer was further extracted with ethyl acetate (2 X 200 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated to give the titled compound (4.5 g). MS (CI) m/z 259 (M+l)+
Example 45C 4-(tert-Buty 1-dimethy 1-silanyloxy)-1 -methyl-cyclohexanecarboxylie acid To a cold (-78 °C) of diisopropylamine (3.44 mL, 24.5 mmol) in tetrahydrofuran (49 mL) was added n-butyl lithium (2.5 M in hexanes, 9.81 mL, 24.5 mmol) dropwise over 10 minutes. The ice bath was removed, and the reaction mixture was allowed to warm to 0 °C and then cooled back to -78 °C. A solution of Example 45B (3.3 g, 12.3 mmol) in tetrahydrofuran (10 mL) was then added. The ice bath was removed and the reaction mixture was heated at 50 °C for 2 hours. The reaction mixture was then cooled back to -78 °C and methyl iodide (0.84 mL, 13.5 mmol) was added followed by stirring for 2 hours. The cooling bath was removed, and the reaction mixture was stirred at room temperature for 1 hour. The reaction solution was then poured into diethyl ether (200 mL) and 1M HCl (200 mL). The layers were separated and the aqueous layer was further extracted with diethyl ether (2 X 200 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated to a crude yellow oil. The crude oil was purified by flash chromatography with 15% ethyl acetate/84% hexane/1% methanol to afford the titled compound (2.37 g) as a light yellow oil. MS(CI)m/z273(M+l)+.
Example 45D (4-ftert-Butyl-dtmethyl-silanyloxy>l-methyl-cyclohexyl)-carbamic acid benzyl ester To a solution of example 45C (832 mg, 3.05 mmol) and triethylamine (596 |iL, 4.27 mmol) in toluene (15 mL) was added diphenylphosphoryl azide (791 |iL, 3.66 mmol) via syringe. The resulting light amber solution was stirred at 23 °C for 1 hour, then benzyl alcohol (1.6 mL, 15.25 mmol) was added. The solution was then heated at 75 °C for 24 hours. The reaction mixture was cooled and the solvents removed in vacuo. The crude oil was purifed by flash chromatography using a linear gradient of 95% hexane/5% ethyl acetate to 30% ethyl acetate/70% hexane to give the title compound (995 mg) as an inseparable mixture of diastereomers. MS (CI) m/z 378 (M+l)+; !H NMR (300 MHz, DMSO) 5 ppm 7.37-7.28 (m, 10H), 6.86 (s, 1H), 6.82 (s, 1H), 4.96 (s,2H), 4.95 (s, 2H), 3.80-3.70 (m, 2H),
WO 2004/026822
PCT/US2003/029018
3.62-3.50 (m, 2H), 2.05 (d, 2H), 1.79-1.75 (m, 2H), 1.64-1.20 (m, 8H), 1.19 (s, 3H), 1.16 (s, 3H), 0.84 (s, 9H), 0.83 (s, 9H), 0.02 (s, 12 H).
Example 45E (4-Hvdroxy-l-methvl-cyclohexyl)-carbamic acid benzyl ester To a solution of example 45D (341 mg, 0.91 mmol) in tetrahydrofuran (5 mL) was added tetrabutylammonium fluoride (1 M solution in THF, 2.0 mL, 2 mmol). The resulting brown solution was stirred at room temperature for 24 hours and then concentrated in vacuo and partitioned between ethyl acetate (100 mL) and water (100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated to afford a crude oil. The crude oil was purified by flash chromatography using a linear gradient of 80% hexane/20% ethyl acetate to 80% ethyl acetate/20% hexane to give the title compound (185 mg) as an inseparable rriixture ofdiastereomers. MS(CI)m/z264(M+l)+.
Example 45F 4-Amino-4-melhyl-cyclohexanol A mixture of example 45E (169 mg, 0.64 mmol), ammonium formate (105 mg, 1.67 mmol) and 10% palladium on carbon (7 mg) in isopropanol (5 mL) was heated at 80 °C for 1 hour. The reaction mixture was cooled and filtered through a plug of Celite. The filter pad was washed with ethyl acetate (50 mL), and the filtrate wasconcentrated in vacuo to afford the titled compound as an inseparable mixture ofdiastereomers. MS (CI) m/z 130 (M+l)+; 'H NMR (300 MHz, CDC13) 5 ppm 3.77-3.71 (m, 2H), 3.65-3.61 (m, 2H), 1.87-1.61 (m, 4H), 1.63-1.33 (m, 10H), 1.15 (s, 3H), 1.11 (s, 3H).
Example 45 (2S,5R)-5-ethynyI-1 -(N-(4-hvdroxy-1 -memylcyclohexyl)glycyl)pyn^liduie-2-carbonitrile A mixture of example 45F (66 mg, 0.51 mmol) and example 8D (50 mg, 0.26 mmol) in acetonitrile (1 mL) was stirred at 23 °C for 48 hours. The reaction mixture was concentrated and the crude material was purified by flash chromatography using using a step gradient of 3% methanol/97% dichloromethane to 5% methanol /95% dichloromethane to give the free base of the title compound (33 mg) as an inseparable mixture ofdiastereomers. The HC1 salt was prepared by taking the free base up in diethyl ether, adding the appropriate amount of 1M HC1 in diethyl ether and removing the solvent in vacuo. MS (CI) m/z 290 (M+l)+; 'HNMR (300 MHz, MeOH-,) 5 ppm 3.94-3.83 (m, 8H), 3.80-3.70 (m, 2H), 3.64-3.59 (m, 2H), 3.16 (d, 1H), 3.15 (d, 1H), 2.50-2.28 (m, 8H), 1.95-1.45 (m, 14 H), 1.29 (s, 3H), 1.23 (s,3H).
WO 2004/026822
PCT/US2003/029018
Example 46 (2S,5R)-5-ethyiivl4-fN-(l-methvl^-transfpvridin--3-vloxv)cvclohexvl)glvcvl}pvrrolidiDe-2-
carbonitrile
Example 46A l-MetfayM-transfpyridm-S-Yloxv^-cyclohexylamine To a mixture of sodium hydride (46 mg, 2.0 mmol) in dimethylformamide (5mL) at 0 °C was added example 45F (116 mg, 0.9 mmol). The resulting mixture was stirred at 23 °C for 30 minutes, men 3-fluoropyridine (73 pX, 0.85 mmol) was added. The mixture was then heated at 80 °C for 1 hour and then cooled. The reaction mixture was poured into saturated sodium bicarbonate-solution-(50jnL). JTheLSolution^was-men jextracted_wiuVemyl acetate (3 X 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude material was purified by flash chromatography using a step gradient of 2% methanol/97.9% dichloromethane/0.1% ammonium hydroxide to 6% methanol /93.9% dichloromethane/0.1% ammonium hydroxide to give the title compound (119 mg). MS (CI) m/z 207 (M+l)+; *H NMR (300 MHz, CDC13) 5 ppm 8.31 (d, 1H), 8.19 (t, 1H), 7.19 (d, 2H), 4.41-4.36 (m, 1H), 2,05-1.90 (m, 2H), 1.76-1.70 (m, 2H), 1.50-1.38 (m, 4H), 1.20 (s, 3H).
Example 46 (2S,5R)-5-emynyl-l-{N-(l-memyl-4-trans(pyridm-3-yto^
carbonitrile A mixture of example 46A (105 mg, 0.51 mmol) and example 8D (50 mg, 0.26 mmol) in acetonitrile (0.75 mL) was stirred at 23 °C for 48 hours. The reaction mixture was concentrated-and-tlie_crude_material was purified by flash chromatography_using aJinear gradient of 2% methanol/97.9% dichloromethane/0.1% ammonium hydroxide to 6% methanol /93.9%-dichloromethane/0.1% ammonium hydroxide to give the title compound (43 mg) as its free base. The HC1 salt was prepared by taking the free base up in diethyl ether, adding the appropriate amount of 1M HC1 in diethyl ether and removing the solvent in vacuo. MS (CI) m/z 367 (M+l)+; 'H NMR (300 MHz, MeOH-d,) 5 ppm 8.67 (d, 1H), 8.65 (d, 1H), 8.29 (dd, 1H), 8.02 (dd, 1H), 4.93 (m, 1H), 4.80-4.72 (m, 1H), 4.25L(AB_quariet,J2H),3.24 (d, 1H), 2.50r2.15_(m, 6H), 2.10-1.75 (m, 6H), 1.52 (s, 3H).
Example 47 (2S,5R)-l-(N-(4-rrans((5-chloropyridm-3-vl)oxy)cyclohe\Tl)glycyl)-5-emYnylpyrrolidine-2-
carbonitrile
WO 2004/026822
PCT7US2003/029018
Example 47 A 4-trans(5 -chloro-pyridin-3 -yloxy)cyclohexylamine To a stirred solution of trans-4-aminocyclohexanol (230 mg, 2 mmol) in DMF (5 mL) at 0 °C was added 60% NaH in mineral oil (240 mg, 6 mmol). The reaction mixture was stirred at 0 °C for !4 hour and then 3-chloro-5-fluoro-pyridine (0.21 ml, 2.4 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodlimvsulfate), filtered, and concentrated under reduced pressure to provide the titled compound. MS (DC1) m/z 227 (M+H)+.
Example 47 (2S,5R)-l^-(4-trans((5^Moropyridfo-3-yI)oxyte^
2-carbonitrile To a stirred solution of (2S,5R>l^cUoioac»tyl>5^mynylpyrroUoUne-2-carbomtrile (0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(5-cUoro-pyridm-3-yloxy)cyclohexylamine (70 mg, 0.31 mmol). The reaction niixture was stirred at room temperature for 18 hours, concentrated underTeduced pressure and purified by flash chromatography with.3% methanol:dichloromethane to provide the titled compound. MS (ESI) m/z 387 (M+H)+; *H NMR (CDC13) 5 8.17 (m, 2H), 7.19 (m, 1H), 4.74 (m, 1H), 4.59 (m, 1H), 4.24 (m, 1H), 3.63 (m, 2H), 2.61 (m, 1H), 2.53 (d, 1H), 2.40 (m, 4H), 2.15 (m, 2H), 2.04 (m, 2H), 1.54 (m, 2H), 1.33 (m, 2H).
Example 48 (2S ,SR)-1 - {N-(4- trans(4»cyanophenoxy)cycIohexyl)glycyl) -5-ethynylpyrrolidine-2-
carbonitrile
Example 48A 4~(4- transaminocyclohexyloxy>ben2X)nitrile To a stirred solution of trans-4-aminocycIohexanol (115mg, lmmol) in DMF (6 mL) __aJ..Q.°C wa^dded_60% NaH.in mineral oil (120 mg^3 mmol). Thfrreaction mixture was stirred at 0 °C for V* hour and then 4-fluorobenzonitrile (151 mg, 1.25 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the titled compound. MS (DCI) m/z 217 (M+H)+.
WO 2004/026822
PCT/US2003/029018
Example 48 (2S,5R)-l-{N-(4-trans(4-cyanophenoxy')cvclohexvnglycyU-5-ethynvlpvrrolidine-2-
carbonitrile To a stirred solution of (2S,5R)-l-(chloroacetyl)-5-ethynylpyrroIidine-2-carbonitriIe (0.03 g} 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(4-aminocyclohexyloxy)-benzonitrile (66 rug, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanolrdichloromethane to provide the titled compound. MS (ESI) m/z 111 (M+H)+; 'HNMR(DMSO) 5 7.74 (d, 2H), 7.14 (d, 2H), 4.95 (m, 1H), 4.84 (m, 1H), 4.39 (m, 1H), 3.92 (m, 1H), 3.44 (m, 2H), 3.16 (m, 1H), 2.28 (m, 2H), 2.17 (m, 6H), 2.14 (d,lH), 1.53 (m,4H).
Example 49
(2S,5R)-5^thynvl4^-(4-trans{(5
yl)oxy>cyclohexyl)glycyl)pyrroHd^e-2H^trr>onitrile
Example 49 A 4-traris(5-trifluoit>memyl-pyridm-2-yloxy)^yclohexylarnine To a stirred solution of trans^arninocyclohexanol (345mg, 3 mmol) in DMF (10 mL) at 0 °C was added 60% NaH in mineral oil (360 mg, 6 mmol). The reaction mixture was stirred at 0 °C for V* hour, and then 2-chloro-5-(trifiuoromethyI)pyridine (652 mg, 3.6 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the titled compound. MS (DCI) m/z 261 (M+H)+.
Example 49 (2S,5R)-5-ethynyl-l-(N-(4-trans{(5-(trifluoromethyl)pyridin-2-yl)oxy} cycIohexyI)glycyl)pyrrolidine»2-carbonitrile To a stirred solution of (2S,5R)-HcWoroac»ryl)-5-propynylpyrTolidine-2-carbonitrile (0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(5-trifluoromethyl-pyridin-2-yloxy)-cyclohexylamine(80mg,0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanol:dichloromethane to provide the
WO 2004/026822
PCTAJS2003/029013
titled compound. MS (ESI) m/z 421 (M+H)+; lH NMR (DMSO) 5 8.58 (m, 1H), 8.06 (m, 1H), 6.97 (d, 1H), 4.97 (m, 1H), 4.86 (m, iH), 4.35 (m, 1H), 3.88 (m, 1H), 3.19 (m, 2H), 2.15- 2.40 (m, 9H), 1.55 (m, 4H).
Example 50
f2S,5RV5-ethynyl-l-(N-{4- trans(3-pyridin-4-yl-4-
(trifluoromemyl)phenoxy)cvclohexyl>glycyl)pyrroUdme-2-carbonitrile
Example 50A 4~g^nsf3-bromo^trifluoromelhyl-phenoxy>K^clohexylamine To a stirred solution of trans-4-aminocyclohexanol (115 mg, 1 mmol) in DMF (3 mL) at 0 °C was added 60% NaH in mineral oil (120 mg, 3 mmol). The reaction mixture was stirred at 0 °C for XA hour and then 2-bromo-4-fluoro-l-(trifluoromethyl)benzene (0.17 ml, 1.2 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture wasuliluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was-dried (sodium suh%te),iiltered, and concentrated under reduced pressure to provide the titled compound, MS (DO) m/z 338 (M+H)+.
Example 50B (4- traris(3-bromo-4-trifluoromemyl-phenoxy)^yclohexyl)-carbamicacid fert-butyl ester To a cold solution (0°C) of 4^3-bromc-4-trifluoromemyl-phenoxy)-cyclohexylamine (1 mmol) and NEt3 (0.42 ml, 3 mmol) in CH2C12 (5 mL) was added (Boc^O (261 mg, 1.2 mmol) in CH2CI2 (1 mL) solution via syringe. The reaction mixture was stirred from 0 °C to room temperature for 2 hours. It was diluted with CH2CI2 and washed with water (2 times) and brine. The organic layer was dried (sodium sulfate), filtered, concentrated under reduced pressure and purified byilash_chromatography with 30% ethyl acetate/hexane to provide the titled compound. JrfS-QESI) m/z 438 (M+H)+.
Example 50C (4- tians(3-pyridin^-yM-toifluoromemYL^henoxy)^cyclohexyl)-carbamic acid /er/-butyl
ester To a solution of (4^2-bromo^uifluoromemyl-phenoxy)^yclohexyl)
74
WO 2004/026822
PCTVUS2G03/029018
washed with water (2 times) and brine. The organic layer was dried (sodium sulfate), filtered, concentrated under reduced pressure and purified by flash chromatography with 30% ethyl acetate/hexane to provide the titled compound. MS (ESI) m/z 437 (M+H)+.
Example 50D ^transQ-pyridin^-vl-^trifluoromethvl-phenoxv^-cvclohexylamine To a solution of (4-(3-pyridin^yl^trifluoromethyl-phenoxy)^yclohexyl)-caibamic acid tert-butyl ester (135 mg, 0.31 mmol) in CH2C12 (1 mL) was added 4N HCl/dioxane (3 ml). The reaction mixture was stirred at room temperature for 3 hours. It was concentrated under reduced pressure to provide the titled compound. MS (ESI) m/z 337 (M+H) .
Example 50 (2S,5R)-5-ethynyl-l-(N-{4-trans(3-pyridin-4-yl^-(trifluoromethyl)phenoxy)cyclohexvl)riycyl)pynoUo%e-2Karbonitrile To a stirred solution of (2S,5R)-l-(chloroacetyl)-5^thynylpyrrolidme-2Karbonitrile (0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(3-pyridm^yM-trifluoromemyl-phenoxy)-cyclohexylamine (0.31 mmol) andNEt3 (0.063 ml, 0.45 mmol). The reaction mixture was stirred at room.temperature for 18 hours, concentrated underxeduced pressure and purified by flash chromatography with 3% methanohdichloromethane to provide the titled compound. MS (ESI) m/z 497 (M+H)+; 2H NMR (CD3OD) 8 8.94 (d, 2H), 8.10 (d, 2H), 7.85 (d, 1H), 7.31 (m, 1H),' 7.08 (d, 1H), 4.94 (m, 1H), 4.85 (m, 1H), 3.18-3.25 (m, 4H), 2.20-2.50 (m, 9H), 1.65 (m, 4H).
Example 51 (2S,5RV5-ethvnyl-l-{N-(4-trans(pyridin-2-yloxy)cyclohexyl)glvcyl)pyrrolidine-2-
carbonitrile Example 51A 4- trans(pyridin-2-yloxy)-cyclohexylamine To a stirred solution of trans-4-aminocyclohexanol (230mg, 2mmol) in DMF (10 mL) atO C was added 60% NaH in mineral oil (240 mg, 6 mmol). The reaction mixture was stirred. aLOJ'CibrJ^-hourand then 2-bromo-pyridine (0.23 ml, 2.4 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted-with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the titled compound. MS (DCI) m/z 193 (M+H)+.
WO 2004/026822
PCTAJS2003/029018
Example 51 r2S.5R)-5-ethvnvl-l-{N-(4-trans(pvridin-2-vloxy)cyclohexvngIycvnpvirolidine-2-
carbonitrile To a stirred solution of (2S,5R)-l^cUoroacetyl)-5-ethynylpyiTolidine-2-carbonitrile (0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(pyridm-2-yloxy)-cyclohexylamine (60 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanolrdichloromethane to provide the titled compound. MS (ESI) m/t 353 (M+H)+; *H NMR (CDC13) 6 8.13 (m, 1H), 7.54 (m, 1H), 6.82 (m, 1H), 6.87 (d, 1H), 5.00 (m, 1H), 4.74 (m, 1H), 4.63 (m, 1H), 3.63 (m, 2H), 2.29-2.60 (m,4H), 2.19 (m, 2H), 2.00 (m, 2H), 1.72 (m, 2H), 1.26-1.56 (m, 4H).
JExample-52
(2^,5JgV5-emynvl-14JV^l^nemvl4-trans(5^vano^pyridin-2-
yloxy)cvclohexyl)glycvl}pyrroUdme-2-carbonitrile
Example 52A 6-(4-Amino-4- transmemylH;yclohexyloxyVnic»tinonitrile Example 52A was prepared in the same manner as example 46A, by substituting 2-chloro-5-cyanopyridine for 3-fluoropyridine. MS (CI) m/z 232 (M+l)+; !H NMR (300 MHz, CDCI3) 5 ppm 8.45 (t, 1H), 7.75 (dd, 1H), 6.75 (d, 1H), 5.25-5.16 (m, 1H), 2.10-1.40 (m, 8H), 1.21(s,3H).
JExample52
(2^,5/?V5-emvnyl-l-{/^l-memyl-4-trans(5-cyano-pvridin-2-yloxy)cyclohexynglycyl>pvrrolidine-2-carbonitrile Example 52 was prepared in the same manner as example 46, by substituting example 52A for example 46A. MS (CI) m/z 392 (M+l)+; 'H NMR (300 MHz, MeOH-d,) 8 ppm 8.52 (d, 1H), 7.96 (dd, 1H), 6,87 (d, 1H), 5.20-5.10 (m, 1H), 4.90-4.80 (m; 1H), 4.20 (AB quarteUH), 3^4 (d, 1H), 2.50-2.20 (m,6H), 2.15-1.70 (m, 6H), 1.-50 (s, 3H).
Example 53 (2S,5R)-5-ethynyl-1 - (N-(4- trans(pyrimidin-2-yloxy)cyclohexyl)glycyl) pyrrolidine-2-
carbonitrile
WO 2004/026822
PCTAJS200J/U2VUJ8
Example 53A 4- trar.s(pyrimidm-2-vloxyVcyclohexylamine To a stirred solution of trans-4-aminocyclohexanol (230mg, 2mmoI) in DMF (10 mL) at 0 °C was added 60% NaH in mineral oil (240 mg, 6 mmol). The reaction mixture was stirred at 0 °C for Vz hour and then 2-chloro-pyrimidine (275 mg, 2.4 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the titled compound. MS (DCI) m/z 194 (M+H)+.
Example 53 (2S,5Ry5-emynyl-l-fN-(4-trans(pyrimid^
carbonitrile To a stirred solution of (2S,5R)-1 -(cUoroacetyl)-5-emynylpyrrolidine-2-carbonitrile (0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(pyriimdm-2-yloxy)-cyclohexylamine (60 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanohdichloromethane to provide the titled compound. MS (ESI) m/z 353 (M+H)+; *H NMR (DMSO) 5 8.58 (d, 2H), 7.09 (m, 1H), 4.91 (m, 1H), 4.75 (m, 1H), 3.57 (m, 1H), 3.52 (m, 2H), 2.20-2.38 (m, 3H); 1.91-2.13 (m, 6H), 1.45 (m, 2H), 1.20 (m,2H).
Example 54 (25,5/gV5-emynyl-l-(AL(4-trans(5-cyano-pyridin-2-vloxv)cyclohexvl)glycyl)pyiToHdine-2-
jcarboni trite
Example 54A 6-(4-trans-aminocyclohexyloxy)-nicotinonitrile To a stirred solution of trans-4-aminocyclohexanol (115mg, lmmol) in DMF (6 mL) at 0 °C was added 60% NaH in mineral oil (120jiig,3.mmoI).^Tnej3eaclionjnixture was stirred at 0 °C for !4 hour and then 2-chloro-5-cyanopyridine (151 mg, 1.25 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours atroom temperature. The reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced
WO 2004/026822
PCT7US2003/029018
pressure to provide the titled compound. MS (DCI) m/z 218 (M+H)+.
Example 54 (2£5/0-5-ethynyl-HA^4-trara(5^yano-pvri^
carbonitrile To a stirred solution of (2S,5R)-HcUoroacetyl)-5^thynylpyrroUdine-2-K^bonitrile (0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 6-(4-aminocyclohexyloxy)-nicotinonitrile (66 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanol:dichloromethane to provide the titled compound. MS (ESI) m/z 377 (M+H)+; *H NMR (DMSO-^j) 8 8.69 (m, 1H), 8.15 (m, 1H), 6.96 (m, 1H), 4.99 (m, 1H), 4.86 (m, 1H), 4.35 (m, 1H), 3.88 (m, 1H), 3.19 (m, 2H), 2.29 (m, 2H), 2.25 (d, 1H), 2.18 (m, 6H), 1.54 (m, 4H).
Example 55 (2S,5R)-5-ethynyl-l-(N-{4-(4- trans(trifluoromemyl)phenoxy)cyclohexyUdycyl)pynx)lidme-
2-carbonitrile
Example 55A 4- trans(4-trifluoromemyl-phenoxy)^yclohexylaniine To a stirred solution of trans-4-aminocyclohexanol (230mg, 2mmol) in DMF (10 mL) at 0 °C was added 60% NaH in mineral oil (244 mg, 6 mmol). The reaction mixture was stirred at 0 °C for Vz hour and then 4-fluorobenzotrifluoride (0.32ml, 2.5mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and^washed-withrwater (3 times) and brine. The organic layer was dried (sodium sult^),iilteredrand-concentratedJunder-redueedpressure^to provide thetitled compound. MS (DCI)m/z260 (M+H)+.
Example 55 (2S,5R)-5-ethynyl"l-(N-(4-(4- trans(trifluoromethyl)phenoxy)cycIohexyl) glycvDpyrrolidine-
2-carbonitrile To a stirred solution of (2S,5R)-l^cUoroaceryl>5^mynylpyrrolidine-2-carbonitrile (0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(4-trifluoromethyl-phenoxy)-cyclohexylamine (79 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by
WO 2004/026322
PC17US2003/029018
flash chromatography with 3% methanol:dichloromethane to provide the titled compound. MS (ESI) m/z 420 (M+H)+; *H NMR (DMSO) 6 7.62 (d,2 H); 7.15 (d, 2H), 4.96 (m, 1H), 4.86 (m, 1H), 4.39 (m, 211), 3.90 (m, 1H), 3.18 (m, 1H), 2.52 (m,lH), 2.29 (m, 2H), 2.19 (d, iH), 2.15 (m, 6H), 1.50 (m, 4H).
i Example 56
aS,5R)-5-ethvnvl-l^N-{4-(f5-fluoropvridin-3-vDoxvVl-
methylcyclohexyl) glycyl)pYirolidine-2-carbonitrile
Example 56 was prepared in the same manner as example 46, by substituting 3,5-
difluoropyridine for 3-fluoropyridine. MS (ESI) m/z 385 (M+H)+; 'H NMR (CDC13) 8 8.13
(m, 1H); 8.08 (d, 1H); 6.94 (m, 1H); 4.75 (m, 1H); 4.64 (m, 1H); 4.30 (m, 1H); 3.58 (m, 2H);
2.40 (m, 4H); 1.65-2.04 (m, 7H); 1.45 (m, 2H); 1.14 (s, 3H).
Example 57 (2^,5^)-5-emynyl-l-(^-(4-tems(4^carboxy-phenoxy)cyclohexyl)glycyl)pyn,olic^
carbonitrile
Example 57A 4-(4- trans-aminocyclohexyloxy)-benzoic acid fer/-butyl ester To a stirred solution of trans-4-aminocyclohexanoI (345mg, 3 mmol) in DMF (9 mL) at 0 °C was added 60% NaH in mineral oil (360 mg, 9 mmol). The reaction mixture was stirred at 0 °C for lA hour and then tert-butyl 4-fluorobenzoate (706 mg, 3.6 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the titled compound. MS (DCI) m/z 292 (M+H)+.
Example 57B (2S,5RV/ra/ty-4-{4-f2-(2-Cyano-5-ethynyl-pyrrolidin-l-vl)-2-oxo-ethylamino)-
cvclohexyloxyl-benzoic acid tert-butyl ester To a stirred solution of (2S,5R)-l-(cUoroa(»ryl)-5^mynylpyrTolidme-2-carbonitriIe (0.03_g,0.15 mmol.Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(4-aminocyclohexyloxy^benzoic acid /ert-buryl ester (89 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanol/97% dichloromethane to provide the titled compound. MS (ESI) m/z 452 (M+H)+; 'H NMR (CDC13) 8 7.91 (d, 2H), 6.86 (d, 2H),
WO 2004/026822
PCTYUS2003/029018
4.74 (m, 1H), 4.60 (m, 1H), 4.28 (m, 1H), 3.64 (m, 2H), 2.32-2.59 (m, 6H); 2.17 (m, 2H), 2.04 (m, 2H), 1.24-1.54 (m, 4H).
Exampe 57 (25.5 Jgl-S-ethynyl-l-fA^-f4- trans (4-carboxy-phenoxv)cvclohexvl)glycyl)pyrrolidine-2-
caibonitrile To a solution of Example 57B (40 mg, 0.088 mmol) in CH2C12 (0.5 mL) was added 4N HCl/dioxane (1 ml). The reaction mixture was stirred at room temperature for 3 hours. It was concentrated under reduced pressure to provide the titled compound. MS (EST) m/z 396 (M+H)+, *H NMR (MeOD) 5 7.95 (d, 2H), 6.98 (d, 2H), 4.45 (m, 1H), 4.24 (m, 2H), 3.18 (m, 2H), 2.20-2.45 (m, 6H); 1.50-1.74 (m, 4H).
Example 58 (2S.5RV5^tfaynyl-l-^N-|4-f2-(2-oxopyrroUdin-l-vl)-4-trans(ttifluoromemyl)phenoxy)cyclohexyl)^
Example 58 A 4-trans(2-bromo^trifluoromethyl-phenoxy)-cyclohexylarnine To a stirred solution of trans-4-amiriocyclohexanol (115 mg, 1 mmol) in DMF (3 mL) at 0 °C was added 60% NaH in mineral oil (120 mg, 3 mmol). The reactiomrdxture was stirred at 0 °C for lA hour and then 3-bromo-4-fluoro-l-trifluoromethyl benzene (0.17 ml, 1.2 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure-to provide the titled compound. MS (DO) m/z 338 (M+H)+.
Example 58B (4- trans(2-bromo^trifluoromethvl-phenoxy)-cyclohexyn-carbarnicacid /er/-butyl ester To a cold solution (0 °C) of 4-(2-bromo-4-trifluoromethyI-phenoxy)-cyclohexylamine (1 mmol) and NEt3 (0.42 ml, 3 mmol) in GH2Cl2 (5 mL) was added (Boc^O (261 mg, 1.2 mmol) in CH2CI2 (1 mL) solution via syringe. The reaction mixture was stirred from 0 °C to room temperature for 2 hours. It was diluted with CH2CI2 and washed with water (2 times) and brine. The organic layerwas dried (sodium sulfate), filtered, concentrated under reduced pressure and purified by flash chromatography with 30% ethyl acetate/hexane to provide the titled compound. MS (ESI) m/z 438 (M+H)
WO 2004/026822
PCT/OS2003/029018
Example 58C {4-trans(3-(2H3xo-pyrrolidin-l-yl)-4-trifluoromethvl-phenoxy)-cyclohexyl}-carbamicacid
5 fert-butyl ester
To a cold solution of (4-(2-bromo-4-trrfluoromethyl-phenoxy)-cyclohexyl)-carbamic acid tert-butyl ester (220 mg, 0.5 mmol) in pyridine(5 mL) was added 2-pyrrolidinone (0.08ml, 1 mmol), Cu powder (64 mg, 1 mmol), and K2CO3 (414 mg, 3 mmol). The reaction mixture was heated to 85 °C for 16 hours. It was diluted with ethyl acetate and washed with 10 water (2 times) and brine. The organic layer was dried (sodium sulfate), filtered,
concentrated under reduced pressure and purified by flash chromatography with 50% ethyl acetate/hexane to provide the titled compound. MS (ESI) m/z 444 (M+H)+.
15 Example 58D
1 -(2-(4- trans-ammo^yclohexyloxy)-5-trifluoromemyl-phenyl>pyirolidine-2-one To a solution of {4-(3-(2-oxo-pyrrolidin-1 -yl)-4-trifluoromethyl-phenoxy)-cyclohexyl}-carbamic acid terf-butyl ester (80 mg, 0.18 mmol) in CH2CI2 (1 mL) was added 4N HCl/dioxane (2 ml). The reaction mixture was stirred at room temperature for 3 hours. It 20 was concentrated under reduced pressure to provide the titled.compound. MS (ESI) m/z 344 (M+H)+.
Example 58
25 (2S,5RV5-ethynyl-l-(N-(4- trans-(2-(2-oxopvrrolidin-l-yn-4-
(trifluoromethyl)phenoxy)cyclohexyl} glycyl)pyrrolidbe-2-carbonitrile To a stirred solution of (2S,5R)-l-(crdoroacetyl)-5^mynyIpyrrolidine-2-carbonitriIe (0.024 g, 0.12 mmol) in acetonitrile-(l mL) at-roomtemperaturewas^dded l-(2-(4-amino-cyclohexyloxy)-5-trifluoromethyl-phenyl)-pyrrolidine-2-one (0.18 mmol) andNEt3 (0.050 30 ml, 0.36 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanol rdichloromcthane to provide the titled compound. MS (ESI) m/z 504 (M+H)+; !H NMR (CD3OD) 5 7.62 (m, IH), 7.59 (m, IH), 7.30 (d, IH), 4.85 (m, IH), 4.35 (m, IH), 3.78 (m, 2H), 3.23 (m, IH), 3.14 (m, 1H),2:53 (m, 2H), 2.44 (m, 2H);2:20-2.33 (m, 7H), 1.62 (m, 35 " 4H).
Example 59 81
WO 2004/026822
PCT/US2003/029018
(2S.5R)-l-{N-(4-trar15(4-cyaDo-2-methoxyphenoxy)cvclohexyI)glycyl)-5-ethynylpynolidme-2-carbonitrile
Example 59A 4-(4-trans-amino-cyclohexYloxy)-3-methoxy-benzonitrile
To a stirred solution of trans-4-aminocyclohexanol (115 mg, 1 mmol) in DMF (5 mL) at 0 °C was added 60% NaH in mineral oil (120 mg, 3 mmol). The reaction mixture was stirred at 0 °C for lA hour and then 4-fluoro-3-memoxy-ben2»nitrile (182 mg, 1.2 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the titled compound. MS (DO) m/z 247 (M+H)+.
Example 59 (2S,5R)-i-(N-(4- trans (4-cyano-2-methoxyphenoxy)cyclohexyl)glycyl)-5-emynylpyiipKdme-2-caifamitrile To a stirred solution of (2S^)-l^cUoroacetyl)-5^mynylpvirolMme-2K^rbonitrile (0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(4-animo^yclohexyloxy)-3-memoxy-benzonitrile (75 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanolrdichloromethane to provide the titled compound. MS (ESI) m/z 407 (M+H)+; !H NMR (DMSO) 8 7.40 (s, 1H), 7.37 (d, 1H), 7.25 (d, 1H), 4.95 (m, 1H), 4.84 (m, 1H), 4.39 (m, 2H), 3.90 (m, 1H), 3.79 (s, 3H), 3.44 (m, 2H), 3.16 (m, 1H), 2.28 (m, 2H), 2.16 (d, 1H), 2.13 (m, 6H), 1.53 (m, 4H).
-Ejcample^O
(2S.5RVl-(N-(4- trans ((5-
2-carbonitrile
Example 60A 4- trans-(5-chloro-pyridin-2-yloxy)-cyclohexylamine To a stirred solution of.trans-4-aminocyclohexanol ^30mg,-2mmol) in DMF (10 mL) at 0 C was added 60% NaH in mineral oil (240 mg, 6 mmol). The reaction mixture was stirred at 0 °C for lA hour and then 2,5-dichIoro-pyridine (356 mg, 2.4 mmol) was added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to
82
WO 2004/026822
PCT/US2003/029018
20
provide the titled compound. MS (DCI) m/z 227 (M+H)+.
Example 60 (2S,5R)-1 -(N-{4- trans ((S-chloropvridin^-vnoxvkvclohexvDglycvlVS-ethvnvlpyrrolidiae-
2-carbonitrile To a stirred solution of (2S,5R)-HcMoroaceryl)-5-ethynylpyrrolidine-2-carbonitrile (0.03 g, 0.15 mmol,Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(5-chloro-pyridm-2-yloxy)-cyclohexylamine (70 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanol:dichloromethane to provide the titled compound. MS (ESI) m/z 387 (M+H)+; 'H NMR (CDCl3) 8 8.07 (d, 1H), 7.49 (m, 1H); 6.63 (d, 1H), 4.93 (m, 1H), 4.74 (m, 1H), 4.62 (m, 1H), 3.63 (m, 2H); 2.31-2.59 (m, 6H); 2.15 (m, 2H), 1.71 (m, 2K); 1.30-1.54 (m, 4H).
Example 61 (2S,5R)-5-ethynyl-l-|N-(l-memyl-4- trans (pyridin-2-yloxy)cyclohexyl)glycyl>pyrrolidine-
2-carbonitrile
Example 61A l-Methyl-4- trans (pyridin-2-yloxy)-cyclohexylarnine Example 61A was prepared in the same manner as example 46A, by substituting 2-chloropyridine for 3-fluoropyridine. MS(Ci)m/z207(M+l)+.
Example 61 (2S,5R)-5-ethynyl-l-(N-(l-methyl-4- trans (pyridin-2-yloxy)cyclohexvl)glycyUpyrroliduie-
2-carbonitrile Example 61 was prepared in the same manner as example 46, by substituting example 61A for example 46A. MS (CI) m/z 367 (M+l)+; 'H NMR (300 MHz, MeOH-d,) 5 ppm 8.38-8.30 (m, 2H), 7.58 (d, 1H), 7.41 (t, 1H), 5.10-4.98 (m, 1H), 4.95-4.90 (m, 1H), 4.23 (AB quartet, 2H), 3.24 (d, 1H), 2.50-2.20 (m, 6H), 2.15-1.70 (m, 6H), 1.53 (s, 3H).
Example 62 (2S.5R)-5-ethynyl-l -(N-f 4- trans ((5-fluoropyridin-3-yl)oxy)cyclohexyl}glycyl)pyrrolidine-
2-carbonitrile
83
WO 2004/026822
PCTAJS2003/029018
Example 62A
4- trans (5-fluoro-pyriojn-3-yloxy)cyclohexylarriine
To a stirred solution of trans-4-aminocyclohexanol (460 mg, 4 rnniol) in DMF (5 mL)
at 0 °C was added 60% NaH in mineral oil (480 mg, 12 mmol). The reaction mixture was
5 stirred at 0 °C for Vi hour and then 3,5-difluoro-pyridine (560 mg, 4.8 mmol) was added. It
was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the titled compound. MS (DO) m/z 211 (M+H)+. 10
Example 62 (2S,5R)-5-ethynyl-l-(N-f4- trans ((5-fluoropvridin-3-vl)oxy)cyclohexyl>fi3vcyl)pyrrolidine-
2-carbonitrile
15 To a stirred solution of ^(2S,5R)-l^cliloroacetyI>5^mynylpvm)Udme-2-carbonitrile
(0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at roomtemperature was added 4-(5-fluoro-pyridin-3-yloxy)cycIohexyIaniine (65 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanohdichloromethane to provide the titled compound.
20 MS (ESI) m/z 371 (M+H)+; 'H NMR (CD3OD) 5 8.52 (s, 2H), 8.14 (d, 1H), 4.65 (m, 1H), 4.34 (m, 1H), 4.17 (m, 1H), 3.35 (m, 2H), 3.21 (m, 1H), 2.61-2.30 (m, 9H), 1.60-1.80 (m, 4H).
25 Example 63
(2S.5RV1 -(N-{4- trans ((5-bromopyridin-2-yr)oxy)cyclohexyl) glycyl)-5-ethynylpyrroHdine-
2-carbonitrile
Example 63A
30 4- trans (5-bromo-pyridin-2-yloxy)-cyclohexylamine
To a stirred solution of trans-4-aminocyclohexanoI (345mg, 3mmol) in DMF (10 mL) at 0 °C was added 60% NaH in-mineral oil (360 mg, 9 mmol). The reaction mixture was stirred at 0_°C for Vx hour and then 5-bromo^;cWoio-pyridmeX700-xng,3v6mmol)Jwas added. It was heated to 60 °C for 2 hours and stirred for 12 hours at room temperature. The 35 reaction mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The organic layer was dried (sodiunrsulfate), filtered, and concentrated under-reduced pressure to provide the titled compound. MS (DCI) m/z 271 (M+H)+.
84
WO 2004/026822 PCT/IJS2003/029018
Example 63 (2S,5RVl-(N-{4-trans ((S-bromopyridin^-vnoxv^cvclohexyUglvcvlVS-ethvnylpyrrolidine-
2-carbonitrile
5 To a stirred solution of (2S,5R)-l-(chloroacetyl)-5-ethynylpyrrolidine-2-carbonitriIe
(0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 4-(5-bromo-pyridin-2-yloxy)-cyclohexylamine (84 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanol:dichloromethane to provide the titled compound. 10 MS (ESI) m/z 430 (M+H)+; JH NMR (CD3OD) 8 8.19 (d, 1H), 7.80 (m, 1H), 6.72 (d, 1H), 4.95 (m, 1H), 4.87 (m, 1H), 3.49 (m, 1H), 3.43 (m, 2H), 3.21 (m, 1H), 2.37-2.47 (d, 3H), 2.20-2.36 (m, 6H), 1.60 (m, 4H).
15 Example 64
(2S,5R)-5-ethynyl-l -{N-(4- trans (pyridm-3-yloxy)cyclohexvDglycyl)pyn:olidme-2^
carbonitrile
Example 64A
20 4- trans (pyridm-3-yloxv)cvcIohexvlaniine
To a stirred solution of trans-4-aminocycIohexanoI (230 mg, 2 mmol) in DMF (5 mL)
at 0 °C was added 60% NaH in mineral oil (240 mg, 6 mmol). The reaction mixture was
stirred at 0 °C for 54 hour and then 3-fluoro-pyridine (0.21 ml, 2.4 mmol) was added. It was
heated to 60 °C for 2' hours and stirred for 12 hours at room temperature. The reaction
25 mixture was diluted with ethyl acetate and washed with water (3 times) and brine. The
organic layer was dried (sodium sulfate), filtered, and concentrated under reduced pressure to provide the titled compound. MS (DCI) m/z 193 (M+H)+.
30 Example 64
(2S.5R)-5-ethynyl-l-(N-(4- trans (pyridin-3-yloxy)cvclohexv0glycyl}pyrrolidine-2-
carbonitrile To a stirred solution of (2S,5R)-l-(chloroacetyl)-5-ethynylpyrroHdine-2-carbonitrile (0.03 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 4-35 (pyridin-3-yloxy)cyclohexylamine (59 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanohdichloromethane to provide the titled compound. MS (ESI) m/z 353 (M+H)+; !H NMR (CDC13) 5 8.29 (s, 1H), 8.19 (m, 1H), 7.19 (m, 2H), 4.74
85
WO 2004/026822
PCT/US2003/029018
(m, 1H), 4.60 (m, 1H), 4.25 (m, 1H), 3.63 (m, 2H), 2.29-2.64 (m, 4H), 2.16 (m, 2H); 2.03 (m, 3H), 1.72 (m, 2H), 1.53 (m, 2H), 1.32 (m, 2H).
Example 65 as^RVS-ethynyl- l-(N-( L13,3-tetramcthvlbutyl)glvcvnpvrrolidine-2-K^rbooitrile To a stirred solution of (2S,5R)-l-(cWoroa(^tyl>5^thynylpyrrolidme-2-^u:borutrile (0.04 g, 0.20 mmol, Example 8D) in acetonitrile (3 mL ) at room temperature under nitrogen was added 1,1,3,3-tetramemylbutylanrine (0.066 g, 0.406 mmol). The reaction mixture was stirred for two days and then concentrated under reduced pressure. The residue was flash chrornatographed with 2% MeOK'CJkCfe to provide the titled compound. MS (DCI) m/z 290 (M+H)+; 'H NMR (300 MHz, DMSO-4?) 5 1.5-2.02 (10H, m), 2.07-2.21 (2H, m), 2.45-2.50 (2H, m), 3.03-3.5(6Hs), 3.76 (1H, d), 3.78-4.53(2H, m), 4.53-4.55 (1H, t), 5.06 (lILm), 5.1(lH,m).
Example 66 (2S,5i?)-l-(.ftK14Hiimeayl-2-(5-cyano-pvri^
2-carbonitrile
Example 66 A 6-(2-arrmio-2-memyl-propoxyVm(X)tinonitrile To a solution of 2-arnino-2-methyl-l-propanol (0.5ml, 5.60 mmol), in DMF (20 mL) was added NaH 60% (0.67g, 16.80 mmol) and then 6-chloronicotinomtriIe (2.03g, 11.22 mmol). The mixture heated to 70 °C for 2 hours and then stirred at room temperature overnight. The reaction mixture was taken up in H2O and extracted with EtOAc. The organic phase was washed with water (3X), dried over Na2$04 and concentrated under reduced pressure to provide the titled compound as a pale yellow solid. MS (DCI) m/z 235 (M+H)+.
Example 66 (2,5/?)-l-(A^(lJ-dimemyl-2-(5^yano-pvridin-2-yloxy)emynglycyl>-5^mypylpyrrolidine--
2^carbonitnle To a stirred solution of (2S^R>Hchloroac^l)-5^mynylpyrroUdme-2-
86
WO 2004/026822
PCT/US2003/029018
solid. MS (DCI) m/z 352 (M+H)+; lH NMR (300 MHz, DMSO-a» 8 2.01-2.04 (2H, m), 2.05 (2H, s), 2.07 (2H, s), 3.03 (IH, m), 3.04 (6H, s), 3.5-4.57 (2H, m), 4.57-4.58 (lKLm), 4.58-5.59 (IH, m), 7.0-7.08 (3H,m).
Example 67 (2S,5R)-l-(N-(tert-butvl)glvcylV5-ethynylpyrrolidbe-2-carbonitrile
To a stirred solution of (2S,5R)-l-(chloroacetyl)-5-ethynylpyrrolidine-2-carbonitrile (0.04 g, 0.203 mmol, Example 8D) in acetonitrile (3 mL ) at room temperature under nitrogen was added tert-butylamine (0.043 ml, 0.406 mmol). The reaction mixture was stirred at ambient temperature overnight. The reaction mixture was concentrated under reduced pressure. The residue was flash chromatographed with 3% MeOH/CItCh to provide the desired compound as a pale yellow oil. MS (DCI) m/z 234 (M+H)+.
The free base and 1 M HC1 in ether were stirred at room temperature for 2 h and then concentrated under reduced pressure. The rsidue was triturated with diethyl ether to provide the desired hydrochloride salt as a white powder. !H NMR (DMSO-
Example 68 (2S,5R)-1 - OKI, 1 ^imemyl-2-(qumolm^yIamino)emyl)glycyl>-5-emynylpyiroUdine-2-
carbonitrile Example 68 was prepared using the same procedure as described for Example 155 substituting 6-chloronicotinonitrile with 4-chIoroquinoline. MS (DCI/NH3) m/z 376 (M+H)+.
Example 69 (2S,5RV5^m\Tivl-l-fN-a-(4-fluorophenvlVia-dimethvlethvl)glvcvl)pyrrolidine-2-
carbonitrile To a stirred solution of (2S,5R)-l-(chloroacetyl)-5-ethynylpynolidine-2-carbonitrile (0.05 g, 0.25 mmol, Example 8D) in acetonitrile (3 mL ) at room temperature under nitrogen was added l-(4-fluorophenyl)-2-methyl-2-propylamine (0.09 g, 0.508 mmol). The reaction mixture was stirred for two days and then concentrated under reduced-pressure. The residue was flash chromatographed with 1-2% MeOH/CfkCb to provide the desired compound as a white powder. MS (DCI) m/z 328 (M+H)+; !H NMR (300 MHz, DMSO-cfe) 5 2.01-2.04(2H, m), 2.05 (2H, s), 2.07 (2H, s), 3.03 (1H, m), 3.04 (6H, s), 3.5-4.57 (2H, m), 4.57-4.58 (lH^ii), 4.58-5.59 (1H, m), 7.0-7.03 (4H?m).
87
WO 2004/026822
PCT/US2003/029018
Example 70 (2S,5R> l-(N-( 1,1 -dimethylpropynglycvlVS-ethynylpyrroliduie-Z-carbonitrile To a stirred solution of (2S,5R)-l-(cWoroa(xtyl)-5-emynyIpyrrolidme-2-carbonitrile 5 (0.03 g, 0.152 mmol, Example 8D) in acetonitiile (3 mL ) at room temperature under nitrogen was added tert-amylamine (0.027 g, 0.228 mmol). The reaction mixture was stirred for two days and then concentrated under reduced pressure. The residue was flash chromatographed with 5% MeOH/CH2Cl2 to provide the titled compound. MS (DCI) m/z 248 (M+H)+.
10
Example 71 f2S.5RVl-m^2-fl3-benzotMazol-2-vlammoVl^-dimemylethvl>glvcyl>-5-
etfaynylpYirolidine-2-carbonitrile Example 71 was prepared using the same procedure as described for Example 155 15 substituting 6-chloronicotinonitrile with 2-chlorobenzothiazole. MS (DCI/NH3) m/z 382 (M+H)+.
Example 74
20 f2S,5R)-1 -(N-1 -adamantylglycyl V5^mvnylpyrrohdine-2-carbonitrile
To a stirred solution of (2S,5R)-l^chJoroacetyl)-5^mynylpyrrolidine-2"Carbomtrile (0.03 g, 0.20 mmol) in acetonitiile (3 mL ) at room temperature under nitrogen was added 1-adamantanamine(0.06 g, 0.408 mmol). The reaction mixture was stirred for two days and then concentrated under reduced pressure. The residue was flash chromatographed with 2% 25 MeOH/CH2Cl2 to provide the titled compound. MS (DCI) m/z 312 (M+H)+.
Example 75 (2S.5RV 1 -(N-cyclohexylelycyl)-5-ethynylpyrrolidine^-carbonitrile
30 To a stirred solution of (2S,5R)-l-(chloroacetyl)-5-ethynylpyrroUdine-2-carbonitrile
(0.035 g, 0.178 mmol, Example 8D) in acetonitrile (3 mL ) at room temperature under nitrogen was added cyclohexylamine (0.041 ml, 0.356 mmol), The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was flash chromatographed with 2-3% MeOH/CH2CI2 to provide the desired
35 compoimdas^^ale-yellow oil. MS (DCI) m/z 260 (M+H)+; lH NMR (300 MHz, DMSO) 8 1.5-2 (10H, m), 2.13-2.31 (2H, m), 2.41-2.48 (2H, m), 3.76 (1H, d), 3.8-4.5 (2H, m), 4.53-4.55 (1H, t), 4.9 (lILm), 5.05 (1H, m).
40 Example 76
88
WO 2004/026822 PCT7US2003/029018
(2S,5R)-5-ethynyl-l-{N-(l-(memoxymethyl)cYclopent^nolYcvl>pyrrol:dine-2-carbonitrile
Example 76A
5 (l-hydroxyrnethyl-cyclopentyD-carbamic acid benzyl ester
To a stirred solution of 1-amino-l-cyclopentanemethanol (1.15 g, 10 mmol) and NaHC03 (0.84 g, lOmmol) in acetone (14 mL)/water (14ml) at room temperature was added benzyl sucxinimidyl carbonate (2.5 g, 10 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash 10 chromatography with 3% methanohdichloromethane to provide the titled compound. MS (DCl)m/z25Q(M+H)Example 76B
15 (l-methoxymethyl-cyclopentyl)-carbamic acid-benzyl-ester
To a cold solution (0°C) of (l-hydroxymethyl-cyclopentyl)-carbamic acid benzyl ester (250 mg, 1 mmol) and 48% aqueous HBF4 (0.13 ml, 1 mmol) in CH2CI2 (4 mL) was added TMSCHN2 (2N in hexane, 2 mL, 4 mmol) via syringe. The resulting mixture was stirred, at 0 °C, for 1/2 hour followed by the addition of water (10 mL). The aqueous mixture 20 was extracted with CH2CI2 (2 X 50 mL), and the combined organic layers were dried (sodium sulfate), filtered, concentrated, and chromatographed with 30% ethyl acetate/hexane to provide the titled compound. MS (DCI) m/e 264 (M+H)+.
25 Example 76C
1 -methoxymethyl-cyclopentylamine To a solution of (l-memoxymethyl-cyclopentyl)-carbamic acid benzyl ester (150 mg, 0.57 mmol) in MeOH (5 mL)-was added HG02NH4-.(216™g, 3.42 mmol), foliowed^y^d/G (10%, 6 mg,0.057 mmol). The resulting mixture was heated, to 70 °C, for 2 hours. The 30 reaction mixture was filteredand concentrated to provide the titled compound. MS (DCI) m/el30(M+H)V
Example 16
35 (2S,5R)-5^mynyl-l-{N-fMmemoxymethyl)cyclopentyl)glycyl)pyrrolidine-2-carbonitrile
To a stirred solution of (2S,5R)-l-(chloroacetyl)-5-ethynylpyrrortdine-2-carbonitrile (0.018 g, 0.09 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 1-memoxymetnyf-cyc/opentyfamine (17 mg, 0.13 mmof}. The reaction mixture was stirred af
89
WO 2004/026822
PCTAJS2003/029018
room temperature for 18 hours, concentrated under reduced pressure and purified by flash
chromatography with 3% methanol: dichloromethane to provide the titled compound. MS
(ESI) m/z 290 (M+H)+;'H NMR (CD3OD) 6 4.84 (m, 2H), 3.48 (m, 2H), 3.41 (s, 3H), 3.31
(m, 2H), 2.43 (d, IH), 2.30-2.48 (m, 4H), 1.72-1.96 (m, 8H). 5
Example 77 (2S,5R)-5-e&ynyl-l-(N-tetoahyQYo-2H-^^ Example 77 was prepared in the same manner as Example 46, by substituting 10 tetrahydro-pyran-4-ylamine for Example 46A. MS (CI) m/z 262 (M+l)+.
Example 78 (2S,5R)r5Tethyflyl-l-{N-((2S>2-hydroxycyd^^
15 To a stirred solution of (2S,5R)-l-(chloroacetyl)-5-emynylpyn'ohQlne-2-carbonitrile
(0.040 g, 0.20 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added trans-2-arninocyclopentanol hydrochloride (56 mg, 0.41 mmol) and triethylamine (0.14 ml, 1.02 mmol). The reaction mixture was stirredjtjxwmiemperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3%
20 methanol:dichloromethane to provide the titled compound. MS (ESI) m/z 262 (M+H)+; IH NMR (MeOH) 4.79 (m, IH), 4.17-4.40 (m, 3H),.3.18 (m, 1H),2.48 (m, 4H); 2.00-2.30 (m, 4H), 1.80 (m, 2H), 1.66 (2ILm).
25 Example 79
(2S,5R)-l-(N-cyclor>entyIglycylV5-emynylpyrroHd^ne-2-carbonitrile
To a stirred solution of (2S,5R)-l-(cUoroa(»tyl)-5-emynylpyrrolidine-2-carbonitrile
(0.04 g, 0.203 mmol, Example 8D) in acetonitrile (3 mL) at ambient termperature under
"mrrogeh was added cyclopenlylamine (O^OTml, 6.406 mmol). The reaction mixture was
30 stirred at room temperature overnight and then concentrated under reduced pressure. The
residue was flash chromatographed with 3% MeOH/CHzCh to provide the desired compound
as a pale yellow oil. MS (DCI)m/z 246 (M+H)+; *H NMR (300 MHz, DMSO) 6 1.5-2 (8H,
m), 2.11-2.21 (2H, m), 2.45-2.48 (2H, m), 3.78 (IH, d), 3.8-4.5 (2H, m), 4.53-4.55 (IH, t),
5.01 (lH,m), 5.05 (lH,m). 35
Example 80 (2S,5R)-5-ethynyl-1 - (N-(l -(hydroxymemvncyclor)entYl)dvcyl>pyrrolidine-2-carbonitrile To a stirred solution of (2S,5R)-1 -(cWoroac«tyl)-5-e%nylpyiTolidine-2-carbonitrile
90
WO 2004/026822
PCT/US2003/029018
(0.030 g, 0.15 mmol, Example 8D) in acetonitrile (1 mL) at room temperature was added 1-amino-1-cyclopentanemethanol (35 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanol: dichloromethane to provide the titled compound, MS (ESI) m/z 276 (M+H)+; !H NMR (DMSO) 5 4.99 (m, 1H), 4.86 (t, 1H), 4.28 (m, 1H), 4.00 (m, 1H), 3.50 (d, 2H), 3.51 (m, 2H), 2.27 (m, 2H), 2.14 (m, 1H), 1.75 (m, 6H), 1.55 (m, 2H).
Example 84 (2S,5S)-l-((2S)~2-airimo-2KiYclopentylemanovl)-5-memylpYnx>Udme-2^arbonitrile
Example 84A 5-MethYl-pyrrolidine-l,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester The ethyl (5S)-5-methyl-L-prolinate was prepared as the trifluoroacetic acid salt as described in Example 6 by substituting methyl magnesium bromide for ethyl magnesiumbromide. Ethyl (5S)-5-methyl-L-prolinate trifluoroacetic acid salt (18.08 mmol), triethyl amine (36.16 mmol) and DMAP (0,906 mmol) were mixed in 40 mL of dichloromethane and then cooled to 0 °C. B0C2O (19.89 mmol) was added and the mixture was stirred overnight The mixture was then diluted with dichloromethane, washed with IN HC1 and then withsaturated NaHC03 solution. The organic layer was dried with Na2SC>4, and then concentrated. The crude product was purified by chromatography (silica gel, 50% then 75-80% EtOAc/hexane) to give the desired titled compound. MS (CI) m/z +258 (M+H)+. (a)20 D--35.9 (c 1.45, MeOH).
Example 84B
(2S,5S)-5-Methyl-pyrrolidine-l,2-dicarboxylic acid 1-tert-butyl ester
Example 84A (3.69 g, 14.34 mmol) in 15 mL of EtOH was treated with 14.3 mL of
1.7 N LiOH solution at room temperature. After 4 h, the mixture was concentrated,:acidified
with IN HGl-and-then-extracted-with EtOAc (3X). The combined organicextracts-were-dried
with Na2S04, and then concentrated to give the crude acid. MS (ESI) m/z 228 (M-H)Example 84C (2S.5S)-2-Carbamoyl-5-methyl-pyrTolidine-l-carboxvlic acid tcrt-butyl ester Example 84B (2.055g, 8.96 mmol) and Et3N (2.24 mL, 1.8 equiv.) were mixed in 15 mL of THF and then cooled to 0 °C. Isobutyl chloroformate (1.51 mL, 1.3 equiv.) was added. After stirring for 35 min, 0.5 M NH3 in dioxane (35.8 mL, 2 equiv.) was added. After stirring at 0 °C for 3 h, the mixture was warmed to room temperature and stirred overnight The volatiles were evaporated, and IN HC1 was added. The mixture was extracted with EtOAc (3X). The combined organic extracts were dried with Na2S04 and then concentrated. The
91
WO 2004/026822
PCT/US2003/029018
crude product was purified by chromatography (silica gel, 50% then 75-80% EtOAc/hexand to give the desired amide. MS (ESI) m/z 229 (M+H)+.
Example 84D (2S,5S)-5-Methyl-pyrrolidine-2-carboxylic acid amide trifluoroacetate Example 84C (2.03 g, 8.89 mmol) in 4 mL of CH2C12 was treated with 6 mL of TFA at room temperature. After stirring for 5 h, toluene was added to azotrope off all the volatiles to afford the crude amine, MS (CI) m/z 129 (M+H)+.
Example 84E f(!SV2-((2S,5SV2-Carbamovl-5-memvl-pvrroUdin-l-ylVl-cyclopentyl-2-oxo-etfaylV
carbamic acid tert-butyl ester Example 84D (296 mg, 0.66mmol), i^tert-biitoxycarbonylamino-cyclopentyl-acetic acid dicyclohexylamine salt (308 mg, .0.726 mmol), and TBTU (275 mg, 0.858 mmol) were mixed m 2.5 mL of DMF. Then 0.275 mL-o£NEt3-(l.9S mmol)-were-added. Approximately another 0.1 mL of NEt3 was added until the pH of the mixture reached 6-7 (by wet pH paper). The mixture was stirred for 10 h, then purified by reverse-phase HPLC to give the desired amide (195 mg, 84%). (ESI) m/z 354 (M+H)+.
Example 84E ((!S)-2-((2S,5S>2yano-5-memyl-pvrrofidm-l-ylVl-cyclopentyl-2-oxo-emylVcaibann
acid tert-butyl ester The dehydration of the above amide was performed in a similar manner as described in Example 6G to provide the desired nitrile. MS (ESI) m/z 336 (M+H)+.
Example 84 (2S,5S)-K(2S)-2-amino-2-cyctopentylemaDOvlV5-memylpynrolidme-2-carbonitrile The removal of Boc group was performed in a similar manner as described jn„ Example 6 to give the title compound. *H NMR (400 MHz, MeOH^U) 6 1.37 (d, J=6.75 Hz, 3 H) 1.43 (m, 2 H) 1.6-1.8 (m, 6 H) 1.90 (m, 1H) 2.13 (ddd, J=12.12,7.36,4.76 Hz, 1 H) 2.39 (m, 4 H) 4.11 (d, J=$.29 Hz, 1 H) 4.40 (m, 1 H) 4.78 (t, >8.44 Hz, 1 H) ppm. MS (ESI)m/z236(M+H)+.
Example 85 (2S,5R)-1 -((2S)-2-amino-2-cvclopentylethanoYl)-5-prop-1 -ynylpyrrolidine-2-carbonttrile
Example 85A dimethyl (2S,5R)-5-propynyI-pyrrolidine-l .2-dicarboxylate
92
WO 2004/026822
PCT/US2003/029018
To a cold -45 °C solution of dimethyl (2S)-5-methoxypyrTolidine-l,2-dicarboxy).ate (10 g, 46.08 mmol, Example IB) and trimethylsilylpropyne (14.24 ml, 92.16 mmol, 2.0 equiv) in methylene chloride (180 mL) was added a solution of tin (IV) chloride (1 M in methylene chloride, 60.0 mL, 60.0 mmol, 1.3 equiv) dropwise via an addition funnel over 30 minutes. To the dark yellow solution was added solid aluminum chloride (8.58 g, 64.52 mmol, 1.4 equiv) in one portion. The resulting mixture was allowed to warm to room temperature and stirred at room temperature for 48 hours. The reaction mixture was carefully quenched by saturated aqueous NH4OH (100 mL) with ice cooling. A white precipitate formed and was removed by filtration. The crude product was obtained after concentration. The residue was chromatographed on a Biotage flash 40 M eluting with 70% hexane/30% ethyl acetate to afford the titled compound. MS (DCI/NH3) m/e 226 (M+H)+.
Example 85B methyl (5R>5-propynyl-L-prolinate A solution of dimethyl (2S,5R)-5-propynyl-pyrrolidine-l,2-dicarboxylate (4.25 g, 18.90 mmol) and iodotrimethylsilane (3.23 mL, 22.7 mmol, Example 85 A) in chloroform (60 mL) was heated to 65 °C for 3 hours, was cooled to room temperature, concentrated under reduced pressure and flash chromatographed with 35% ethyl acetate/ 65% hexane to provide the titled compound. MS (DCI7NH3) m/e 168 (M+H)+.
Example 85C Memyl-//-(fg^butoxyc^bonyl)^yclopentyl-L-glycyl-(5R>5-propynyl-L-prolinate To a solution of methyl (5R)-5-propynyl-L-prolinate (334 mg, 2 mmol), dimethylaminopyridine (244 mg, 2 mmol), N-methylmorpholine (0.33 mL, 3 mmol), and Boc-cyclopentyl-L-glycine.dicyclohexylamine (1.02 g, 2.4 mmol) in dichloromethane (10 mL) at room temperature was added l-(3-dimemylaminopropyl)-3-euiylcarbodiimide hydrochloride (383 g, 2.4 mmol). The resulting mixture was stirred 16 hours at room temperature, and partitioned between ethyl acetate (100 mL) and 1 A/HC1 (20 mL). The aqueous layer was further extracted with ethyl acetate (100 mL). The combined organic layers were dried (sodium sulfate), filtered, and concentrated. The residue was chromatographed with 70% ethyl acetate/hexane provide the titled compound (67%). MS (ESI) m/e 393 (M+H)+.
Example 85D
7/-(/gr/-butoxvcarbonyl)-cyclopentvl-L-glycyl-(5R)-5-propynyl"L-proline
To a solution of methyl 7/-(/erNbutoxycarbonyl)-cyclopentyl-L-glycyl-(5R)-5-
93
WO 2004/026822
PCT/US2003/029018
propynyl-L-prolinate (1.34 g, 3.42 ramol) in THF (10 mL)/water (5 ml) at room temperatuf^h was added lithium hydroxide (358 mg, 7.52 mmol). The resulting mixture was stirred at room temperature for 6 hours. The reaction was diluted with 1 A/HO solution, and the aqueous mixture was extracted with ethyl acetate (3X10 mL). The combined organic layers were dried (sodium sulfate), filtered, and concentrated to provide the titled compound. MS (ESI)m/e379(M+H)+.
Example 85E JV^te^butoxy
Example 85F
jy-(fer^butoxycarbonyl>cvclorjentvl-^
To a cold solution (-35 °C) of Ar-(/e/-/-butoxycarbonyl)-cyclopentyl-L-glycyl-(5R)-5-propynyl-L-prolinamide (280 mg, 0.743 mmol) and imidazole (51 mg, 0.743 mmol) in pyridine (6 mL) was added POCI3 (0.14 mL, 1.49 mmol) via syringe. The resulting mixture was stirred, maintaining the temperature below -20 °C, for 1 hour followed by the addition of
1 M HC1 (10 mL). The aqueous mixture was extracted with ethyl acetate (3 X 50 mL), and the combined organic layers were dried (sodium sulfate), filtered, concentrated and chromatographed with 30% ethyl acetate/hexane to provide the titled compound. MS (ESI) m/e 348 (M+H)+; lH NMR (300 MHz, CDCI3) 5 ppm 5.15 (t, 1H), 4.95 (d, 1H), 4.71 (t, 1H), 4.53 (ddd, 1H), 2.50 (d, 1H), 2.50-2.28 (m, 4H), 1.75-1.57 (m, 3H).
Example 85 (2S,5R>H(2S)-2-ammo-2-cyclopentylemanoylV5-prop-l-ynylpyn-oIidine-2-carbonitrile To a solution of 7/-(rert-butoxycarbonyl)-cyclopentyl-L-glycyl-(5R)-5-propynyl-L-pyrrolidine-2-carbonitrile (490 mg) in ether (1 mL) was added 4 AfHCl in dioxane (8mL).
94
WO 2004/026822
PCT/US200.V0290I8
The resulting mixture was stirred at room temperature for 2 hours and the solvents removed under reduced-pressure. The white solid was triturated with ether to provide the titled compound. MS (ESI) m/e 260 (M+H)+; 'HNMR (DMSO) 5 ppm 5.16 (m, IH), 4.73 (m, IH), 4.04 (m, IH), 3.42 (m, IH), 2.03-2.47 (m, 4H), 1.85 (d, 3H), 1.39-1.70 (8H,m).
Example 86 (2S,5R)-5-prop-1 -ynyl-1 -(N-(4-(4-(trifluoromethvl)phenoxy)cyclohexvU glycyl)pyrrolidine-
2-carbonitrile To a stirred solution of (2S,5R)-l-(cUoroacetyl)-5-propynylpyrroUdme-2-carborutrile (0.030 g, 0.15 mmol, Example 88D) in acetonitrile (1 mL) at room temperature was added 4-(4-trifluoromethyl-phenoxy)-cyclohexylamine (79 mg, 0.31 mmol, Example 55A). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanol:dichloromethane to provide the titled compound. MS (EST) m/z 434 (M+H)+; JH NMR (DMSO) 8 ppm 7.63 (d, 2H), 7.15 (d, 2H), 4.86 (m, IH), 4.20-4.41 (m, 2H), 3.94 (m, IH), 2.09-2.43 (m, 8H), 1.88 (d, 3H), 1.41-1.65 (m,4H).
Example 87 (2S,5R)-l-{N-(l-(hvdroxvmemyl)cvclopentyl)glycyl)-5-prop-l-ynylpyrrolidine-2-
carbonitrile To a stirred solution of (2S,5R)-l-(cMoroacetyl)-5-propynylpyrrolidine-2-carbonitrile (0.03 g, 0.14 mmol, Example 88D) in acetonitrile (1 mL) at room temperature was added 1-amino-1-cyclopentanemethanol (35 mg, 0.28 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanol/ 97% dichloromethane to provide the titled compound. MS (ESI) m/z 290 (M+H)+; JH NMR (DMSO) 5 ppm 4.86 (m, IH), 4.16 (m, IH), 3.52 (m, 2H), 3.44 (m, 2H), 2.06-2.39 (m, 4H), 1.96 (m, 2H), 1.86 (d, 3H), 1.75 (m, 6H), 1.56 (m, 2H).
Example 88 (2S.5R)-l-(N-cyclopentylfilycyl)-5-prop-l-ynylpyrrolidine-2-carbonitrile
Example 88 A
methyl (5RV1 -(chloroacetyl)-5-propynyl-L-proHnate
To a stirred solution of methyl (5.R)-5-propynyI)-L-prolinate (1.5 g, 8.98 mmol,
Example 85B) and triethylamine (1.87 raL, 13.47 mmol) in dry tetrahydrofuran ( 20 mL) at 0
°C was gradually added chloroacetyl chloride (0.86 mL, 10.78 mmol). After stirring at room
95
WO 2004/026822
PCT7US2003/029018
temperature for 2 hours, the mixture was filtered. The solid cake was washed with THF, ^ the filtrate and washings were combined, dried over sodium sulfate and concentrated under reduced pressure. The residue taken up in toluene and concentrated to dryness under reduced pressure to provide the titled compound. MS (DCI) m/z 244 (M+H)Example, 8.&B (5R)-1 -(cMoroacetyD-S-propynyl-L-proline To a stilted solution of methyl (5R)4-(chloroacetyl)-5-propynyl)-L-prolinate (1.26 g, 5.19 mmol) in THF (12 mL) and H2O (6 mL) at room temperature was added LiOH«H20 (326 mg, 7.78 mmol). The reaction mixture was stirred at ambient temperature overnight and concentrated under reduced pressure. The reaction mixture was acidified to pH ~ 3 by adding 1M HC1 dropwise. The solution was extracted with ethyl acetate (3X). Combined ethyl acetate layers were washed with brine, dried (NajSO^, filtered and concentrated under reduced pressure to provide the titled compound. MS (DCI) m/z 230 (M+H)+.
Example 88C (5RVHcMoroacetyl)-5-piX)pynyl-L-prolinamide To a stirred solution of (5R)-l-(chloroacetyl)-5-propynyl-L-proline (1.10 g, 4.8 mmol) in CH2CI2 (24 mL) at -15 °C under nitrogen was added 4-methylmorpholine (0.64 mL, 5.76 mmoJ)> and then isobutyl chloroformate (0.81 mL, 6.24 mmol) over 10 minutes. A white precipitate formed. The reaction mixture was stirred at -15 °C under nitrogen for 30 minutes, and a solution of NH3 in dioxane (0.5 M, 29 mL, 14.4 mmol) was added. The reaction mixture was stirred at -15 °C for 30 minutes, warmed to room temperature, and stirred at that temperature for 16 hours. The reaction mixture was diluted with 1M HC1 to ~ pH 4 and extracted with ethyl acetate (3X). The extracts were combined, washed with brine, dried (Na2SC>4)» filtered and concentrated under reduced pressure. Purification by flash column chromatography (60-75% ethyl acetate /hexane) provided the titled compound. MS (DCI)m/z229(M+H)+.
Example 88D (2S,5RV 1 -fchloroacetyl)-5-propvnvlpyrrolidine-2-carbonitrile To a stirred solution of (5R)-l-(chloroacetyl5-5-propynyl-L-proIinamide (0.28 g, 1.23 mmol) and imidazole (0.084 g, 1.23 mmol) in dry pyridine (6 mL ) at-35 °C under nitrogen was added POCI3 (0.23 mL, 2.46 mmol) dropwise. The reaction mixture was stirred between
96
WO 2004/026822
PCT/US20G3/029018
-35 °C to -15 °C for 1 hour and evaporated. The residue was diluted with dichloromethane and washed with H:0 (2X), dried (Na2S04), filtered and concentrated under reduced pressure. Purification by flash chromatography (10% ethyl acetate /hexane) provided the titled compound. MS (DCI) m/z 211 (M+H)+.
Example 88 (2S,5R)-l-(N-CYclopeatylglycvl)-5-prop-l-YnvlpyrrQlidine-2-carbonitrile To a stirred solution of (2S,5R)-l^cUoroace1yl)-5-propynylpyrrolidine-2-carbonitrile (0.018 g, 0.086 mmol) in acetonitrile (1 mL) at room temperature was added cyclopentyl amine (0.017 mL, 0.17 mmol). The reaction mixture was stirred at room temperature for 18 hours, concentrated under reduced pressure and purified by flash chromatography with 3% methanol/ 97% dichloromethane to provide the titled compound. MS (ESI) m/z 260 (M+H)+; 'H NMR (DMSO) 8 ppm 4.89 (m, 1H), 4.84 (m, 1H), 4.07-4.13 (m, 2H), 3.52 (m, 1H), 2.05-2.42 (m, 4H), 1.96 (m, 2H), 1.87 (d, 3H), 1.70 (m, 4H), 1.52 (m, 2H).
Example 91 (2S,5S)-l-(N-cyclopentylglycyl)-5-methylpyrrolidine-2-carbonitrile
Example 91A (2S,5S)-l-(2-Chloro-acetyl)-5-methyl-pyrrolidine-2-carboxylic acid amide (2S,5S)-5-Methyl-pyrrolidine-2-carboxylic acid amide trifluoroacetate (2.0 g, 8.2 mmol, Example 84D) and triethyl amine (1.9 mL, 24.6 mmol) were dissolved in CH2CI2 (6 mL), and the mixture was cooled to 0 "C. Chloroacetyl chloride (0.39 mL, 9.0 mmol) was added slowly via syringe. After 2 h, saturated NaHCC>3 was added, and the mixture was extracted with EtOAc (3X). The combined organic extracts were dried (Na2SC>4), concentrated and purified by flash chromatography (10% MeOH/EtOAc) to give the title compound. MS (DCI) m/z 205 (M+H)+.
Example 9 IB (2S.5S)-l-(2-Chloro-acetyl)-5-methyl-pyrrolidine-2-carbonitrile (2S,5S)-l-(2-Chloro-acetyl)-5-methyl-pyrrolidine-2-carboxylic acid amide (0.25 g, 1.2 mmol) and imidazole (85 mg, 1.25 mmol) ware mixed in pyridine (5 mL). The mixture was cooled to -35 °C and POCI3 (0.18 mL, 1.8 mmol) was added slowly. The mixture was stirred at -35 °C for 1 h. Saturated NH4CI (20 mL) was added, and the mixture was extracted with EtOAc (3x). The combined organic layers were dried (Na2SC>4), filtered and concentrated under reduced pressure. The oil was purified by flash chromatography (hexane: EtOAC, 2:1) to yield the title compound. MS (DCI) m/z 187 (M+H)+.
97
WO 2004/026822 PCT/US2003/029018
10
Example 91 (2S,5S)-l-(N-cvclopentylglvcyl)-5-methylpyrrolidine-2-carbonitrile (2S,5S)-l-(2-Chloro-acetyl)-5-methyl-pyrrolidine-2-carbonitrile (50 mg, 0.30 mmol) and cyclopentylamine (0.059 mL, 0.6 mmol) were dissolved in acetonitrile (2 mL) and stirred overnight. The product was purified by reverse phase HPLC eluting with 0% to 70% acetonitrile/ 0.1% aqueous trifluoroacetic acid. !H NMR (300 MHz, methanol-^) 5 ppm 1.36 (d, J=6M Hz, 3 H), 1.68 (m, 5 H), 1.85 (m, 3 H), 2.16 (m, 3 H), 2.38 (m, 3 H), 3.60 (m, 1 H), 4.20 (m, 1 H)5 4.77 (m, 1 H). MS (ESI) m/z 236 (M+H)+.
Example 92
(2S,5SH,4-d^itorc>-5-memYl-l-L-valylpyrroUdbe-2K^bonitrile
This compound was prepared from 51 mg (0.23 mmol) of (iS)-N-tert-
15 butoxycarbonylvaline and 50 mg (0.23 mmol) of (2,5-cw) 4,4-difluoro-5-methyl-pyrrolidine-
2-carboxylic acid methyl ester hydrochloride (Example 95G) according to the same five step sequence as for (2S,5S)^J4-difluoro-l-Meucyl-5-memylpyirolidine-2-carbonitrile (example 95H through example 95L) to give the titled compound as a colorless foam. JH NMR (500 MHz, DMSO-f/,0 (mixture of rotamers, major rotamer only) 8 ppm 0.99 (m, 6 H) 1.37 (m, 3 20 H) 2.11 (m, 1 H) 2.96 (m, 1 H) 3.09 (m, 1 H) 4.09 (bs, 1 H) 4.65 (m, 1 H) 5.06 (t, ^8.6 Hz, 1 H) 8.31 (bs, 3 H) MS (ESI) m/z = 246 (M+H)+.
Example 94
25 (2S,5S)-l-{N-(l-(hvdroxymemyl)cyclor^ntyl)glycyU-5-memylpyrroUdine-2-carbonitrile
The tide compound was prepared using the conditions described in Example 91
substituting 1 -amino- 1-cyclopentanemethanol for cyclopentylamine. *H NMR (300 MHz,
methanol-^) 5 ppm 1.38 (d, .£=6.44 Hz, 3 H), 1.80 (m, 8 H), 2.32 (m, 2 H), 3.29 (m, 4 H),
3.62 (s, 2 H), 3.96 (m, 1 H), 4.20 (m, 1 H), 4.77 (m, 1 H). MS (ESI) m/z 266 (M+H)+. 30
Example 95 (2S,5S)-4.4-difluoro-l-L-leucvl-5-methylpyrrolidine-2-carbonitrile
35 Example 95A
Dibenyzyl fumarate. To 13.92 g (120 mmol) of fumaric acid was added 250 mL of toluene and 41.8 mL (240 mmol) of /^//-diethylisopropylamine. The mixture was stirred until only a small amount of solid was present, then 28.5 mL (240 mmol) of benzyl bromide was added. The
98
WO 2C04/026822
PCT/JJS2003/029018
reaction was stirred at 80 °C for 5 h, then it was cooled and extracted with water (1 x 50 mL), 1M HCl(a?) (2 x 50 mL), saturated NaHC03(a9), and brine (1 x 50 mL), dried over MgS04, filtered, and concentrated to a solid. This was recrystallized from 75 rnL of hexanes togive the titled compound as colorless crystals. !H NMR (300 MHz, DMSO-
Example 95B (J?VN-re;-/-butoxycarbonvlalanine benzyl ester To a solution of 11.19 g (59.1 mmol) of (ii)-iV-fe^-butoxycarbonylalanine in 70 mL of//,iV-dimethylformamide was added 6.7 g (48.5 mmol) of K2C03, and 6.9 mL (58.0 mmol) of benzyl bromide. The reaction was stirred at 80 °C for 40 min, then poured into 350 mL of H2O. The aqueous mixture was extracted with diethyl ether (3 x 50 mL), then the combined ether layers were back extracted with H20 (2 x 50 mL), and brine (1 x 50 mL), dried over MgSC>4, filtered, and concentrated in vacuo to furnish the titled compound as a colorless oil. MS (ESI) 771/2= 280 (M+H)+, 297 (M+Nft,)*, 302 (M+Na)+: 'H NMR (300 MHz, DMSO-4J) 5 ppm 1.25 (d, .7=7.5 Hz, 3 H) 1.37 (s, 9 H) 4.06 (m, 1 H) 5.07 (d, J=12.9 Hz, 1 H) 5.15 (d, J=12.5 Hz, 1 H) 7.34 (m, 6 H).
Example 95C 5-Methyl-4"OXO-pvrrolidine--1^2,3-tricarboxylic acid 2,3-dibenzyl ester 1-tert-butyl ester To a solution of 5.59 g (20.0 mmol) of (J?)-iV-fer^-butoxycarbonylalanuie benzyl ester and 5.92 g (20.0 mmol) of dibenzyl fumarate in 60 mL of toluene was added 1.60 g (40 mmol) of 60% NaH in mineral oil. The reaction was stirred at ambient temperature under N2 for 24 h, then diluted with 300 mL of diethyl ether. The solution was extracted with 1M HCl(a?.) (1 x 50 mL), saturated NaHC03(a?.) (3 x 50 mL), and brine (1 x 50 mL), dried over MgS04, filtered, and concentrated to provide the titled compound as an oil.
Example 95D 5-Methyl-4-oxo-pyrrolidtne-l,2-dicarboxylic acid 1-tert-butyl ester To a suspension of 600 mg of 10% Pd-C in 25 mL of 2-propanol was added a solution of 8.9 g of crude 5-methyI-4-oxo-pyrrolidine-l,2,3-tricarboxylic acid 2,3-dibenzyl ester 1-ter/-butyl ester in 100 mL of 2-propanol. The reaction was shaken under 60 psi of H2 for 1.5 h, then filtered and concentrated to an oil. This was taken up in 20 mL of 2M NaOH(
WO 2004/026822
PCT/US2003/029018
Example 95E 5-Memyl-4-oxo-pyrrolidine-l,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester To a solution of 3.0 g of crude. 5-methyl-4-oxo-pyrrolidine-l,2-dicarboxylic acid 1-5 tert-butyl ester in 25 mL of A^-drmethylformamide was added 1.2 g (8.7 mmol) of feCC^ and 1.2 mL (19.3 mmol) of methyl iodide. The mixture was stirred at 80 °C for 20 min, cooled to ambient temperature, then diluted with 125 mL of 0.2M HC1(09.). This was extracted with diethyl ether (3 x 20 mL), then the combined ether layers were extracted with water (1 x 20 mL), and brine (1 x 20 mL), dried over MgSCU, filtered, and concentrated to an 10 oil. The product was purified via silica gel chromatography, eluting with 20% ethyl
acetate/hexanes to give the 2,5-cis isomer. The 2,5-trans isomer eluted slightly-faster than the desired cisisomer. ,HNMR(300MHz,DMSO-rftf)8ppml.30(d,^7.1 Hz,3H) 1.40 (m, 9 H) 2.59 (dd, J=19.2,3.2 Hz, 1 H) 3.12 (dd, J=\ 8.3,11.2 Hz, 1 H) 3.66 (s, 3 H) 3.92 (q, J=6.S Hz, 1 H) 4.63 (dd, .7=10.7,3.6 Hz, 1 H), NOE observed between H-2 and H-5, not 15 observed in the corresponding trans isomer; MS (ESI) m/z = 256 (M-H)+.
Example 95F (2,5-cis) 4,4-Difluoro-5-methvl-pyrTolidine-l,2-dicarboxylic acid 1-tert-butyl ester 2-methyl
ester
20 To a solution of 710 mg (2.76 mmol) of (2,5-cw)-5-methyl-4-oxo-pyrrolidine-l,2-
dicarboxylic acid 1-tert-butyl ester 2-methyl ester in 10 mL of CH2CI2 at -78 °C was added
800 uL (6.05 mmol)of TY^-m^mylammosulfur trifluoride (DAST). The reaction was put
under N2, warmed to ambient temperature, and stirred for 18 h. The excess DAST was
quenched by slowly adding the reaction mixture to 20 mL of ice cooled saturated
25 NaHC03(a9.). After vigorously stirring the biphasic mixture for 10 min, the layers were
separated. The aqueous layer was extracted with CH2CI2 (1x10 mL), then the combined
organic layers were back extracted with brine (1x10 mL), dried over MgSCj, filtered, and
concentrated to an oil. The product was purifed via silica gel chromatography, (75 mL silica
gel) eluting with 10% ethyl acetate/hexanes, then stepping to 20% ethyl acetate/hexanes after
30 collection of the forerun to give the titled compound as a colorless oil.' H NMR (300 MHz,
CDCI3) 8 ppm 1.35 (dd, .7=6.78,3.05 Hz, 3 H) 1.49 (s, 9 H) 2.37 (m, 1 H) 2.65 (m, 1 H) 3.76
(m, 3 H) 4.09 (bs, 1 H) 4.36 (bs, 1 H); MS (ESI) m/z = 280 (M+H)\ 297 (M+NH
(M+Na)+. —- -- - '-— -
35 . Example 95G
(2,5-cis) 4.4-Difluoro-5-methvl-pyrrolidine-2-carboxylic acid methyl ester hydrochloride To 363 mg (1.30 mmol) of 2,5 cis-difluoro-5-methyl-pyrrolidine-l,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester was added 3 mL of 4M HC1 in dioxane. The solution
100
WO 2004/026822
PCT/US2003/07.9018
was stirred at ambient temperature for 2 h, then concentrated in vacuo to furnish the titled
compound as a white solid. !H NMR (300 MHz, DMSO-tfe) 8 ppm 1.34 (dd, .7=7.0,1.5 Hz, 3
H) 2.72 (m, 1 H) 2.91 (m, 1 H) 3.78 (s, 3 H) 3.93 (m, 1 H) 4.76 (t, 7-9.3 Hz, 1 H) 10.49 (bs,
2 H); MS (ESI) m/z =180 (M+H)+. 5
Example 95H
l-((^-2-/e^Butoxy(^rbonvlaniino-4-methyl-pentanovl)-(2,5-c^)-4,4-difluoro-5-methyl-
pyrrolidine-2-carboxylic acid methyl ester
To 58 mg (0.23 mmol) of 7V-(/cr/-butoxycarbonyl)-5-leucine and 100 mg of
10 (dimethylamino-((l ,2,3)tria2»lo(4J5-b)pyridin-3-yloxy)-memylene)-dimemyl-ammonium
hexafluorophosphate (HATU) was added 1 mL of T/.iV'-dimethylformamide, then 90 U.L (0.52
mmol) of N.N-dusopropylethylamine. The mixture was stirred for 1 min, then added to
another flask containing 50 mg (0.23 mmol) of (2,5-ciy) 4,4-difluoro-5-methyl-pyrrolidine-2-
carboxylic acid methyl ester hydrochloride. After 2 h, the reaction was diluted with 5 mL of
15 H2O and extracted with diethyl ether (3x5 mL). The combined ether layers were back
extracted with 1M HC1(0?.), saturated NaHC03(og.), and brine (1x5 mL), dried over MgS04,
filtered, and concentrated to an oil. The product was purified via silica gel chromatography,
eluting with 30% ethyl acetate/hexanes to give the titled compound as a colorless foam. *H
NMR (300 MHz, DUSO-d6) 8 ppm 0.88 (m, 6 H) 1.31 (m, 3 H) 1.36 (s, 9 H) 1.55 (m, 3 H)
20 2.50 (m, 1 H) 2.82 (m, 1 H) 3.64 (m, 3 H) 4.18 (m, 1 H) 4.44 (t, J=9.0 Hz, 1 H) 4.71 (m, 1 H)
7.32 (d, J=8.1 Hz, 1 H); MS (ESI) m/z = 393 (M+H)+, 410 (M+NH,)"*", 415 (M+Na)+.
Example 951
l-(d$0-2-/gr/-Butoxycarbonylaniino-4-methvl-pentanoyl)-(2,5-c/.y)-4,4-difluoro-5-methyl-
25 pyrrolidine-2-carboxylic acid
To a solution of 69 mg (0.18 mmol) of l-((S)-2-/er/-butoxycarbonylamino-4-methyl-pentanoyl)-(2,5-c/j)-4,4-difluoro-5-methyl-pyrrolidine-2-carboxylic acid methyl ester in 2 mL of ethanol was added 0.4 mL (0.8 mmol) of 2M KOH^.). The reaction was stirred at ambient temperature for 1.5 h, then concentrated in vacuo. The residue was taken up in 5 mL 30 of H2O, and acidified with 2 mL of 1M HCI(0
diethyl ether (3x5 mL). The combined ether layers were back extracted with brine (1x5
mL), dried over MgSO^, filtered, and concentrated to provide the titled compound as a
colorless foam. 'H NMR (300 MHz, DMSCW6) 5 ppm 0.88 (m, 6 H) 1.31 (m, 3 H) 1.37 (m,
9 H) 1.57 (m, 3 H) 2.48 (m, 1 H) 2.81 (m, 1 H) 4.18 (m, 1 H) 4.33 (t, J=9.2 Hz, 1 H) 4.72 (m,
35 1 H) 7.30 (d, 7=7.8 Hz, 1 H), 12.80 (bs, 1H); MS (ESI) m/z = 377 (M-H)+.
Example 95J (l-(y)((2,5-c^)-5-Carbamoyl-3,3-difluoro-2-methyl-pyrrolidine-l-carbonyl)-3-methvl-butyl)-
101
WO 2004/026822
POYUS2003/029018
carbamic acid tert-butyl ester i-
To a solution of 60 mg (0.159 mmol) of l-((5)-2-/err-butoxycarbonylamino-4-methyl-pentanoyl)-(2,5-ci*5)-4,4-difluoro-5-methyl-pyrrolidine-2-carboxylic acid in 1 mL of tetrahydrofuran was added 24 pX (0.22 mmol) of AT-methylmorpholine, then 24 pL (0.19 mmol) of isobutyl chloroformate. The mixture was stirred at ambient temperature for 1.5 h, then 0.3 mL of 15MNK»OH was added. After 3.5 h, the reaction was concentrated in vacuo, The residue was taken up in 10 mL of ethyl acetate and extracted with H2O (1x3 mL), 1M HC1 (1x3 mL), saturated NaHC03(aq.) (1x3 mL), and brine (1x3 mL), dried over MgS04, filtered, and concentrated in vacuo to furnish the titled compound as a colorless foam. TLC 75% ethyl acetate/hexanes, stains with nmhydriri. !H NMR (300 MHz, DMSO-rf
Example 95K (H^-((2,5-cf5)-5-Cyano-3,3-difluoro-2Hmemyl^^
carbamic acid tert-butyl ester To 58 mg (0.15 mmol) of (l-(S)((2,5-czj)-5-carDamoyl-3,3-difluoro-2-methyl-pyrrolidine-l-carbonyl)-3-methyl-butyl)-carbamic acid tert-butyl ester was added 1 mL of pyridine, then 11 mg (0.16 mmol) of imidazole. After the imidazole had dissolved, the reaction was cooled with an ice bath, and 30 mL (0.32 mmol) of phosphorous oxychloride was added. The reaction was stirred for 2 h, then concentrated in vacuo. The residue was taken up in 10 mL of ethyl acetate and extracted with 1M HCl^.) (2 x 5 mL), saturated NaHCCH (1x5 mL), and brine (1x5 mL), dried over MgSC>4, filtered, and concentrated to a foam. The product was purified via silica gel chromatography, eluting with 20% ethyl acetate/hexanes to give the titled compound as a colorless foam. 'H NMR (300 MHz, DMSO-rf
Example 95 (2S,5S)^,4-difluoro-l-L-leucyl-5-methylpvrTolidine-2-carbonitrile To 34 mg (0.095 mmol) of (l-(5H(2,5-c/5>5-cyano-3,3-difluoro-2-methyl-pyrrolidine-l-carbonyl)-3-methyl-butyl)-carbamic acid tert-butyl ester was added 0.5 mL of trifluoroacetic acid. The solution was allowed to stand at ambient temperature for 10 min, then concentrated in vacuo to give the titled compound as a colorless foam. 'H NMR (300 MHz, DMSO-rf,j) (mixture of rotamers, major rotamer only) 8 ppm 0.95 (m, 6 H) 1.35 (m, 3 H) 1.72 (m, 2 H) 3.07 (m, 2 H) 4.28 (m, 2 H) 4.76 (m, 1 H) 5.03 (t, .7=8.65 Hz, 1 H) 8.31 (s, 3
WO 20()4702f.822 PCT/US2003/029018
H); MS (ESI) in/z = 260 (M+H)+.
Example 96 (2S,5R)-l-((2SV2-amino-2-cvclohexvlethanoylV5-vinvlpviTolidiiie-2-carboriitrile
Example 96A (2S,5R)-l-((2S)-24ert-ButoxYcarboRYlammo-2^vclohexvl-acetvlV5-trbiethvlsilanvlethyiiyl-
pyrrolidine-2-carboxylic acid methyl ester To a stirred solution of methyl (5R)-5^(trimethylsilyl)ethynyl)-L-prolinate (2 g, 8.87 mmol, Example IE) in dichloromethane (50 mL ) at room temperature under nitrogen was added 4-dimemylaminopyridine (1.08 g, 8.87 mmol), 4-methylmorpholine (1.46 mL, 13.31 mmol), l-(3-(dimemylamino)propyl)-3-ethyl (^rbodiimide hydrochloride (2.04 g, 10.65 mmol), and Boc-Gly(cyclohexyl).OH. (2.7 g, 10.65 mmol). The reaction mixture was stirred at room temperature overnight. Tlie^eacu^n-mixture'was diluted with ethyl acetate and washed with 1M HC1. The aqueous layer was further extracted with ethyl acetate (2X). The combined ethyl acetate layers were dried (Na2S04) and evaporated. Purification by flash chromatography 30% EtOAc/hexane gave the desired compound as a white powder. MS (DCI)m/z465(M+H)+.
Example 96B (2S,5R)-l-((2S)-2-tert-Butoxycarbonylarm^o-2^yclohexyl-acetvl)-5-emynyl-pyrrolidine-2-
carboxylic acid To a stirred solution of 96A (4.3 g, 9.25 mmol), in MeOH (30mL) and H20 (30 mL) at room temperature was added LiOH-HbO (0.58 g, 13.88 mmol). The reaction mixture was stirred at ambient temperature overnight and then evaporated. Water was added to the residue, and the mixture was extracted with Et20 (2X). The aqueous layer was acidified to pH ~ 4 by adding 4% KHSO4 dropwise. The clear solution was extracted with EtOAc ( 3X ). Combined EtOAc layers were washed with brine, dried over (Na2S04) and evaporated to give the desired compound as a white solid. MS (DCI) tn/z 379 (M+H)+.
Example 96C ((2S)-2-((2S,5RV2-Carbamoyl-5-ethvnyl-pyrrolidtn-1 -yl)-1 -cyclohexvl-2-oxo-ethyl)-
carbamic acid tert-butyl ester To a stirred solution of the compound from Example 96B (3.07 g, 8.11 mmol) in THF (60 mL) at -15 °C under nitrogen was added 4-methylmorpholine ( 1.07 mL, 9.73
WO 2004/026822
PCT/US2003/02901S
mmol ) and then isobutylchloroformate (1.2 mL, 8.92 mmol) over 2 minutes. A white precipitate was formed. The reaction mixture was stirred at -15°C under nitrogen for 30 minutes, and a solution of NH3 in dioxane (81.10 mL, 40.55 mmol) was added. The reaction mixture was quenched with 4% KHSO4 to ~ pH 4 and extracted with EtOAc (3X ). The organic extracts were combined, washed with brine, dried (NaiSO-j) and evaporated. Purification by flash column chromatography (5% MeOH / CH2CI2) gave the desired compound. MS (DCI) m/z 378 (M+H)+.
Examp e 96D ((2SV2^(2S,5RV2-CYano-5-emvnyl-pYrrolidm4-vl)-l^Yclohexvl-2K>xo-emyl)-carbarnic
acid tert-butyl ester To a stirred solution of Example 96E (1 g, 2.46 mmol) and imidazole (0.18g, 2.64 mmol) in dry pyridine at -35 °C.under N2 was added POC13 dropwise. The reaction mixture was stirred between —35 and -20 °C for 2hours and then permitted to warm to room temperature. The reaction mixture was concentrated, CH2CI2 was added, the white solids were removed by filtration, and the filterate was concentrated. The white solid was purified (30% EtOAc/hexane) to give the desired compound as a foam. MS (DCI) m/z 360 (M+H)+.
Example 96E ((2S)-2-('(2S,5R)-2-Cyano-5-vmyl-pyrrolidin-l -yl)-l -cyclohexyl-2-oxo-ethyl)-carbamic acid
tert-butyl ester To a solution of ((2S)-2-((2S,5R)-2-cyano-5-ethynyl-pyrrolidin-l-yl)-l-cyclohexyl-2-oxo-ethyl)-carbamic acid tert-butyl ester (0.2g, 0.53 mmol) and quinoline (0.22 ml)in EtOAc (20 ml) was stirred under hydrogen (20 psi) over 5% Pd/BaSO* (80 mg). The mixture was stirred at room temperature for 7 minutes. The mixture was diluted with EtOAc and washed with 1.0M HC1. The organic layer was dried over Na2SC*4 and concentrated. Purification by flash chromatography (3% MeOH-CH2Cl2) gave the desired compound as an oil. MSTDCI) m/z379(M+H)+.
Example 96 (2S.5RVl-((2S)-2-amino-2-cyclohexylethanoyl,)-5-vinylpyrrolidine-2-carbonitrile The reaction mixture of ((2S)-2-((2S,5R)-2-cyano-5-vinyl-pyrrolidin-l-yI)-l-cyclohexyl-2-oxo-ethyl)-carbamic acid tert-butyl ester (0.03 mg, 0.087 mmol) and 4 M HC1 in dioxane (0.15 mL, 0.6 mmol) was stirred at room temperature for 2 h and evaporated under reduced pressure. The residue was triturated with ether to provide the titled compound as a
WO 2004/026822
PCT/US200J/0290I8
white powder. MS (DCI) m/z 362 (M+H)+; lH NMR (300 MHz, MeOH) 5 1.4-1.9 (10H, m), 2.2-2.28 (2H, m), 2.4-2.68 (3H, m), 3.19 (1H, d), 4.3 (1H, d), 4.8 (1H, t), 5.05 (1H, m), 5.9-6.04 (2H, m).
Example 98 (2S,5S)-l-(N-((2R,5SVhexahydro-2,5-methanopentalen-3a(lH')-vnglycvU-5-
methylpyrrolidine-2-carbonitrile The title compound was prepared using the conditions described in Example 91 substituting 1-adamantaneamine for cyclopentylamine. 1H NMR (300 MHz, Methanol-d4) 8 ppm 136 (d, 7-6.44 Hz, 3 H) 1.67 (m, 4 H) 1.98 (m, 8 H) 2.43 (m, 5 H) 3.88 (m, 1 H) 4.21 (m, 2 H) 4.78 (t, >7.80 Hz, 1 H). MS (ESI) m/z 288 (M+H)+.
Example 99 (2£5 /Z)-5-ethynyl-1 -(//-(1 -tert-butoxy carbonyl-piperidin-4-yl)glycyl)pyrrolidine-2-
carbonitrile Example 99 was prepared in the same way as Example 42 by substituting 4-arnino-piperidine-1-carboxylic acid tert-butyl ester for fra/w-4-aminocyclohexanol. MS (ESI) m/z 361 (M+H)+.
Example 100 (2^,5ig)-5-ethynyl-l-(JV'-(l-(5-cyano-pyrioMn-2-vnpiperidm-4-yl)glYcyl)pyrrolidine-2-
carbonitrile Example 100 was prepared in the same manner as Example 31 by substituting 2-chloro-5-cyanopyridine for 5-bromonicotinitrile. MS (CI) m/z 363 (M+l)+.
Example 101 (2S,5R)-1 - (N-( 1 -(4-chlorobenzoy l)-4-methylpiperidin-4-y Delycy 1} -5-ethynylpyrrol idine-2-
carbonitrile The titled compound was prepared in the same manner as Example 32 by substituting 4-chlorobenzoyl chloride for 4-chlorocarbonyl-benzoic acid methyl ester. MS (CI) m/z 413 (M+l)Example 102 (2S,5R)-l-{N-(l-(3-cyanophenyl)-4-methylpiperidin-4-yl)glycyl)-5-ethynylpyrrolidine-2-
WO 2004/026822
PCT/US2003/02901S
carbonitrile The titled compound was prepared in the same manner as described in Examples 30 and 31 by substituting 3-bromobenzonitriie for 5-bromonicotinonitrile and (4-methyl-piperidin-4-yl)carbamic acid benzyl ester for piperidin-4-yl-carbamic acid tert-butyl ester. MS (CI) m/z 376 (M+l)+.
Example 103 (2S,5RVl-fN-n-f4-cvanoben2pyl)^methvlpir^ridm^yl)glycYU-S-emvnylpyrroh^ine-2-
carbonitrile The titled compound was prepared in the same manner as example 39 by substituting isonicotinyl chloride with 4-cyanobenzoyl chloride. MS (CI) m/z 404(M+1)+
Example 105 (2S,5R)4-(N^1^4-bromobenzoyI)^memvlpiperidto^yl)glycyU-5^mynylpvrrolidine-2-
carbonitrile The titled compound was prepared in the same manner as example 39 by substituting isonicotinyl chloride with 4-bromobenzoyl chloride. MS (CI) m/z 458(M+1)+.
Example 106 (2S,5R)-5-ethvnyl-l -(N- (4-methyl-l -(4-(rrifluoromethvl)pvridin-2-vl)piperidin-4-
yl) glycyl)pyrrolidine-2-carbonitrile The titled compound was prepared in the same manner as example 29 by substituting 2-fluoropyridine with 2-chloro-4-(trifluoromethyl)pyridine. MS (CI) m/z 420 (M+l)+.
Example 107 (2S,5R)-l-fN-f4-rrans(r4-cyano-2-fluorophenoxy)cyclohexyI)gIycyl>-5-ethynylpyrrolidine-2-
carbonitrile The titled compound was prepared in the same way as example 48 by substituting 3,4-difluorobenzonitrile for 4-fluorobenzonitrile. MS (ESI) m/z 395 (M+Hf.
Example 108 (2S,5R)-5-emynvl-l-{N-(4-tram(3-fluorophenoxy)-I-methyIcyclohexvnglycyI)pyrrolidme-
2-carbonitrile
WO 2004/026822
PCT/US2003/029018
The titled compound was prepared in the same way as example 46 by substituting 1,3-difluorobenzene for 3-fluoropyridine. MS (ESI) m/z 384 (M+H)+.
Example 109
5 (2S,5R)-1 -{N-(4- trans (3-cvanophenoxv)cvclohexyl)glycyl}-5-ethynvlpyrrolidine-2-
carbonitrile The titled compound was prepared in the same way as example 48 by substituting 3-fluorobenzonitrile for 4-fluorobenzonitrile. MS (ESI) m/z 377 (M+H)+.
10 Example 111
(2S,5R)-l-(N-(4-trarjs((5-cmoropyrid^-2-yl)oxy)cvclohexvl)glycyl)-5-ethynylpyrrolidine-
2-carbonitrile
The titled compound was prepared in the same way as example 48 by substituting 2,5-
dichloropyridine for 4-fluorobenzonitrile. MS (ESI) m/z 387 (M+H) . 15
Example 112 (2S,5R)-5-ethynyl-l-(N-(4- trans {(4'-fluoro-2-(,trifluoromethvl)-ia'-biphenvl-4-
yl)oxv}cyclohexyl)glycyl)pyrroUd^e-2-carbonitrile The titled compound was prepared in the same way as example 43 by substituting 1-20 bromo-4-fluoro-2-trifluoromethyl benzene for 3-bromo-4-fluoro-l-trifluoromethyl benzene. MS(ESI)m/z514(M+H)+.
Example 113
(2S,5RV 5-ethynyl-l -(N-(4- trans ((4'-fiuoro-6-(trifluoromethviy 1.1 '-biphenyl-3-
25 yl)oxy)cyclohexyl)glvcyl)pyrrolidine-2-carbonitrile
The titled compound was prepared in the same way as example 43 by substituting 2-bromo-4-fluoro-l-trifluoromethyl benzene for 3-bromo-4-fluoro-l-trifluoromethyl benzene. MS (ESI) m/z 514 (M+H)+.
30 Example 114
(2S.5RV 1 -(N- f 4-(3-cvano-4- trans (trifluoromethyl)phenoxy)cyclohexyl) glycyl)-5-
ethynylpyrrolidine-2-carbonitrile The titled compound was prepared in the same way as example 48 by substituting 5-fluoro-2-trifluoromethyl-benzonitrile for 4-fluorobenzonitrile. MS (ESI) m/z 445 (M+H)+.
Example 115 (2S,5RVl-(N-(4-trans (3-bromophenoxy)cyclohexyl)glycyl}-5-ethynylpyrrolidine-2-
WO 2004/026322
PCT7US2003/029018
carbonitrile The titled compound was prepared in the same way as example 48 by substituting 1-bromo-3-fluoro-benzene for 4-fluorobenzonitrile. MS (ESI) m/z 431 (M+H)+.
Example 116 (2S,5R)-l-(N-(4- trans (4-cyano-3-fluorophenoxy)cycIohexyl)glycyl>-5-ethynyIpyrrolidine-
2-carbonitrile The titled compound was prepared in the same way as example 48 by substituting 2,4-difluorobenzonitrile for 4-fluorobenzonitrile. MS (ESI) m/z 395 (M+H)+.
35
Example 117 (2S,5R)-l-(N-(4-(2-cyano-4- trans (trifluorometfayl)phenoxy)cyclohexyl}glycyl)-5-
etfaynylpyrrolidine-2-carbonitrile The titled compound was prepared in the same way as example 48 by substituting 2-fluoro-5-trifluoromethyl-benzonitrile for 4-fluorobenzonitrile. MS (ESI) m/z 445 (M+H)+.
Example 118 (2S,5R)-l-(N-(4-tmts(3^yanophenoxyVl-memylcyclohexyl)glycyl}-5^mynylpyrrolidine-
2-carbonitrile The titled compound was prepared in the same way as example 46 by substituting 3-fluorobenzonitrile for 3-fluoropyridine. MS (ESI) m/z 391 (M+H)+.
Example 119 (2S,5R)-l-{N-(4- trans (4-chlorophenoxy)cyclohexyl)glycyU-5-ethynylpyrrolidine-2-
carbonitrile The titled compound was prepared in the same way as example 48 by substituting 1-chloro-4-fluoro-benzene for 4-fluorobenzonitrile. MS (ESI) m/z386 (M+H)+.
Example 120 (2S,5R)-5-ethynyl-l-(N-(4- trans f(6-methyl-4-(trifluoromethyI)pyridin-2-yl)oxy}cyclohexYl)elycyl)pyrrolidine-2-carbomtrile The titled compound was prepared in'the same way as example 48 by substituting 2-chlorc~6^memyl-4-trifluoromemyl-pyrid,ine for 4-fluorobenzonitrile. MS (ESI) m/z 435 (M+H)+.
Example 121 (2S,5R)-1 -(N-{4- trans (2-cyano-3-(trifluoromethyl)phenoxy)cyclohexyl) glycyl)-5-
WO 2004/026822
PCT/US2003/C29018
ethynylpyrrolidine-2-carboiiitrile The titled compound was prepared in the same way as example 48 by substituting 2-fluoro-6-trifluoromethyl-benzonitrile for 4-fluorobcnzonitriIe. MS (ESI) m/z 445 (M+H) .
5 Example 122
(2S,5R)-5-ethynyl-l-(N-f4- trans (4-pyridin-4-yl-3-
(trifluoromethvDphenoxy)cyclohexyl} glvcyl)pyrrolidine-2-carbonitrile
The titled compound was prepared in the same way as example 43 by substituting 4-
pyridyl boronic acid for 4-fluorophenyl boronic acid and 2-bromo-5-fluorobenzotrifluoride
10 for 3-bromo-4-fluoro-l -trifluoromethylbenzene. MS (ESI) m/z 497 (M+H)+.
Example 123 (2S,5R)4-(N-{4-tra3a^(3-cyano-5^rrifluoromethyl)phenoxv")cyclohexyl)glycyl)-5-
ethynyIpyrrolidine-2-carbonitrile
15 The titled compound was prepared in the same way as example 48 by substituting 3-
fluoro-5-trifluoromethyl-benzonitrile for 4-fluorobenzonitrile. MS (ESI) m/z 445 (M+H)+.
Example 124
(2S,5R)-5-ethynyl-1 - (N-(4-(4-fluorophenoxy)-1 -methylcyclohexyl)glycyUpyrrolidme-2-
20 carbonitrile
The titled compound was prepared in the same way as example 46 by substituting 1,4-difluorobenzene for 3-fluoropyridine. MS (ESI) m/z 384 (M+H)+.
Example 125
25 (2S,5R)-5-ethynyl-1 - (N-(4-(3-fluorophenoxy)-1 -methylcyclohexyl)glycyl} pyrrolidine-2-
carbonitrile The titled compound was prepared in the same way as example 46 by substituting 1,3-difluorobenzene for 3-fluoropyridine. MS (ESI) m/z 384 (M+H)+.
30
Example 127
(2S,5RV5-ethynyl-l-(N-(4- trans (3-
(trifluoromethyDphenoxv^cyclohexvUelycyDpyrrolidine^-carbonitrile
The titled compound was prepared in the same way as example 48 by substituting 1-
35 fluoro-3-trifluoromethyI-benzene for 4-fluorobenzonitrile. MS (ESI) m/z 420 (M+H)+.
Example 128
WO 2004/026822
PCT/US2903/0290I8
.T:f
j2gi5^-l-(N-{4-txans((3-bromopyndin-2-yt)oxy)cyclohexyl}glycyl)-5-ethynylpyrrolidiDe-
2-carborutrile The titled compound was prepared in the same way as example 48 by substituting 3-bromo-2-chloro-pyridine for 4-fluorobenzonitrile. MS (ESI) m/z 432 (M+H)+.
Example 129 (2S,5RV5-ethynyI-l-(N-f4- trans ((4-(triJauoromethyl)pyridin-2-vl)oxY}cyclohexyl)glvcYl)pyrrolidine-2-carbonitrile The titled compound was prepared in the same way as example 48 by substituting 2-chloro-4-trifluoromethyl-pyridine for 4-fluorobenzordtriIe. MS (ESI) m/z 421 (M+H)+.
Example 130 f2S,5R)-l-(N-f4- trans ((5^Moropyriduv-2-yl)oxyVl-methylcyclohexvUglycyl)-5-
emynylpyrroUdine-2-carbonitrile The titled compound was prepared in the same way as example 46 by substituting 2,5-dichloropyridine for 3-fluoropyridine. MS (ESI) m/z 401 (M+H)+.
Example 131 (2S,5R)-1 -{N-(4- trans (3-cyanophepoxy)-l-methylcyclohexyl)glycyI>--S-ethynylpyrrolidine-
2-carbonitrile The titled compound was prepared in the same way as example 46 by substituting 3-fluoTobenzdnitrile for 3-fluoropyridine. MS (ESI) m/z 391 (M+H)+.
Example 132 (2S,5iQ-5-ethynyl-I-flY-f4- trans (4-(trifluoromethyl)-5-(carboxy)phenoxy)cyclohexyl}glycyl)pyrrolidme-2-carbonitrile The titled compound was prepared in the same way as example 48 by substituting 2-fluoro-5-trifluoromethyl-benzoic acid for 4-fluorobenzonitrile. MS (ESI) m/z 464 (M+H)+.
Example 133 (2S.5R)-1 - (N-(4- trans (3-chlorophenoxy)cyclohexyl)glycyl) -5-ethynylpyrrolidine-2-
carbonitriie The titled compound was prepared in the same way as example 48 by substituting 1-chloro-3-fluoro-benzene for 4-fluorobenzonitrile. MS (ESI) m/z 386 (M+H)+.
Example 134 (2gJ5R)-5-ethynvl-l-(N-(l-methyl-4- trans ((5-(trifluoromethyl)pvridin-2-
WO 2004/026822
PCT/US2003/029018
y0oxv}cvclohexyl)glycynpvrrolidhe-2-carbonitrile The titled compound was prepared in the same manner as example 46 by substituting 2-chloro-5-trifluoromethylpyridine for 3-fluoropyridine. The titled compound is a mixture of diastereomers at the ether bearing carbon. MS (CI) m/z 435 (M+l)+.
Example 135 (2S,5R)-1 - (N-(4- trans (4-bromophenoxy)cyclohexvl')glycyl| -5-ethynylpyrrolidine-2-
carbonitrile The titled compound was prepared in the same way as example 48 by substituting 1-bromo-4-fiuorobenzene for 4-fluorobenzonitrile. MS (ESI) m/z 431 (M+H)+.
Example 136
(2£5 R\-\-{N-{ 1 J-dmiemvl-2^(3-cyano-6-memvlpyridm-2-vl)arnino)ethvn grycylVS-
15 ethynylpyrrolidine-2-carbonitrile
The titled compound was prepared using the same procedure as described for Example 155 by substituting 6-chloronicotinonitrile with 2-chloro-3-cyano-6-methylpyridine. MS (DCI/NH3) m/z 365 (M+H)+.
20 Example 137
f 2S,5RV 1 -fN-(l, 1 -dimethyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy) etfayI)glycyl)-5-
ethynylpyrrolidine-2-carbonitrile
The titled compound was prepared using the same procedure as described for
Example 66 substituting 2-chloro-5-(trifluoromethyl)pyridine for 6-chloronicotinonitrile. MS
25 (DCI/NH3) m/z 394 (M+H)+.
Example 138 (2S,5R)-1 -(N- {1.1 -dimethyl-2^(3-cvano-6-methvlpyridin-2-yl)oxy)ethvl) glycyl)-5-
ethynylpyrrolidine-2-carbonitrile The titled compound was prepared using the same procedure as described for Example 66 substituting 2-chIoro-3-cyano-6-methylpyridine for 6-chloronicotinonitriIe. MS (DCI/NH3) m/z 366 (M+H)+.
Example 139 (2S,5R)-5-emynvl-l^-(tetrahvdromran-2-ylmethvl)glycyl)pyrrolidine-2-carbonitrile The titled compound was prepared in the same way as example 42 by substituting C-
WO 2004/020822
PCT/US2003/0290I8
(tetrahydro-niran-2-yl)-methylaniine for /7wi?-4-aminocyclob.exanol. MS (ESI) m/z 262
Example 140 (2S,5R)-5-ethynyl-l-(N-(pyridin-2-ylmethyl)glycyl)pyrrolidine-2-carbonitrile The titled compound was prepared in the same manner as example 42 by substituting C-pyridin-2-yl-methylamine for trans-4-aminocyclohexanol. MS (CI) m/z 435 (M+l)+.
Example 141 (2S,5R)-5^mynyl-l-(N^2-pyrioUn^ylemyl)^ycyl)pyrrolidUne-2^arbonitrile The titled compound was prepared in the same manner as example 42 by substituting 2-pyridm-4-yl-emylamine for traris^-aminocyclohexanol. MS (CI) m/z 283 (M+l)+.
Example 142 (2£5Jg>5-ethynyl-l-{AT-((l-tert-buto^
carbonitrile The titled compound was prepared in the same way as example 42 by substituting 4-aminomethyl-piperidine-1-carboxylic acid ter/-butyl ester for /ra/w^-arninocyclohexanol. MS(ESI)m/z375(M+H)+.
Example 143 (2S,5R)-5
Example 144 (2S,5&)-5-ethvnvl-l-(Ar-(4-tert-butyloxycarbow
The titled compound was prepared in the same way as example 42 by substituting 4-amino-butyric-acid /er/-butyl ester for taws^aminocyclohexanol. MS (ESI) m/z 320 (M+H)+.
Example 145 (2S,5RV5^mvnvl-1^^3-hydroxy-2,2^mtemylpropy0glycyl)pyTrolidine-2-carbonitrile The titled compound was prepared as described in Example 160 substituting neopentanolamine for cyclopropylamine. MS (DCI/NH3), m/z = 264 (M+H)+.
Example 146
WO 2004/026822
PCTAJS2003/029018
Structure possibly contains amino acid derivative which is not supported in current version!
The titled compound was prepared using the same procedure as described for Example 155 by substituting 6-chloronicotinonitrile with 2-chloro-4-cyanopyridine. MS (DCI/NH3) m/z 351 (M+H)+..
Example 147 (2S,5RV 1 -OH 1,1 -dimethyl-2- ((4-(trifluoromefcvnpyrimidm-2-vnamino) ethvDglycyl)-5-
ethvnylpyrrolidine-2-carbonitrile The titled compound was prepared using the same procedure as described for Example 155 by substituting 6-chloronicotinonitrile with 2-chloro-4-(trifluoromethyl)pyrimidine. MS (DCI/NH3) m/z 395 (M+H)+.
Example 148 Structure possibly contains amino acid derivative which is not supported in current version! The titled compound was prepared using the same procedure as described for Example 155 substituting 6-chloronicotinonitrile with methyl 6-chloronicotinate. MS (DCI/NH3) m/z 424 (M+H)+.
Example 149 (2S,5R)-l-{N-(2-(2-cyano-5-fluorophenoxvVlJ-dimethvlethvnglvcyl>-5-ethynylpyrrolidine-2-carbonitrile The titled compound was prepared using the same procedure as described for Example 66 by substituting 2,4-difluoroben2»nitrile for 6-chloronicotinonitrile. MS (DCI/NH3) m/z 369 (M+H)+.
Example 150 (2S,5RV5-ethynyl-l-(N-(4-iodobenzyl)glvcyl)pyrrolidine-2-carbonitrile The titled compound was prepared in the same way as example 42 by substituting 4-iodo-benzylamine for /rans-4-aminocyclohexanol. MS (ESI) m/z 394 (M+H)+.
Example 151 (2£5fl)-5-ethynyl-l - W3-(methylamino)-3-tert butyloxv carbonylpropyl)glycyl)pyrrolidine-2-carbonitrile The titled compound was prepared in the same way as example 42 by substituting (3-amino-propyl) methyl carbamic acid ter/-butyl ester for /ra/7s-4-aniinocyclohexanol. MS (ESI) m/z 349 (M+H)+.
113
WO 200-J/026822
PCT/US2003/029018
Example 152 C2.S,5i?)-5-ethynyl-1 -(N-(4-carboxvbutvDglvcv^pyrrolidine-2-carbonitrile The titled compound was prepared by treating Example 144 with 4 M HCl in dioxane. MS (ESI) m/z 263 (M+H)+.
Example 153 r2S.5RVl-a^-f24(3^hloro-5^trmuoromemvnpvrioUn-2-vl)ammo)ethvnglvcvlV5-
ethynylpvrrolidine-2-carbonitrile Example 153 was prepared in the same way as example 42 by substituting Nl-(3-cnloro-5-trifluoromemyl-pyrid^-2-yl)^thane-l}2-diamine for frmw-4-aminocyclohexanol. MS (ESI) m/z 400 (M+H)+.
Example 154 (2S,5RV5-emynyl-l^-(3-isoprorx)xvpropvl)dycyl)pyn-olidme-2K;arrx>nitrile The titled compound was prepared in the same way as example 42 by substituting 3-isopropoxy propylamine for fra/u-4-aminocyclohexanol. MS (ESI) m/z 278 (M+H) . .
Example 155
(2g,5J?)-l"(A^-(14-dimemvl-2
ethynylpyrrolidine-2-carbonitrile
Example 155 A 6-f2-Arnino-2-methyl-propylamino)-nicotinonitrile A mixture of l,2^diamino-2-methylpropane(3.14ml, 30 mmol), and 6-chloronicotinonitrile (2.77g, 20 mmol) were heated to 120 °C for 2 days. The reaction mixture^was"filtered, and the inorganic saltAvas rinsed with EtOAc. The filterate was concentrated under reduced pressure to provide the titled compound as a pale yellow solid. MS (DO) m/z 191 (M+H)+.
Example 155 (2S,5i?H - f JV-f 1,1 -dimethyl-2-(5;:cyanopvridin-2-vlamino)ethyl)glycyl) -5-emynylpyrrolidine-2-carbonitrile To a stirred solution of (2S,5R)-l-(chIoroacetyI)-5-euiynylpyrrolidine-2-carbonitrile (0.05 g, 0.255 mmol, Example 8D) in acetonitrile (3 mL) at room temperature under nitrogen was added 6-(2-amino-2-methyl-propylamino)-nicotinonitrile (O.lg , 0.51 mmol). The reaction mixture was stirred overnight and then concentrated under reduced pressure. The
114
WO 2004/026822
PCT/OS2003/029018
residue was flash cliromatographcd with 2% Me0H/CH2O2 to provide the desired compound as a white solid. MS (DCI) m/z 351 (M+H)+; !H NMR (300 MHz, DMSO-4?) 5 2.03-2.5(2H, m), 2.55 (2H, s), 2.1 (2H, s), 3.5(1H, m), 3.82 (6H, s), 3.9-4.6 (2H, m), 4.7-4.82 (lH,m), 4.88-5.5 (1H, m), 7.3-7.5 (3H,ra).
Example 156 (2S,5R)-1 -(AL(2-(4-carboxyanilino)-1,1 -dimethvlethyl)glycYl)-5-ethvnylpyrrolidine-2-
carbonitrile
Example 156A (2S,5i?Vl-(JV-(2-f4-tert-butoxycarbonvlVaiinmo-ia-dimethvlethvl')glycyl)-5-
ethynylpyrrolidine-2-carbonitrile The titled compound was prepared using the same procedure as described for Example 155 substituting tert-butyl 4-fluorobenzoate for 6-chloronicotinonitrile. MS (DCI/NH3) m/z 424 (M+H)+.
Example 156 (21S,5J?Vl-(Ar-(2-(4-carboxyaDilmoVlJ-dimemvlemyl)glycyl)-5-emynylpyiTolidm
carbonitrile A mixture of the tert-butylbenzoate described above in 4 M HC1 in dioxane was stirred at 23 °C for 2 hours. The dioxane was removed in vacuo, and the crude solid was triturated several times with diethyl ether. The resulting white solid was dried in vacuum oven overnight to afford the HC1 salt of the titled compound. MS (DCI/NH3) m/e 368(M+H)+.
Example 157 (2S,5R)-5-ethvnvl-1 - f N-( 1 -(1 -hydroxy-1 -methvlethyQcyclopentyDglycyl) pyrrolidine-2-
carbonitrile The titled compound was prepared in the same way as example 42 by substituting 2-(l-amino-cyclopentyl)-propan-2-ol for /ra/tf-4-anunocyclohexanol. MS (ESI) m/z 304 (M+H)+.
*
Example 158
(2S,5R)-5-ethvnyl-l-{N-((2R,5S)-hexahvdro-2,5-methanopentalen-3a(lrD-
yQglycyl }pvrrolidine-2-carbonitrile
115
WO 2004/026822
PCT/US2003/029018
The titled compound was prepared in the same way as example 42 by substituting 3W noradamantanamine for frd7W-4-aminocyclohexanol. MS (ESI) m/z 334 (M+H)"1".
Example 159 (2£5iO-l-(iV-cvclopentylglycyl-(N- methyl l-aminocyclopentanecarboxy)-5-
ethynylpyrrolidine-2-carbonitrile The titled compound was prepared in the same way as example 42 by substituting 1-amino-cyclopentane carboxylic acid methyl ester for /ra/w-4-aminocyclohexanol. MS (ESI) m/z 304 (M+H)+.
Example 160 (2S,5R)-l^M^clopropylglvcylV5^mvnylpyrroiidme-2-carbonitrile To a stirred solution of Example 8D (0.045 g, 0.228 mmol) in acetonitrile (2 mL) at room temperature under nitrogen was added cyclopropylamine (0.032_ml, 0.457 mmol). The reaction mixture was stirred overnight and then concentrated under reduced pressure. The residue was flash chromatographed with 3% MeOH/CKfeCb to provide the desired compound as a pale yellow oil. MS m/z 218 (M+H)+; *H NMR (300 MHz, DMSO-4J) 5 1.5-2 (4H, m), 2.11-2.21 (2H, m), 2.45-2.48 (2H, m), 3.78 (1H, d), 3.8^.5 (2H, m)} 4.53-4.55 (1H, t), 5.01 (lH,m), 5.05 (1H, m).
Example 161 (2S,5RV5-emynyl-l-(N-piperidm-4-ylglycyl)pyrrohdine-2-carbonitrile The titled compound was prepared by treating Example 99 with 4 M HO in dioxane. MS (ESI) m/z 261 (M+H)+.
Example 162 (2S,5R)-5-emvnvl-l-(N-((5R,7S)-3-hvdroxy-l-adamantyl)glycvnpyrrolidine-2-carbomtrile
To a stirred solution of Example 8D (0.06 g, 0.305 mmol) in acetonitrile (3 mL ) at room temperature under nitrogen, was added 3-amino-l-adamantanol (0.1 g, 0.61 mmol). The reaction mixture was stirred for two days and then concentrated under reduced pressure. The residue was flash chromatographed with 5-7% MeOH/CH2Cl2 to provide the desired compound as a pale yellow oil. MS (DCI) m/z 328 (M+H)+; *H NMR (300 MHz, DMSO-tf*) 5 1.5-2 (14H, m), 2.11-2.21 (2H, m), 2.45-2.48 (2H, m), 3.78 (1H, d), 3.8-4.5 (2H, m), 4.53-4.55 (1H, t), 5.01 (lH,m), 5.05 (1H, m).
Example 163 (2S.5R)-5-ethvnyl-l-((3R)-N-teteuiydbofurani-3-vlKlycyl)pvn:olia^e-2-carboru^le
WO 2004/026822
PCT/US2003/0290J8
To a stirred solution of Example 8D (0.03 g, 0.153 mmol ) and potassium carbonate (0.2g7 1.53 mmol) in acetonitrile (2 mL), at room temperature under nitrogen was added R(H-)-3-anrinotetrahydrofuran toluene-4-sulfonate (0.08 g, 0.32 mmol). The reaction mixture was stirred overnight and then concentrated under reduced pressure. The residue was flash chromatographed with 2% MeOH/CKbCh to provide the desired compound as a paie yellow oil MS (DCI) m/z 248 (M+H)+; 'H NMR (300 MHz, DMSO-4*) 5 1.5-2 (2H, m), 2.11-2.21 (2H, m), 2.45-2.4$ (2H, m), 1.1Z (1H, d), ^.%A5 (2H, «i), 4.5E--4.55 (AH, t), 5,01 (lH,m), 5.05 (1H, m), 5.43-5.9 (4H,m).
Example 164 (2S,5RVl-(N-cvcloheptylglycyl)-5-emvnylpyn-oUdine-2-carbonitrile The titled compound was prepared as described in Example 160 substituting cyclopropylamine with cycloheptylamine. MS (DCI) m/z 274 (M+H)+; !H NMR (300 MHz, DMSO-^) 6 1.5-2 (12H, m), 2.11-2.21 (2H, m), 2.45-2.48 (2H, m), 3.78 (1H, d), 3.8-4.5 (2H, m), 4.53-4.55 (1H, t), 5.01 (lH,m), 5.05 (1H, m).
Example 165 (2S,5R)-l-(N-cyclobutylglycyI)-5-emvnylpyrroUdme-2-carbonitrile The titled compound was prepared as described in Example 160 substituting cyclopropylamine with cyclobutylamine. MS (DCI) m/z 232 (M+H)+; 'H NMR (300 MHz, DMSO-cfc) S 1.5-2 (6H, m), 2.11-2.21 (2H, m), 2.45-2.48 (2H, m), 3.78 (1H, d), 3.8-4-5 (2H, m), 4.53-4.55 (1H, t), 5.01 (lH,m), 5.05 (1H, m).
Example 166 (2S,5R)-5-ethynyl-l-(3-methvl-L-valvl)pyrrolidine-2-carbonitrile The ttikd compound "was prepared according to tine procedures for £xaxnp\e ^7-5 substituting N-(/-butoxycarbonyl)-L-t-butylglycine for N-(r-butoxycarbonyl)-L-leucuie monohydrate in the step described in Example IF. MS (DCI/NH3) m/z 233 (M+H)+.
Example 167
(2S.5R)-5-ethynyl-1 -(3-pyridin-4-yl-L-alanyl)pyrrolidine-2-carbonitrile
The titled compound was prepared in the same manner as example 1 by substituting (2S)-tert-butoxycarbonylamino-3-pyridin-4-yl-propionic acid for N-(tert-butoxycabonyl)-L-
leucine monohydrate. MS (CI) m/z 269 (M+l)+.
Example 168 (2S,5RVl-L-leucyl-5-prop-l-ynylpyrrolidine-2-carbonitrile
WO 2004/026822
PCT/US2003/02901S
25
The titled compound was prepared in the same way as example 85 by substituting t-Boc-L-Lcucine for Boc-cyclopentyl-L-glycine.dicyclohexylamine. MS (ESI) m/z 248 (M+H)+.
Example 169 (2S.5R)-1 -(3-methyl-L-valyl)-5-prop-l -ynylpyrrolidine-2-carbonitrile The titled compound was prepared in the same way as example 85 by substituting Boc-L-terf-leucine for Boc^yclopentyl-L-glycme.dicyclohexylamine. MS (ESI) m/z 248 (M+H)+.
Example 170 (2S,5R)-1 -(N-cyclobutylglycyD-S-prop-l -ynylpyrrolidme-2-carbonitrile The titled compound was prepared in the same way as example 88 by substituting cyclobutylamine for cyclopentylamine. MS (ESI) m/z 246 (M+H)+.
Example 171 (2S,5R)-l^-(4-U-anshydroxycyclohexyl)giycylV5-prop-l-ynyIpyrroKdme-2K;arbonitrile The titled compound was prepared in the same way as example 88 by substituting /raw^-arninocyclohexanol for cyclopentylamine. MS (ESI) m/z 290 (M+H)+.
Example 172 (2S,5R)-l-{N-((2S)-2"hydroxycyclopentyl)riycyU-5-pror>-l-ynylpyrrohdme-2-carbomtrile The titled compound was prepared in the same way as example 88 by substituting 2-amino-cyclopentanol for cyclopentylamine. MS (ESI) m/z 276 (M+H)+.
Example 173 (2S,5S)-5-memyl-l-(N^(lS,2S,3S,5RV2,6,6-trimethylbicyclo(3.1.nhept-3-yl)glycyl>pvrrolidine-2-carbonitrile The titled compound was prepared using the methodology described in Example 91 substituting (+>isopinocampheylamine for cyclopentylamine. MS (DCI) m/z 304 (M+H)*.
Example 174 (2S,5S)-l-{N-((5R,7S)-3-hydroxy-l-adamantvl)glycvl}-5-methylpyrrolidine-2-carbonitrile The titled compound was prepared using the methodology described in Example 91
WO 2004/026822
PCT/US2003/029013
substituting 3-amino-l-adamantanol for cyclopentylamine. MS (DCI) m/z 318 (M+H)+.
Example 175 (2S,5S)-l-{N-(2-(3,4-dimethoxvphenyDethvlklvcvl}-5-methvbvrrolidiiie-2-carbonitrile
The titled compound was prepared using the methodology described in Example 91 substituting homoveratrylamine for cyclopentylamine. MS (DCI) m/z 332 (M+H)+.
Example 176 (2S,5SV4,4-difluQro-5-methyl4^(5SV5>metfavl-L-prolyl)pvn-oUdine-2
Example 177 (2S,5S)-l-(N-isopropylElycyl)-5-memylpyrrolidine-2-carbonitrile The titled compound was prepared using the methodology described in Example 91 substituting isopropylamine for cyclopentylamine. MS (DCI) m/z 210 (M+H)+.
Example 178 (2S,5S)-l-L-isoleucyl-5-methylpyrrolidine-2-carbonitrile The titled compound was prepared using methodology described in Examples 91,28 and 6 substituting N-(terf-butoxycarbonyl)-L-isoleucine for N-(terM)utoxycarbonyl)-L-leucine hydrate. MS (DCI) m/z 224 (M+H)+.
Example 179 (25,5.y)-5-methyl-l-{jy-(2-(5-cyano-pyridin-2-ylamino)ethyl)glycyl)pvrrolidine-2-
carbonitrile The titled compound was prepared using methodologies described in Example 91 and in Villhauer, E.B.; Brinkman, J.A.; Naderi, G.B.; Burkey, B.F.; Dunning, B.E.; Prasad, ¥L; Mangold, B.L.; Russell, M.E.; Hughes, T.E. J. Med. Chem. 2003,46,2774-2789. MS (DCI)m/z313(M+H)+.
WO 2004/026822
PCT/US2003/0290I8
Example 180 (2S.5S)-5-methyl-l-((3SVK2,3,4-tetrahydroisoQuiiiolin-3-vlcarbonvI')pvrrolidine-2-
carbonitrile The title compound was prepared as described in Example 28 substituting Boc-L-Tic-OH for JV-(ter^butoxycarbonyl)-L-leucine hydrate. MS (ESI) m/z 270 (M+H)+.
Example 181 (2S,5S)-l-(3-cyclopropyl-L-alanyl)-5-methylpyrrolidine-2-cafbonitrile The title compound was prepared as described in Example 28 substituting beta-cyclopropyl-L-alanine Boc for JV-(tert-butoxycarbonyl)-L-leucine hydrate. MS (DCI) m/z 208 (M+H)+.
Example 182 (2S,5S)-5-methyl-l-D-prolYlpyrrolidme-2-carbonitrile The title compound was prepared as described in Example 28 substituting Boc-L-proline for A^-(/ert-butoxycarbonyl)-L-leucine hydrate. MS (DCI) m/z 322 (M+H)+.
25
Example 183 (2S ,5 S)-1 -(N-2,3 -dihydro-1 H-inden- l-ylglycvlV5-methylpyrrolidine-2-carbonitrile The titled compound was prepared using the methodology described in Example 91 substituting 1-aminoindane for cyclopentylamine. MS (DCI) m/z 284 (M+H)+.
Example 184 (2St5S)-5-methyl-l-L-valylpyrrolidine-2-carbonitrile The title compound was prepared as described in Example 28 substituting N-(tert~ butoxycarbonyl)-L-vatine for /V-fterf-butoxycarbonyO-L-leucine hydrate. MS (DCI) m/z 211 (M+H)+.
Example 185 (2S,5S)-5-methvl-1 -(4-methyl-L-leucyl)pyiTolidine-2-carbonitrile The title compound was prepared as described in Example 28 substituting N-(tert-butoxycarbonyl)-L-t~butyI-alanine for N-(/err-butoxycarbonyl)-L-leucine hydrate. MS (DCI)
WO 2004/026822
PCT/US2003/029GI8
m/z238(M+H)+.
Example 186 (2S.5S)-1 -(N-(4- trans hydroxycyclohexyl)glycylV5-memylpvrrolidine-2-carbonitrile The titled compound was prepared using the methodology described in Example 91 substituting trans^-aminocyclohexanol for cyclopentylamine. MS (DCI) m/z 266 (M+H)+.
Example 187 (2S,5S)-l-(N-(tert-butyl)glycyl)-S-methylpyrrolidine-2-carbonitrile The titled compound was prepared using the methodology described in Example 91 substituting /-butylamine for cyclopentylamine. MS (DCI) m/z 224 (M+H)+.
Example 188 (2S,5S)-5-memyl-l-ff5SV5-memyl-L-proIyDpyn:olidine-2-carbonitrile The title compound-was prepared using the methodology described in Examples 28,6, and 176. MS (DCI) m/z 222 (M-fH)+.
Example 189 (2S,5S)-l-(3^yclohexyl-L-alanyl)-5-memylpyrrolidine-2-carbonitrile
The title compound was prepared as described in Example 28 substituting N-{tert-butoxycarbonyl)-L-cyclohexylalanine for N-(terr-butoxycarbonyl)-L4eucine hydrate. MS (DCI)m/z264(M+H)+.
It will be evident to one skilled in the art that the present invention is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
1. A compound of fonntda(T),
ox phannaceirtically acceptable salt ■ thereof ■wherein,
X is a member selected from the gronp consisting of CBa, CHF andCF^
R is selected frora the group consisting of aftylcarbonyl, aryicarbony], cyano, heterocyclecfflfcanyl, R^NC(0>-,B(OIU)2. (l^^oxPOoidane^M^^^BtaDielhyl-(lA3)-dioxDborolane;
Ri is selected from. the group consisting of alkoxyalkyl, aDcyl, alkylcarbonyl, alkenyi, alkyuyi, allenyi, arylalkyl, cycloalkyl, cycIoaDsyla&yl, cyano, haloalkyl, haloalkpnyl, hetEwocyclealkyl, andhydroxyalkyl;
R2 and Rg are independently selected from the group consisting of hydrogen, alkoxyaflqfl, alky!, alkenyi, alkynyl, cycloalkyl, cydoajkylaliyl, aryl, arylalkyl, heterocycle, heterocydealkykhydtaxyalkyl; or
RaandRjtaJcentogedierv^lheatoinsto bicyolic htisrccycle selected from the grosp consisting of 2-iadolinyl, 2-tadciyi, 3-isoqtnnoline, 2-$iperazme, 2-piperioine, 2-pyiroKdine, 2-pynole, 2-pyridine, 2-qumciSnyl, 2-tdrabydroqoiiiolmyi, and 3-tetiah.ydroisoqumoBiiyl, vibaxfa. said heterocycle may be substituted-^0^,2 or 3 Hd?stimer^
alkoxyalkyl alkoxycarbonyl, dkoxycarbonyklkyl, afleyl, alkyicarbonyl, alkylcarbanyklky], alkylcaxbonyloxy, altylsuKbnyi, alkyltbio, alkynyl, aryl, arylaflcoxy, arylaflcyl, arylcarbonyi, arylosy, earboxy, carboocyalkyl, cyano, cyanoalikyl, fonnyi, halogen, baloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, phenyl, RARBN-, RCRDNC(0>-, and RCRDNS(0)2-;
R4, Rs and R$ are each independently selected from tile groim amaisting ofiydtogen, sliryL andarylalkyi;
RA and RB are each independently selected from the gjo\m consisting of alkyl» aliylcarbanyi, aDcoxycarbonyl, alkylsulfonyl; or R* and Se taken together with, the nitrogen to which they are attached form a ring selected fiona the group consisting of piperidme, piperazine and moiphojine; and
Re and RD are each independently selected from the group consisting of hydrogen and
alkyli or
/
when R is cyano, Ri is a member selected from the group consisting of alkyl, alkenyl, and alkynyl, Ra is hydrogen, Rr is a member selected from the group consisting of hydrogen and alkyl, and R? is a member selected from the group consisting of aryi and heterocycle; or
Rjis
i Re
where Rj is aryi or heterocycle either of which may be optionally substituted with 0,1, 2 or 3 substitueats represented by Rio, which is independently selected from the group consisting of alkyl, alkoxy, alkoxyalkyl, alkoxyalkenyl, alkanoyl, alkanoyloxy, alkanoyioxyalkyl, alkauoyloxyalkenyl, alkoxycarbonyl, alkoxycaxbouylalkyl, alkaxycarbonylalkenyl, alkylsulfonyl, alkylsulfonylalkyl, alkylsulfonylalkenyl, amino, aminoalkyl, aminoalkcnyl, aminosulfonyl, anunosnlfonylaUcyl, ammosulfonylalkenyl, carboxaldehyde, (carboxaldehyde) alkyl, (carboxaldehyde) alkenyl, carboxamido, carboxanndoalkyl, carboxamidoalkenyl, carboxy, carboxyalkyl, cartayalkenyl, cyano, cyanoalkyl, cyanoalkenyL, halo, haloalkyl, haloalkenyl, hydroxy, hydroxyalkyl, hydroxyalkenyl, nitro, perfltioroalkyl, perfluoroalkoxy, perfluoroalkoxyalkyl, perfluoroaJkoxyalkenyl, thioalkoxy, thioalkoxyalkyl, thioalkoxyalkenyl, aryi, and heterocycle, and R? is a member selected from the group consisting of hydrogen and alkyl, when Ris cysno. Ri is a member selected from the group consisting of alkyl, alkenyl, and alkyayl, and Ra is hydrogen; or
where R« is arylcarbonyl or heterocyclecarbonyl either of which may be optionally substituted with 0,1,2 or 3 substituents represented by Rio as defined above, and R7 is a member selected from the group consisting of hydrogen and alkyl, when R is cyano, R is selected from the group consisting of alkyl and alkynyl; and Ra is hydrogen; or
R3 is a member selected from the group consisting of aryl-O-alkyl-, aiyl-NH-allcyl-, heterocycle-O-alkyl- and heterocycle-NH-alkyl- wherein the aryl group of arylNflalkyl- and aryl-O-alkyl- and the heterocycle of heterocycleNHalkyl- and heterocycle-O-alkyl- of R3 are optionally substituted with 0,1,2 or 3 substituents represented by R;o as defined above, when R is cyano, Rj is a member selected from the group consisting of alkyl and alkynyl, and R2 is hydrogen; or
R3 is a member selected from the group consisting of arylalkyl and heterocyclealkyl, wherein the aryl group of arylalkyl and the heterocycle of heterocyclealkyl of Rj are optionally substituted with 0,1,2 or 3 substituents represented by Rio as defined above, when Ris cyanc^ R, is a member selected from the group consisting of alkyl, alkenyl, and alkynyl; and Ra is hydrogen; or
Rj is R^O-cyclohexyl wherein R$ is a member selected from the group consisting of aryl and heterocycle, when R is cyano, R* is a member selected from the group consisting of alkyl, alkenyl and alkynyl, and & is a member selected from the group consisting of alkyl, cycloalkyl and heterocycle; or
R,is
where R» is heterocycle and R7 is a member selected from the group consisting of hydrogen and alkyl, when R is cyano, Ri is a member selected from the group consisting of alkyl and alkynyl, and Ra is a member selected from the group consisting of alkyl, cycloalkyl and heterocycle; or
where R» is heterocycle and R7 is a memher selected from the group consisting of hydrogen and alkyl, when R is cyano, R» is ethynyl or propynyl, and & is hydrogen; or
Rais
where R« is heterocyclecarbonyl and R7 is a member selected from the group consisting of hydrogen and alkyl, when R is cyano, Ri is a member selected from the group consisting of alkyl and alkynyl, and R2 is hydrogen; or
Ra is a member selected from the group consisting of aryl-O-alkyl, aryl-NH-alkyl, heterocycle-O-alkyl and heterocycle-NH-alkyl, when R is cyano, Ri is a member selected from the group consisting of alkyl and alkynyl, and Rj is a member selected from the group consisting of alkyl, cycloalkyl and heterocycle; or
Rj is a member selected from the group consisting of aryi-O-allsyl, aryl-NH-alkyl, heterocycle-O-alkyl and heterocycle-NH-alkyl, when R is cyano, Ri is etnynyl or propynyl, and R2 is hydrogen; or
Rjis
Rs is a member selected from the group consisting of hydrogen, aryl, pyridine, and pyrimidine wherein the aryl group or pyridyl group of R* may be optionally substituted with 0,1,2 or 3 substituents represented by Ru> as defined above, and R7 is
a member selected from the group consisting of hydrogen and alkyl, when R is cyano, R, is a member selected from the group consisting of alky I and alkynyl, and Rj is hydrogen; or
Rj is alkyl which may be optionally substituted with 0,1,2 or 3 substituents independently selected from alkoxy, alkoxyalkyl, alkoxyalkenyl, alkanoyl, alkanoyloxy, alkanoyloxyalkenyl, alkoxyearbonyl, alkoxycarbonylalkenyl, alkylsulfonyl, alkylsulfonyialkenyl, amino, aminoalkenyl, arninosulfonyi, aminosulfonylalkenyl, carboxaldehyde, (carboxaldehyde) alkenyl, carboxamido; carboxamidoallcenyl, carboxy, carboxyalkenyl7 cyano, cyanoalkenyl, halo, haloalkenyl, hydroxy, hydroxyalkenyl, nitro, perfluoroalkyl, perfluoroalkoxy, peifluoroalkoxyallcenyl, thioalkoxy, thioalkoxyalkenyl, aryl and heterocycle, when R is cyano, Ri is a member selected from the group consisting of alky 1 and alkynyl, and R2 is hydrogen; or
R3 is a member selected from the group consisting of bicycloalkyl, cycloalkyl, heterocycle and tricycloalkyl, any of which may be optionally substituted with 0,1,2 or 3 substituents independendy selected from alkoxy, alkoxyalkyl, alkoxyalkenyl, alkanoyl, alkanoyioxy, alkanoyloxyalkenyl, alkoxycarbonyl, alkoxycarbonylalkenyl, alkylsulfonyl, alkylsulfonylalkenyl, amino, aminoalkenyl, arninosulfonyi, ammosulfonylalkenyl, carboxaldehyde, (carboxaldehyde) alkenyl, carboxamido, carboxamidoalkenyl, carboxy, carboxyalkenyl, cyano, cyanoalkenyl, halo, haloalkenyl, hydroxy, hydroxyalkenyl, nitro, perfluoroalkyl, perfluoroalkoxy, perfluoroalkoxyalkenyl, thioalkoxy, thioalkoxyalkenyl, aryl and heterocycle, when R is cyano, R
Rs is
»
>
rt-hers Ra is a member seltscted from the &ffip consisting of arylcarbonyl and hctcrocyclecarbonyl, and R7 is a member selected from the groiro consisting of -hydrogen, alkyl and alkoxyalkyl, when R is cyano, Rj is selected j&om the group consisting of alkyl, alkenyl and alkynyl, and R^ is hydrogen; or
R3 is a member selected from the group consisting of aryl-O-alkyl-, aryl-NH-aflsyl-, heterocycle-O-alkyl- and heterocycle-NH-alkyl-, when R is cyano, R] is selected from the group consisting of alkyl, alkenyl, alkynyl, allenyl and cycloalkyl, and R2 is hydrogen;
wherein unless otherwise specified
alkyl by itself or as part of another group contains from 1 to 10 carbon atoms, wherein
said alkyl may be optionally substituted with 0,1 or 2 substituents selected from the
group consisting of alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy,
alkylsulfonyl, alkylthio, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, halogen,
hydroxy, alkoxycarbonylNR,, alkylNR, wherein R* is a member selected from the
group consisting of hydrogen and alkyl;
alkenyl contains from 2 to 10 carbon atoms and at least one carbon-carbon double
bond;
alkynyl contains from 2 to 10 carbon atoms and at least one carbon-carbon triple bond
wherein said alkynyl may be substituted with 0,1,2, or 3 substituents independently
selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,
alkylcarbonyl, alkylcarbonylalkyl heterocycle, heterocyclealkyl, hydroxy, and
hydroxyalkyl;
alkoxy by itself or as part of another group is alkyl-O-;
allenyl contains from 3 to 10 carbon atoms and two double bonds between three
contiguous carbons;
aryl by itself or as part of another group refers to a monocyclic-ring system, or a
bicyclic- or a tricyclic-rused ring system wherein one or more of the fused rings are
aromatic and said aryl may be substituted with 0,1,2, or 3 substituents independently
selected from alkyl, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl,
alkoxycarbonylalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy,
alkylsulfonyl, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl,
halogen, haloalkyl, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, mercapto,
nitro, phenyl, RERFN-, RcBaNC(0)-, and RGRHNS(0)J-, wherein Re and R* are each
independently selected from the group consisting of alkyl, alkylcarbonyl,
alkoxycarbonyl, alkylsulfonyl, and Ra and RH are each independently selected from
the group consisting of hydrogen and alkyl;
oycloalkyl refers to a monocyclic, bicyclic, or tricyclic ring system, wherein
monocyclic ring systems are selected from a saturated cyclic hydrocarbon group
containing from 3 to 8 carbon atoms, bicyclic ring systems are selected from a bridged
monocyclic ring system in which two non-adjacent carbon atoms of the monocyclic
ring are linked by an alkylene bridge of between one and three additional carbon
atoms, and tricyclic ring systems are selected from a bicyclic ring system in which
*?'0 *»
bridge of between one and three carbon atoms, wherein said cycloaliyl may be
substituted with 0,1,2 or 3 substituents selected from alkyl, alkylcarbonyl, alkoxy,
alkoxycarbonyl, alkenyl, alkynyl, aryl, cyano, halogen, hydroxy, hydroxyalkyl, nitro,
RfiBfN"JR
selected from the group consisting of alkyl, alkylcarbonyl, alkoxycarbonyl,
alkylsulfonyl, and Ro and RR are each independently selected from the group
consisting of hydrogen and alkyl;
unless otherwise specified, heterocycle by itself or as part of another group refers to a
monocyclic, bicyclic, or tricyclic ring system, wherein monocyclic ring systems are selected from any 3- or 4- membered ring containing a heteroatom independently selected from oxygen, nittogen and sulfur, or a 5-, 6- or 7~membexed ring containing one, two or three heteroatoms wherein the heteroatoms are independently selected from nitrogen, oxygen and sulfur, the 5-membered ring having from 0-2 double bonds and the 6-and 7-membered ring having from 0-3 double bonds, wherein bicyclic ring systems are selected from any of the above monocyclic ring systems fused to an aryl group as defined herein, a cycloalkyl group as defined herein, or another monocyclic ring system, wherein tricyclic ring systems are selected from any of the above bicyclic ring systems fused to an aryl group as defined herein, a cycloalkyl group as defined herein, or a monocyclic ring system, and wherein said heterocycles may be substituted with 0,1,2 or 3 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkyl, arylcarbonyl, aryloxy, carboxy, carboxyalkyl, cyano, cyanoaJkyi, formy£ halogen, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, phenyl, RBRFN-, RGRHNC(0)~, and RGKflNS(0)r, wherein RE and R* arc each independently selected from the group consisting of alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, and Re and Ra are each independently selected from the group consisting of hydrogen and alkyl.
The compound according to claim 1, wherein Riacyano.
The compound according to claim I, wherein
Riacyano; and
Rl is a member selected from the group cpwastfog
The compound according to claim 1, wherein Riacyano;
Ri is a member selected from the group consisting of alkyl, alkenyi, and alkynyl; and Ra is a member selected from the group consisting of alkoxyalkyl, alkyl, cycloalkyl, loaDcylalkyL, arylalkyl, and heterocyclealkyl.
The compound according to claim 1, wherein Riacyano;*
Ri is a member selected from the group-consisting of alkyl, alkenyi, and alkynyl; and Ra is a member selected from the group consisting of hydrogen, alkyl, cycloalkyl, and erocycle;and Rj is hydrogen.
The compound according to claim 1, wherein Ris cyano;
Ri is a member selected from the group consisting of alkyl, alkenyi, and alkynyl; and Ri is hydrogen; and
Ri is cycloalkyl, wherein cycloalkyl is a member selected from the group consisting cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, and cyclooctyL
The compound according to claim 1, wherein
R is cyano,
Rt is a member selected from the group consisting of alkyl, alkenyi, and alkynyl; and
Rj is hydrogen; and
R3 is
R7 is a member selected from the group consisting of hydrogen and alkyl; and
R$ is a member selected from the group consisting of hydrogen, aryl, and heterocycle.
8.. The compound according to claim 1, wherein
R is cyano;
Ri is a member selected from the group consisting of alkyl, alkenyl, and alkynyl;
Rats hydrogen;
R? is alkyl; wherein the alkyl group of R3 is optionally substituted with, a member of the group consisting of altofey, aQcoxycarbonyU' alkoxycarboaylNR,, alkyiNR,, carboxy, and hydroxy; and
R» is a member selected Jfrom the group consisting of hydrogen and aflcyL
9- The compound according to claim 1, wherein
R is cyano;
Ri is a member selected from the group consisting of alkyl, alkenyl, and aDcynyl;.and
R2 is hydrogen; and
R3 is a member selected from die group consisting of aryl and heterocycle; wherein said heterocycle is a member selected from die group consisting of aretidinyl, azepanyl, aaridinyl, diazepinyl, 1,3-dioxolanyl, dioxanyl, dithianyl, furyl, bnidazolyi, imidazolinyl, imidazotidinyl, isothiazolyl, isothiazolinyl, isothiazoIidinyl« isoxazolyl, isoxazolinyi, isoxazolidmyl, marpholinyl, oxadiazolyl, oxadiazolinyl, oxadiazolidinyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyl, pyranyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridinyl, pyrimidmyl, pyridazinyl, pyrrolyi, pyrrolmyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrazinyl, tetra2olyl, thiadiamlyl, thiadiazolmyl, tbiadiazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl, thienyl, tbiomorphohnyl, 1,1-dioxicbrhiornozpholinyl (thiomorpholine sulfone), thiopyranyi, triazinyl, triazoh/1, and trithianyL
10. The compound according to claim 1, wherein
R is cyano;
Ri is a member selected from the group consisting of alkyl, alkenyl, and afltynyl; and
Ri is hydrogen; and
Rj is a member selected JBtom uw group consUtm^
/
11. The compound according to claim 1, wherein Riscyano,
Rj is a member selected from the group consisting of alky 1, alkenyl, and alkynyl; Rab hydrogen; Rais
R7 is a member selected from the group consisting of hydrogen, alkyl and alkoxyalkyl; and
Rj is a member selected from the group consisting of hydrogen, aikylcaxbonyi, aryl aodheterocycle.
12. The compound according to claim, 1, wherein Riscyano;
Ri is selected from the group consisting of alkyl, alkenyl, and alkynyl; and Ra is hydrogen; and Rsis
R7 is a member selected from the group consisting of hydrogen, alkyl and alkoxyalkyl; and
Rs is a member selected from the group consisting of atylcaruonyl and hetexocyclecarbonyL
13. The compound according to claim 1, wherein
Riscyano;
Pi i« *» member selected from the group constating .of JuTcyi. alkenyl, alkynyl, allenyi and cycloalkyl; and
Rj is hydrogen; and
Rj is a member selected from the group consisting of aryl-O-alkyl-, aryl-NH-alkyl-, heterocyclc-O-alkyl- and heterocycle-Nk-alkyl-.
14. The compound according to claim I, wherein
Riscyano;
Ri is selected from the group consisting of alkyl, alkcnyl, and alkynyl; and
Ra and R3 taken together with the atoms they are attached form a mono orbicyclic
hetexocycle selected from the group consisting of 3-isoquinoline, 2-pyrrolidinyi, 2Hjuinolinyl,
2^etrahydroqumofinyl, and 3-tetrah.ydroi3oquiiioIinYt
15. The compound according to claim 1 , that is a member selected from the group
consisting of
(23,5R)-5-emynyl-l-L4eucylpyrroUdme-22-^urttno-2l^(2S)-2-ainuu>-2^yclopencylethanoy^^ (2S,5R)-1 ^(2R)-2-airnW2-cydohexyIcUMnayl)-5^m^ (2S^SVH(2S>2-^mjmo-2^clopentyleumoyl>5-oiemylpynoUo%ie-2^ carbordtrile;
(2S^SH,4-difhioro-5-methyl-1 -L-vdylpynoUa^e-2s:arbonitdle; (2S^S)-414-difluoio- l-L-leucyl-5-methylpyrroHo%^2^sa^onitrile; (2S^HK(2S>2-amiiio-2
(2S^R>l^(2R>2-armrio-2^clopentyletharM>yI>5-vir^
C2S^>5-edrynyi-l^-methyH,-val^^^
(2S,5R>5-edrynyl-l^-pyridm^yl-L-alanyl)pyrroliQ^e-2
(2S,5R)-Hrleucyl-5-5rotM-yiry^ (2S,5R)-l^HtnrihyH,-valyiy5-pro^ (^^$)-M,-^eucyio-inmyipynou^^ C^^S)-l^^clopror^l^^anyl>5-rnemylpyrioUdirje-2H^^
(2S^S>5Hnemyl-14^valyhpyrrou\^
(2S,5S>5-niemyl-H4-me*hyl-Weu
(2S,5S)- l-
carbcmitnlc;
C2S^>1^0R,4S>Wcydo
(2S^>l^-l-adan»aitylgly(^I)-5^ C2S,5R>l^^dob^lgiycyI)-5^ynylpyOT^ (2S,5R)-5^ynyl-l-{N^Hin£thjaxyme^ carbonitrile;
(2S^>5^ynyl-l-{NK(2S>2^yoroxycydo^ carbonitrile;
C2S^>l^^yclopentylglycyl>55^thynyI-l-{NH;l^ydroxymetfayl)cyciopmtyI)gIycy^ carbonitrile;
(2S,5R>l-{N^l^ydroxyme%l)cydopen^ carbonitrile;
(2Sr5R)-l-(N-cyclopeatylglycyl)-5-prop-l -ynyJ^ynoUdm^2-«arbonitrilc; (2S^S>l^-cyclopentylglycyl)-5-me^ (2S^S)-l-{N^l^ydroxymi^yI)cydopenty^ carbonitrile;
(2SpSyi-{N^US>aexafayc^^ nidhylpynoUd1ne-2Harboratdle;
(2S^R.)-5-ethyiiyl-l-{N-(l-(l-hydioxy-l-metfaylcthyl)cydopratyI)glycyl}pynoUdiiie-2H»rboin1iilc;
C2S^>5^yiiyi-l-{lSK
(2S4J?H^2-caii)oiuMe;
(2S^Vl^^clopiooyiglycyl>5H%iiylpynQlidine (2S,5R>5^ynyl-i-{N3^4^ carbonitrile;
pS^HKN^dafaeptytglycyiys^ynyl^^ (2S.5RVl^-cydohuty\glycy^S-cJiiywlp^ (2S^>HN-l-{N^C^2^ydioxy
(2S^S>5^e%l-l-{N2A6-tiiin^^ y0glycyi}pyrroddme-2-carbonitrile;
(2S,5SH^K(^7S>3-bydroxy-l-adamantyl)^ carbonitrilej
^S^)-5-cthynyl-1^^4-tiaQs-hydroxycycIolifiX7l)glycyl)pyiroUdmc-2-
carbonitrilc; '
(2S,5R>5^ynyl4^4-trai^{(4^flno^ yI)oxy}(7clofafixyI)glycyl)pyitoUduiB-2-caxbQoitrile;
(2S,5R)-5-
(2S,5R)-5^ynyl-1^^44iydYcHy4-me%^ carbomtrilc;
(2S^>5H^hynyl-l-(N-(l-niethyl-4-1ian3 (pyridD.3-yloxy)Gyclohcxyl)gly
(2S,5R)-l-S-e^ynyipynolidinc-2HMrbonitrilc;
(2S^R)-l-{N-(4- trans (4Hjyanophenoxy)cydor^0gly
C2S,5R)-5-ethynyl-l-(N-(4- trans {(5-{trifi\u>romediyI)pyri(Un-2-yl)oxy}
(2S,5R)-5-ethynyl-l-(N-{4- trans (3-pyridh>4-yl-4-(trifluoromdhyl)plienQxy)^
(2S,5R)-5-dhynyl-l-{N-(4- trans (pyri(hn-2-yloxy)cycloht^I)giy(7l}pyiioU
(25,5J?)-5-cihynyl-l-{7V"-(l-methyl-4- trans (5-cyano-pyridin-2-ylaxy^clohexyQ^ycylJpynoUdine^-^^bonitrile',
(2S^R)-5-cthynyH-{N-(4- trans (pyrimidm-2-yloxy)cyclohcxyI)glycyi}pyiioUdine-2-carbonitrilc;
(2S,5R)-5-diiynyl-l-{N-(4- trans (5-cyano^yridin-2-yloxy)cyclohexyl)gly(^l}pynoUdnc-2-
(2S^R>5Hsthyrryl-l-(N.{4- trans (4-(lnilnoraniethyl)pbcnoxy)cyd^
(2SI5R>5-ethyny^l^-{4^(5-fl^oropyridin-3-yl)l-Tne%lcyclohcxyl}glycyl)t^iToUdine-2-carboni
(2S,5fl)-5-«thynyM-(7/-(4- trans (4-
(2S^R>5-eilryrjyH-(NM4- trans C2^xopym>lidui4-yi)-4-(tafhioiaircthyl)phenaxy)cydohe^^
(2S,5R)-l-{N-(4- trans (4^ano-2^iierthoxyphenoxy)c^^ ediyaylpynoUdine-2-carbonitrilc;
(2S,5R)-l-(N-{4- trans ((5-chloropyridin-2-yl)oxy)cyclohexyl}grycyi>5-cthynylpynolidinc-2-carbonitrile;
C2S,5R>5-«hynyH-{N-{l-«nctbyl-4- trans (pyridb-2-
yloKy)cydohexyl)glycyI}pyrroUdinc-2-carboDitrilc; .
(2S,5R)-5-ethynyH-
(2S,5R>l-(N-{4- trans ((5%omopyridinr2-yl)oxy)cyclohfixyl}glycyI)-5-cthynylpyrrolidine-2-carbonitrilc;
(2S^R)-5-€thynyl-l-{N-(4- trans (pyridui-3-yloxy)cyclohoxyl)gIy
(2S,5R)-5-prop-l.ynyH-(N-
(2S,5R>-l-{N-
(2S,5R}-5-ethynyH-{N-(4- trans (3-fluorophBnDry>l-mcthylcyclohe^l)gLycyl}pyiiolidine-2-carfaoiiitrile;
(2S,5R)-l-{N-
(2S,5R>5H^ynyl4^
(2S,5R>l-(N-{4- trans ((5^hloropyridin-2-yl)oxy)cyclobexyl}glycyi)-5-cthynylpyrrolidhie-2-carbonitrilc;
(2S,5R)-5-ethynyl-l-{N~(4- trans {(^-fluoro^^trifluoromethylVM'-biphenyl-^-^l)oxy}cyclohexyI)gly(7L)pyrroUdinc-2-caibonitrile;
(2S,5R)-5-cthynyM-(N-(4- trans {(4'-fluon>^(trmuoiomctfayl>-l,r-biphsnyl-3-yl)oxy}cydohexy!)glycyl)pynx)Udine-2-carbonitrile;
(2S75R>l-
(2S,5R>l-{N-(4- trans (3-bromophenoxy)cyddiexyl)glyoyl}-5^tliynylr^rroUdine-2-carbonitrile;
(2S,5R)-l-{N-(4- trans (4-
(2S^R)-l-0SI-{4-(2-cyanD-4- trans (trifluoromethyl)pheaoxy)cyclohe3cyl}glycyl)-5-ethynylpyrroHdine-2Hau^rutrile;
(2S,5R)-l-{N-(4- trans (3^anopbjcaoxy)-l-mctbylcydoh«cy0giycyl}-S-edrjTLyIpynolidiiic-2-sarbonJtrilc;
(2S,5R)-l-{N-(4- trans (4n:hlQiophcnoxy)
(2S^R)-5-ethynyl-L-(N-(4- trans {(6-mediyl^trifluoromethyl)pyridm-2-yI)oxy}cydobcxyl)glycy0pyn:olidine-2-carbonitrile;
(2S,5R)-l-{Nf-{4- trans (2^ano-3-(triiluoromethyl)phenoxy)cydohexyl}gIycyl>-5-
cthynylpynolidinc-2-caibonitrilc;
G2S,5R)-5-cthynyl-l-(N-{4- trans (4-pyridin-4-yl-3-(trifluoromethyi)phaio^>^doh^
C2S,5R>-l-(N-{4- trans 0-(tfano-5^trifli]oiome^ ctfaynylpyrroUdino-2Marbonitrik;
(2S^)-S
(2S,5R)-5-ctnynyl-l-{N-(4-(3-fluorophaiQxy)-l-me%l
(2S^)-5^thynyl-l^^l^e%l^{(5^trmuorome%l)pyridin-2-yl)oxy}
(2S^R>5-cfliyayl-l-(N:{4- trans (3-(trifluoronifitiiyOphena:^)^
(2S,5R)-l-{N-{4- trans ((3-bromopyridin-2-yl)oxy)cycloliexyl}glycyl)-5-ethynyIpyirolidinc-2-carbomtriIe;
(2S,5R.)-5-«thynyH-(N-{4- trans {(4^trifluoromcthyI)pyricim-2-yl)oxy}cyclohcxyI)glycyl)pyrrolidJije-2
(2S^R.)-l-(N-{4- trans ((5-cUoxopyridm-2-yl)oxy>l-methylcycloaGcyl}giycyl>S-ethyiiylpyrrolidijie-2-carbonitrile;
(2S,5R)-l-{N-{4- trans (3-cyanophenoxy)-l-ajetfa.yIcyclobe3£yl)glycyI}-5-ethynylpyrroUdinc-2-carbonitrilc;
(2S£Ry5-dhjayl-l-{N-iA- trans (2-carboxy-4-(trMuoromcthyl)plicnoxy)cyclohcxyl}glycyl)pyiioUdmc-2-carbonitrile;
(2S,5R)-l-{N-(4- trans (3-
(2S^)-5-^thynyl-l-(N-{l-inetbyi-4- trans {(5^tn^uormnetnyl)pyriQni-2-yl)oxy)cydofae}cyI)glycyI)pyin)Iidme-2-
(2S,5R)-l-{N-(4- trans (4-bromortooxy)cydohexyOgly
(2S,5R)-l-(N-(4- trans hydroxycyclohejcyl)glycyl)-5-prQp-l-ynylp7irolidine-2-carbonitrile;
(2S.5S) ! 5-ffl^^^
(2S^>5-lKNKtm4>uiyl)glycyl>S-ethyn^^^ (2S^>l^^l,lHiiinediylpropyI)gty^ (2S,5R>5^th)aiyM-{N^^mdiiylan^
(2S,5R>5^thyttyl-l^^ carbonitrile;
C^t5it>5^tliynyl4-{JV'
(M^i^5-«%nyl-H#^4H;;ttboxyb^
(2S,5R> 5-^ynyl-l ^^-tsopropo^
(2S^S>l^-4sopropylgiycyl>5^ethylpyiiolidme-2^arfaoni1iile;
(2S^S>l^
(2S,5R)-5^ynyl-t^^iiahydro-2Hijym^
(^S.SRJ-S^thynyM-^CN^etrahydra^^ and
(2S^S>l
C2S^R.)-5-ethynyl-l-{N-(2-{4-fluoropheiiy 1)-1,1 niimethylethyL)glycyl}pynolidine-2-catbdnitnle;
(2S^S>l-{N^^,4-diiikthoxypheayJ^ carbonittile;
(2S^)-5^ynyW^KtetehydrofiMn-2-y^^ carbonittile;
C2S;5R)-5-ethyjxyl4^-{pyri^
(2S^)-5-
(2S^)-5^thynyl-1^^44od0bav2yl)glycyl^^
C2S^>5-dhynyl-l^^4-me%M^yrid^^ carbonitrile;
yI)glycyl)pyiroli(iine-2-carbonMe;
(^,5^5
(25^10-5-«ihyiryl-l-{fl^4Hnethyl-1^4M^ yOglycyl} pyrrottdine-2-caxbanxtrile;
(2S,5R>5^ynyM^-{4-mdhyl-H5^trffluon^^ yl}^ycyl)pyrrQlidme-2-caiboni
(2S,5R>l^^H5-
(2S,5R)-5^ynyl-l^^li?yiidii^2-ylpiperi^
»
carbonitrile;
(2S,5R>5
(2S;5IE>-SH^ynyl-Htf
(2S,5iE>-5-cthynyi- l^i\H[4-nidhy]-1^5^yaro-pyridm-3-yl)piperidia-4-yl)glycyl)pym)Iidine-2-caibQnitrilc;
(2S;5^5^ynyl-KA^l-tert-buto3[ycaibonyl-pi^ carbonitrile;
(2S,5iO-5-ediynyl-l^^l-5H;yano-pyridin-2-ylpipeiidin^ carbonitrile;
C2S^>l-{N^l^
(2S^>5-etbyiryl-l^{4-methyM
(2S,5R)-5^ynyMHN-piperidin^ylgly^
(2SAR)-S-cthynyl- l-{#^4~mrihyi-1^4-mfitli0xyca^ yl)glycyl}pyiTQHdinc-2Karbonitdle;
(2S^>l-{N^H4
(2S,5RV5-ethynyM^^l-isamcat^ catbonitrile;
(2S^>l-{l>HH4
(2S,5R>l-{^K4^ryaaob
(2S,5R>l-{N^H4-bioroobeinnyI^^ cthynyJpyrrolidiiie-2-carbonitca£5
cthynylpytroJidiiic-2--carbonitrileJ;
(2S^H-{N^UHiim^yl-2
(2S^R)-l-{N^^3-bemo1hiaz»l-2-yIammo>l4-^ ethyaylpynolidine--2-carboiiitrjlc;
C2S^J0-l^{U-dimethyl-2
(2S^HHN^U^ethyl-2^(5-(trifluoromet^^^ dfaynyIpynolidiiip-2-carboaittile;
(2^iQ-l^-{l,l^imclJiyi-2^(3H7aao-6^ethylpyridm-2-yl)(x^ dtiyD.yJpynoIidinc-2-carbcaiitdle;
(2S^Jl)-l-{/^(l,lHlmediyl-2
C2S3>-l^^,lHlbttetfayl-2H(M^MtonM%l)py^ yI)aniino}ediyl)glycyiy5
(2jS4R>-l^JV^l,lKlimerfiyl-2^5Hnca]oxycaibony^^ dliynyipynoUdinc-2-carbomtDlc;
dfaynylpynolidin&-2-caTbomtrfle;
^^-l^^-/(3^|/nT%-^tci>»»mnnie^yn^
dhynylpynoUdia^2-c2ffboiritril^
C!S4HH^*H^4-c^xy-fflrii^^ 2-carbonitrile;
(2$5S)-5-metbyl- l-{AK2
(2S,5R5HAyil-K(3Sl,2tetiydroi3oquinolin-3-ylcarbonyi)pyirolidine-2-
carbonitrile;
5S)4i44jflUoro-5Mnethyl4(5S5-mcthyI-LilyI)pyiiolidm (4S5-mcthyl-K(3S)-l,4-trahydroiaoquiiiolin-3-yl
caibonitrile;
(5S>5Hndhyl-l-L-proiyipynoUdinc-2-caiboDitrilc-,
(2SS5ethyl-K(5S5-methyl-Liiioty
|